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Lung cancer is the most common and leading cause of cancer death worldwide. Despite 
the clinical and technological advances, the majority of the patients are lately diagnosed with 
either locally advanced or metastatic disease. Moreover, the current treatments are ineffective as 
the therapeutic molecules barely reach deep lung tumors.  
To address this problem, nanotechnology and pulmonary delivery have been the focus for 
the generation of novel and potentially effective delivery systems, able to target the deep lungs. 
Hence, multifunctional nanodevices combining high doses of anti-cancer drugs and small inter-
fering RNA (siRNA) can be efficiently delivered to a defined area of the respiratory tract where 
the tumor is confined, enhancing treatment efficacy while minimizing adverse side effects. In an 
attempt to engineer respirable microparticles, sustainable methodologies using supercritical car-
bon dioxide (scCO2), like supercritical assisted spray drying (SASD), combined with nano and 
micro technologies were optimized. Therefore, two nanosystems were successfully engineered: 
i) gold nanoparticles (AuNPs) functionalized with biocompatible and fluorescent coatings (pro-
duced under scCO2 conditions), and targeting sequences, able to target and enter into lung can-
cer cells; ii) and Layer-by Layer (LbL) assemblies comprising a nanolayer of siRNA to knock-
down specific genes linked to lung cancer genetic pathway. Our results highlight the extraordi-
nary outcomes that arise from the combination of scCO2 technology in different steps of the 
process, with multifunctional nanocarriers in the development of ultrafine dry powders. Suitable 
aerodynamic performances for deep lung delivery, together with optimal release profiles (from 
50 to 90% over a period of 4 or 5 days, at lung cancer pH), make these types of nano-in-micro 
formulations ideal for pulmonary delivery. Furthermore, the preliminary in vivo results of mi-
cronized LbL nanovehicles proved that the developed formulations are adequate for future lung 
cancer gene therapy through the pulmonary route. 
Altogether, the work herein detailed represents a broad skill set for engineering and man-
ufacturing dry powder formulations comprising nanodevices for the diagnosis and treatment of 
lung cancer.  
  
 
Keywords: lung cancer, nanotechnology, pulmonary delivery, supercritical carbon diox-





O cancro do pulmão é o tipo de cancro mais comum e mortal em todo o mundo. Apesar 
dos avanços clínicos e tecnológicos, a maioria dos pacientes é diagnosticada tardiamente com 
doença local ou metastizada. Além disso, os tratamentos actuais são ineficientes, uma vez que 
os agentes terapêuticos não chegam à zona mais profunda do pulmão. 
De forma a combater este problema, a combinação da nanotecnologia e engenharia de 
partículas tem permitido o desenvolvimento de sistemas de inalação eficientes capazes de atin-
gir zonas alvo do pulmão. Assim sendo, nanosistemas multifuncionais que combinem elevadas 
doses de drogas anti-cancerígenas e ARN interferente silenciador (ARNsi), podem ser adminis-
trados de forma eficiente à região do tracto respiratório onde o tumor está confinado, melhoran-
do a eficácia do tratamento e minimizando efeitos secundários adversos. Numa tentativa de de-
senvolver metodologias sustentáveis para produzir micropartículas respiráveis, combinou-se a 
atomização assistida por dióxido de carbono supercrítico (SASD), com tecnologias nano e mi-
cro. Assim, foram produzidos com sucesso dois tipos de nanosistemas: i) nanopartículas de ouro 
(AuNPs) funcionalizadas com revestimentos biocompatíveis e fluorescentes (produzidos em 
scCO2), e com sequências de direccionamento, capazes de atingir e entrar de forma específica 
nas células do cancro do pulmão; ii) e sistemas de deposição em camada de polielectrólitos 
(LbL) contendo uma nanocamada de ARNsi para silenciar genes específicos associados com a 
via genética do cancro do pulmão. Os nossos resultados evidenciam os avanços extraordinários 
que surgem através da combinação de tecnologia scCO2 em diferentes etapas de processamento, 
com os nanosistemas multifuncionais, na produção de pós secos ultrafinos. As adequadas carac-
terísticas aerodinâmicas dos microsistemas capazes de atingir a zona mais profunda do pulmão, 
juntamente com os óptimos perfis de libertação dos nanosistemas (de 50 a 90%, por um período 
de 4 ou 5 dias), tornam estes tipos de formulações nano-em-micro ideais para administração 
pulmonar. Além disso, os resultados preliminares dos estudos in vivo realizados para os pós 
contendo os nanosistemas de LbL, provam que as formulações desenvolvidas são adequadas 
para futura terapia génica do cancro do pulmão através da administração pulmonar.  
No seu todo, o trabalho constitui um amplo conjunto de ferramentas para a produção o 
desenvolvimento e produção de formulações para inalação contendo nanosistemas com aplica-
ções no diagnóstico e tratamento de cancro do pulmão.  
Palavras-chave: cancro do pulmão, nanotecnologia, libertação pulmonar, dióxido de car-
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Au-OEtOx-SH AuNP coated with OEtOx-SH  
Au-OEtOx-SH-YIGSR AuNP coated with OEtOx-SH and grafted with YIGSR 
BET Brunauer emmett teller  
BF3.OEt2  Boron trifluoride etherate 
BUN Blood urine nitrogen 
CHT Chitosan  
CLSM Confocal laser scanning microscopy  
COPD Chronic obstructive pulmonary diseases 
CREAT Creatinine 
CROP Cationic ring-opening polymerization 
CTAB Cetyltrimethylammonioum bromide  
dae Aerodynamic diameter 
DLS Dynamic light scattering  
DMEM Dulbecco’s modified eagle’s medium 
DMF Dimethylformadide 
DMPE Dimyristoylphosphatidylethanolamine  
DP Dry powders  
DPI Dry powder inhalers  
DPPC Dipalmitoylphosphatidylcholine 
DUSA Dosage unit sampling apparatus  
Dv Volume mean diameter 
E% Entrapment efficiency 
ED Emitted dose  
EDX Energy dispersive X ray spectroscopy  
EtOH  Ethanol 
FBS Fetal bovine serum 
FDA Food and drug administration 
FPF Fine particle fraction 
FTIR-ATR  Fourier transform infrared-attenuated total reflection  
xxiv 
 
GFP Green fluorescence protein 
GNP Gold nano probe 
GSD Geometric standard deviation  
H&E Hematoxylin and eosin 
HA Hyaluronic acid   
HAuCl4.3H2O Tetrachloroauric (III) acid  
HD Hydrodynamic diameter  
Hdase Hyaluronidase 
HPLC  High-performance liquid chromatography 
ICP Inductively coupled plasma  
ICP-AES Inductively coupled plasma-atomic emission spectrometer  
IR Infrared 
k Rate constant 
K- Negative control 
K+ Positive control  
LbL Layer-by-Layer 
LPPS Large porous particles  
Maldi-TOF Matrix assisted laser desorption ionization – Time of flight 
MeOTH Methanol 
MeOPEGMa PMMA-methoxy(polyethylene glycol)methacrylate  
MMAD Mass median aerodynamic diameter  
mPES Modified polyethersulfone  
MPM Homobifunctional maleimide poly(ethylene glycol) 
MSN Mesoporous silica nanoparticles  
MSN_IR-780 IR-780 dye loaded MSN 
MTS 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl) 
-2-(4-sulfophenyl)-2H-tetrazolium  
n Diffusion exponent  
NC siRNA Silencer Negative Control siRNA (NC siRNA) 
NIAD National Institute of Allergy and Infectious Diseases  
NIR Near-infrared 
NSCLC Non-small cell lung cancer 
OA Oligoaziridine biosensor  
OCT Optimal cutting temperature  
OEI-CS Oligo(ethyleneimine-N-chromylium salt) 
OEtOx Oligo(2-ethyl-2 oxazoline) 
OEtOx-OH Oligo(2-ethyl-2 oxazoline) end capped with water 
OEtOx-SH Oligo(2-ethyl-2 oxazoline) end capped with cysteamine 
OOxs Oligo(2-alkyl-2-oxazolines)  
PBS Phosphate-buffered saline 
PDI Polydispersity Index  
Pe Peclet number  





PGSS Particles from gas saturated solutions 
Pkase Proteinase K 
PLA Poly-L-arginine  
PLGA Poly (lactic-co-glycol acid) 
pMDI Pressured metered dose inhalers  
PMMA Poly(methyl methacylate)  
PMS  (Phenazine methosulfate) 
PNAPs Porous nanoparticle-aggregate particle  
PTT Photothermal therapy 
RESS Rapid expansion of supercritical solutions 
ROI Region of interest 
SAS Supercritical antisolvent 
SASD Supercritical assisted spray drying  
scCO2 Supercritical carbon dioxide  
SCFs  Supercritical fluids  
SCLC Small cell lung cancer  
SEM  Scanning electron microscopy 
SFEE Supercritical fluid extraction of emulsions  
siRNA Small interference ribonucleotide acid 
STEM Scanning TEM  
TEM Transmission electron microscopy  
TEOS Tetraehtyl orthosilicate  
TFF Tangential flow filtration  
TGA Thermal gravimetric analysis  
TPCM Two photon correlation microscopy  
UV-Vis Ultraviolet-visible 
Wr% Percent weight remaining  
x Particle dynamic shape factor 
XRD X-ray power diffraction  
YIGSR Laminin fragment (Cys-Asp-Pro-Gly-Tyr-Ile-Gly-Ser-Arg) 
ρ0 Unit density 





Lung cancer (including both non-small cell lung cancer (NSCLC) and small cell lung 
cancer (SCLC)) is the most common and leading cause of cancer death in both men and women 
worldwide. Despite the clinical and technological advances, the majority of the patients are late-
ly diagnosed with either locally advanced or metastatic disease. In fact, only about 14 % of the 
patients with lung cancer survive for five years, while the rest dies within two years. 
1,2
 
The main reason for the poor survival rates among the patients with lung cancer is the 
limited efficiency of traditional treatments.
2
 In fact, the efficacy of a treatment mostly depends 
on the techniques by which the drug is delivered and the optimum concentration to exert an ac-
curate therapeutic effect.
3
 The ideal anticancer therapy would involve the local administration of 
high drug concentration directly to the target tissue for the maximum treatment effect and thus 
low unwanted side effects.
2,4
 Bearing this knowledge in mind, new strategies based on interdis-
ciplinary approaches like polymer science, pharmaceutical technology, bioconjugate chemistry 
and molecular biology have been fully implemented to generate advanced drug delivery sys-
tems. For more than 20 years the potential benefits of nanotechnology have been providing ex-
traordinary improvements in both drug delivery and targeting. In fact, nanotechnology-based 
therapeutics exhibited several benefits over the unmodified drugs, including improved half-
lives, retention, and targeting efficiency, substantially decreasing patient side effects.
3,5
 
Theranostics (a combination of therapy and diagnosis) is considered the pathway to personal-
ized medicine, which will lead to an entirely new era of healthcare delivery. Nano-based 
theranostics can offer many benefits for lung disease patients including real time diagnosis of 
lung inflammatory state and treatment, optimal therapy for individual patients and reduction in 
adverse drug effects. Therefore, innovative design of nanoparticles will allow for the tailoring 
of multifunctional airway targeting nanocarriers that allow for the integration of multiple func-
tions, such as cell targeting, ultra-sensitivity imaging and therapy, all into one system. Surface 
functionalized gold nanoparticles, multifunctional quantum dot conjugated, liposomes and mul-
ti-layered assemblies have been extensively exploited to face the urgent need to further develop 
novel multifunctional nanosystem theragnosis of lung complications.
6–9
 
In this context, this work starts by portraying the developed multifunctional theragnostic 
nanoparticles. There are many types of nanoparticulated systems being explored for lung deliv-
ery. In fact, nanoparticle systems can be engineered to exhibit several desirable features for di-
agnosis and therapy (theragnosis) of specific conditions. Gold nanoparticles (AuNPs), for in-
stance, have been widely investigated as carriers and biosensors for lung cancer treatment.
10
 




bulk gold. They are easily synthetized, reproducible and functionalized to perform specific 
functions. Actually, several works already described that functionalized AuNPs selectively tar-
get lung cancer cells enabling diagnosis and treatment of the disease.
11,12
 Nanoparticles func-
tionalization also provides a stealth surface to prevent opsonisation, therefore increasing their 
residence time and enhancing therapeutics delivery at the accurate site of action. Usually, such 
protection is performed by hydrophilic polymers like poly(ethylene glycol) (PEG). For imaging 
purposes, AuNPs are usually tagged with fluorescent probes.
13
 However, the well-known plas-
mon resonance effect depicted by AuNPs usually self-quench these fluorescence coatings. In 
this concern, the work detailed in CHAPTER 2 aim to the development of robust gold biotags 
where a convergent strategy using PEG and a fluorescent oligoaziridine compound, produced in 
supercritical carbon dioxide (scCO2) conditions, successfully resulted in a bilayered fluorescent, 
and non-quenched, gold nanoprobes (GNP). 
As the time evolves, recent reports have been stating that increasing amounts of PEG may 
lead to undesired hepatic accumulation leading to an inflammatory response triggered by the 
liver. To overcome such problem, new oligomers (oligo-oxazolines), produced in scCO2, a to-
tally green process, have been widely investigated as PEG substitutes. Such oligo-oxazolines 
are highly stable, water-soluble, amphiphatic, non-toxic, very flexible and hydrated in water, 
and have already been used in several biological applications as an alternative to PEG. Moreo-
ver, due to the known tumor anatomical abnormalities like the existence of overexpressed re-
ceptors on the surface of cancer cells, it is possible to improve nanoparticles selectivity to pro-
mote the specific recognition by cancer cells. Hence, structures like antibodies, antibody frag-
ments, small molecules, nucleic acids and peptides, vitamins and carbohydrates have all demon-
strated ability to induce nanoparticle-targeting to cancer cells. Such modifications confer not 
only an additional benefit of sustaining systemic effects, but also the potential to reduce dosing 
frequency.
14,15
 Bearing all this concepts in mind, CHAPTER 3 describes the substitution of both 
PEG and additional flourescent tagging, by totally “green” oligo-oxazolines produced under 
scCO2 conditions, resulting in stable, biocompatible and non-quenched POxylated gold nano-
particles. Moreover, these nanoconstructs were further conjugated with a specific peptide se-
quence, known to bind to overexpressed receptors in the cancer cell line in study, enhancing 
cellular uptake by these nanosystems. A future conjugation of these nanovehicles with therapeu-
tic drugs is envisaged for effective theragnostic applications.  
Local administration of nanotherapeutics to the lungs is the best alternative to improve 
lung cancer outcomes.
1,2
 Hence, the merging of nanotechnology and pulmonary delivery of aer-




several types of lung and systemic diseases. Such type of lung delivery is expected to circum-
vent the lack of effective methods for targeted delivery of therapeutics specifically to lung tis-
sues and cells. However, nanoparticles are in a size range which is not suitable for deep lung 
delivery as they are easily exhaled or mucociliary cleared out before reaching the underlying 
epithelia.
9,16
 Therefore, the major challenge for pulmonary delivery of nanoparticles is to find a 
proper carrier system. Prolonging nanoparticles or drugs presence in lung epithelium can be 
manipulated by using mucoadhesive materials such as the biodegradable polysaccharide chi-
tosan.
17,18
 Increased effectiveness of an inhalation treatment may be achieved by the quick dis-
solution of powder particles in the airway mucus and rapid diffusion to the destination tissue.
19–
21
  Hence, a novel particulate form incorporating nanoparticles into micro-scale structures has 
been engineered to overcome the issues of storing and delivering drugs and other biomolecules 
to the lungs. Micro and nanotechnologies are enabling the design of new materials and methods 
with enormous impact on medical technology, greatly improving the performance of many ex-
isting drugs and enabling the use of entirely new therapies. Full description of nano-in-micro 
particles engineering for pulmonary delivery can be accessed in CHAPTER 1, where a review 
of the most sustainable strategies to construct such formulations is given in detail. Targeted 
therapy of drugs to lungs provides maximum deposition of suitable therapeutic agents at the 




By bringing all these concepts together, nano-in-micro formulations comprising a chi-
tosan matrix and POxylated gold nanoparticles were efficaciously engineered by using scCO2 
methodologies like Supercritical Assisted Spray Drying (SASD) and the work is detailed in 
CHAPTER 4. Our proof-of-concept systems show ideal characteristics for effective pulmonary 
delivery and optimal in vitro release profiles for lung cancer situation.  
Notwithstanding, to achieve the clinical translation promise of this SASD technology, it 
is critical to adapt not only the carriers but also the materials used to build the nanoconstructs to 
a broad range of biodegradable and highly biocompatible polymers. Also, the nanosystems 
should be replaced by the most common and currently FDA approved nanocarriers, which are 
already accepted for several forms of cancer and can be readily adapted to a number of thera-
peutic approaches. In such attempt, our POxylated gold nanoparticles were substituted by layer-
by-layer (LbL) nanosystems comprising of a mesoporous silica nanoparticles (MSN) core. This 
type of materials also offer several advantages related to good physical-chemical stability, high 
loading capacity and controlled and sustained released. Moreover, MSN have been found to be 
non-toxic, biocompatible and biodegradable 
22




mainly eliminated from the body through urine). The simplicity of LbL has also led to recent 
and extremely accelerated growth of new drug delivery systems. The ability to incorporate a 
broad range of therapeutic molecules with meaningful loadings has greatly impaired to this rev-
olution. Cancer therapy has been evolving in a way of minimizing the use of chemotherapeutic 
drugs.
23
 Therefore, combined strategies of anti-cancer drugs with small interference RNA (siR-
NA) or isolated genetic therapy have been strongly investigated in the recent years and there 
already numerous successful studies proving the ability of siRNA to specifically silence mutat-
ed oncogenes.
24–27
 Moreover, due to their unique advantages, combined strategy of LbL with 
siRNA has already been investigated by some authors with regard to the ability to target gene 
silencing both in vitro and in vivo cancer cell lines.
25
 
Therefore, CHAPTER 5 describes the extraordinary outcomes that result through the 
merging of LbL technology with siRNA lung cancer therapy. Moreover, in order to produce 
particles that can be locally delivery to the lungs through the pulmonary route, LbL siRNA 
nanoconstructs were micronized into chitosan powders using SASD technology and effective 
gene silencing of the mutate oncogene was successfully achieve in vitro. Finally, the produced 
powders were administered to healthy mice in order to assess the biodistribution of this novel 
type of particles. The successful outcomes that resulted from this latest work are truly exciting 
and provide a potential strategy to deliver siRNA to the lungs and open new insights to effective 
gene therapy in lung adenocarcinoma situations. 
Ultimately, CHAPTER 6 briefly revises all the investigation work developed during this 
thesis, while evaluating the accomplishment of the major goals of this PhD:  i) to development 
of new biocompatible, biodegradable and targeted nanosystems to be use in theragnosis lung 
cancer situations; ii) to produce nano-in-micro dry powders formulations with suitable aerody-
namic properties and adequate release and degradation profiles, while preserving nanoparticles 
integrity; and iii) to evaluate in vivo powders biodistribution in mice lungs. Future expectations 
and forthcoming works that can arise from this thesis are also given in this chapter. 
 
THESIS ORGANIZATION AND OUTLINE 
Based on the evolution attained during the development of this PhD, this thesis is based 
on five manuscripts (listed below) that are presented as individual chapters (1 to 5). The first 
two have already been published (the following two were submitted for publication at the time 
this thesis was concluded, and the remaining one was being prepared for submission) in peer 




published content. The chapters were organized considering the main goals for this PhD work, 
and are in agreement with the association between the scientific subjects addressed in each one. 
Each chapter is preceded by a title page containing the reference of the publication, conference 
attendances (if applicable), and the specific author contributions. Briefly, each chapter includes 
the following contents: 
CHAPTER 1 – A.Sofia Silva, Márcia T.Tavares, Ana Aguiar-Ricardo. 2014. Sustainable strate-
gies for nano-in-micro particle engineering for pulmonary delivery, Journal of Nanoparticle Re-
search, 16:2602-2619. 
 
CHAPTER 2 - A. Sofia Silva, Vasco D. B. Bonifácio, Vivek P. Raje, Paula S. Branco, Paulo 
F.B. Machado, Ilídio J. Correia and Ana Aguiar-Ricardo. 2015. Design of oligoaziridine-PEG 
coatings for efficient nanogold cellular biotagging Royal Society of Chemistry Advances, 5: 
10733-10738. 
 
CHAPTER 3 - A. Sofia Silva, Marta C. Silva, S P Miguel, Vasco D.B. Bonifácio, Ilídio J. Cor-
reia, Ana Aguiar-Ricardo. Nanogold POXylation: Towards always-on fluorescent lung cancer 
targeting. Submitted manuscript 
 
CHAPTER 4 - A. Sofia Silva, A. M. Sousa, Renato Cabral, Marta C. Silva, S P Miguel, Vasco 
D.B. Bonifácio, T. Casimiro, Ilídio J. Correia, Ana Aguiar-Ricardo. Aerosolizable gold nano-in-
micro dry powder formulations: New prospects for lung cancer theragnosis. Submitted manu-
script. 
 
CHAPTER 5 - A.Sofia Silva, Kevin E.Shopsowitz, Santiago Correa, Stephen W. Morton, Erik 
C. Dreaden, Teresa Casimiro, Ana Aguiar-Ricardo, Paula T. Hammond. Micronized Layer-by-
Layer nanovehicles for siRNA pulmonary delivery: A novel approach for lung cancer therapy. 
Manuscript in preparation  
 
CHAPTER 6 – Final overview, concluding remarks and future prospects. 
This chapter provides an overall summary of the subjects addressed in the five chapters, high-





All chapters were formatted using a unique style of references being cited by sequential 
numbers and listed in the References section. Finally, appendixes relative to each chapter are 
also compiled in a single section at the end of this thesis named Appendix.
 
CHAPTER 1. Sustainable strategies for nano-in-micro 













This chapter corresponds to the contents (with minor changes) of the following publication: 
2014, Journal of Nanoparticle Research, 16:2602-2619  
A.Sofia Silva, Márcia T.Tavares, Ana Aguiar-Ricardo 
Sustainable strategies for nano-in-micro particle engineering for pulmonary delivery 
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With the increasing popularity and refinement of inhalation therapy, there has been a 
huge demand for the design and development of fine-tuned inhalable drug particles capable of 
assuring an efficient delivery to the lungs with optimal therapeutic outcomes. To cope with this 
demand, novel particle technologies have arisen over the last decade agreeing with the progress 
of pulmonary therapeutics that were commonly given by injection. Nanotechnology holds a 
considerable potential in the development of new release mechanisms of active ingredients to 
the deep lungs. For an accurate deep lung deposition and effective delivery of nanoparticles, 
respirable nano-in-micro formulations have been extensively investigated. Microparticles with 
nanoscale features can now be developed and their functionalities have contributed to stabilize 
and improve the efficacy of the particulated dosage form. This chapter reviews the different 
types of the aerosolizable nano-in-micro particles, as well as their sustainable production and 
characterization processes as dry powders. This review also intends to provide a critical insight 
of the current goals and technologies of particle engineering for the development of pulmonary 
drug delivery systems with a special emphasis on nano-micro dry powder formulations prepared 
by spray drying and supercritical fluid assisted techniques. The merits and limitations of these 
technologies are debated with reference to their application to specific drug and/or excipient 
materials. Finally, a list of most recent/ongoing clinical trials regarding pulmonary delivery of 
this type of formulation is described. 
1.2. INTRODUCTION 
In the last decade, investigation on the interactions between nanoparticles and lung tissue 
has been strengthened, specifically in terms of potential health risk of particle inhalation. Not-
withstanding, the huge advances in the nanotech field also brought new insights for novel deliv-
ery strategies, diagnosis and therapeutic approaches through the inhalative route.
28
 With rapid 
advances in nanotechnology, the use of drug nanoparticles has become a subject of a very active 
research, and it has triggered the interest in the lungs as a major route of drug delivery for both 
systemic and local treatment.
16
 Nanoparticles have been foreseen as an efficient way to develop 
controlled release delivery systems for the lungs. There are many types of nanoparticulated sys-
tems being explored for lung delivery. In fact, nanoparticle systems can be engineered to exhibit 
several desirable features for diagnosis and therapy (theragnosis) of specific conditions. Despite 
their ability to protect therapeutics at both extracellular and intracellular levels and then release 
them in a sustained and controlled manner, they are still able to penetrate into deep tissue and 




provides a stealth surface to prevent opsonisation, therefore increasing their residence time and 
enhancing therapeutics delivery at the accurate site of action. Nano-based theranostics offer a 
pathway for personalized medicine allowing real time diagnosis of lung inflammatory state and 
carrying the optimal therapy for individual patients with reduction of the undesirable drug side 
effects. Innovative design of nanoparticles allows for the assimilation of several functions, such 
as cell targeting, ultra-sensitivity imaging and therapy, all into one system. Surface functional-
ized gold nanoparticles (AuNPs), multifunctional quantum dot conjugated, liposomes and multi-
layered assemblies have been extensively exploited to face the urgent need to further develop 
novel multifunctional nanosystem theragnosis of lung complications.
6–9
 The combination of 
nanotechnology and the pulmonary route for administration of aerosolizable drugs brings out 
new and exciting breakthroughs for the diagnosis and therapy of several types of lung and sys-
temic diseases. Such type of delivery to the lung (air-to-lung) and via the lung (air-to-blood) can 
circumvent the lack of effective methods via other routes of administration. However, nanopar-
ticles are in a size range which is not suitable for deep lung delivery and be easily exhaled or 
mucociliary cleared out before reaching the underlying epithelia.
9,16
 Moreover, nanoparticles’ 
nature poses noteworthy challenges in powders development. Their increased surface area re-
sults in high Gibbs free energy, which may lead to particles agglomeration and consequent for-
mulation instability. Therefore, the major challenge for pulmonary delivery of nanoparticles is 
to find a proper carrier system. Increased effectiveness of an inhalation treatment may be 
achieved by the quick dissolution of powder particles in the airway mucus and rapid diffusion to 
the destination tissue. Hence, a novel particulate form incorporating nanoparticles into micro-
scale structures has been engineered to overcome the issues of storing and delivering the drugs 
and other biomolecules to the lungs. Aerosols for inhalation therapies may be produced by 
pneumatic or ultrasonic nebulizers, pressured metered dose inhalers (pMDI) and dry powder 
inhalers (DPI).
18
 From all the formulations available for inhalation, dry powders are usually pre-
ferred as they exhibit the most suitable behavior for pulmonary delivery such as stability and 
bioavailability of active ingredients, when compared to their aqueous counterparts.
29,30
 Moreo-
ver, storage and distribution in a cool-chain are not necessary as the usage of a DPI provides 
longer storage stability to the powders therein.
21
 In DPI formulations, drug nanoparticles have 
been blended with carrier materials, producing nano-in-micro formulations like Trojan and 
Strawberry particles or particles with nanofeatures. In DPI, the lower density of such nanoparti-
cles agglomerates results in smaller mass median aerodynamic diameter (MMAD) and conse-
quently, increases lung deposition and powder flowability. Moreover, nanoparticles in inhaled 
therapeutics have also been demonstrating an increased residence time in the lung muco adhe-
sive surfaces and reduced mucociliary clearance.
31
 




Although microparticles can be manufactured by many different processing methods, this 
review focuses mainly on spray drying and supercritical fluids technology in the production of 
totally  ‘green’ dry powders formulations. Wet chemistry, phase separation processes and other 
drying methods such as spray freeze drying, have also been widely used for particle engineering 




1.2.1. The lung as a delivery target for nanomaterials: nano-delivery via aerosol 
Lungs, skin and intestinal tract are in direct contact with the environment. Therefore, 
these organs are likely to be a first port of entry for nanomaterials into the body. In fact, epide-
miological studies regarding the exposure of the body to atmospheric particles showed a posi-
tive correlation between the increase of such contact and the short-term increase in morbidity 
and mortality.
34,35
 Since inhalation is by far, the most significant exposure route for air-borne 
nanoparticles, the number of studies regarding on nanoparticles deposition along the respiratory 
tract has been increasing. Bearing this knowledge in mind, the systemic administration of pro-
teins or other macromolecules is being surpassed by the delivery of such molecules through the 
pulmonary inhalation route.
16,31,36–41
 Actually, needle-free drug delivery systems have been re-
ceiving increased attention as a noninvasive alternative owing to the unique physiological fea-
tures of the lungs.
42
 Ones are characterized by large absorptive surface area (> 100 m
2
), thin 
blood-barrier membrane (0.1 - 0.2 µm), elevated vascularization and low enzymatic activity 
which, together, facilitate macromolecule transport into systemic circulation, leading to very 
rapid action and high bioavailability. Furthermore, drug and other molecules delivery through 
lungs are not subjected to hepatic first pass-effect.
16,29,31,36,43
 Moreover, the favorable physiolog-
ical environment of the deep lungs, such as physiological pH and reduced mucociliary action, 
overcomes many problems of  other non-invasive vaccine targets, like rapid clearance, poor ab-
sorption, exposure to digestive enzymes and the antigenic tolerance.
43
 So far, several protein 
based drugs, such as insulin, human growth hormone, calcitonin and deslorelin, have been re-
ported to reach the systemic circulation following aerosol administration. Hence, pulmonary 
delivery holds a great potential for the treatment of several respiratory diseases like asthma, tu-
berculosis, influenza, cystic fibrosis, Chronic Obstructive Pulmonary Diseases (COPD) and 
lung cancer. Actually, recent studies regarding cancer immunotherapy using genetically engi-
neering T-cells to target cancer cells have shown remarkable results. With more people living 
beyond age 65, cancer’s incidence is projected to rise even more in the coming years. Therefore, 
the population who might benefit from immunotherapy is potentially quite large. By combining 




lism may be avoided and cancer, especially non-small lung cancer (one of the leading cause of 
death worldwide) may be effectively treated.
44
 
Localized drug delivery shows a great promise not only in the treatment of such diseases 
but also reduces the systemic toxicity.
40
 Although advantageous, efficient pulmonary delivery 
and effective delivery of biologic drugs inside cells of the deep lung are also very challenging 
missions.
16
 In fact, particle deposition and retention in the different pulmonary stages are deter-
mined by three main factors: respiratory tract anatomy, breathing pattern and droplet/particle 
size.
28
 Though some conflicts regarding the range for optimal aerodynamic diameter (dae) to 
efficiently reach the deep lungs may exist, the most recent works state that the aerodynamic di-
ameter of aerosol particles should be between 0.5 and 5 µm. Smaller particles may fail to depos-
it and are exhaled, whereas bigger ones may accumulate in the mouth and throat.
16,37,45
 Moreo-
ver, smaller particles are more likely phagocytized and have the tendency to aggregate due to 
van der Waals and electrostatic forces
19
 making large porous particles with low density suitable 
for lung delivery.
46
 When the MMAD is more than 5 μm, inertial impaction exists in the oro-
pharynx and large conducting airways, while the smaller airways are reached when the aerody-
namic diameter is smaller than 5 μm.
32,47
 Table 1.1 describes the mechanism of dry powder 
deposition along the respiratory tract.   
 
Table 1.1-Mechanism of aerosol deposition.
32,47
 
Site Particle size Mechanism 
Large conducting airways >5 μm Inertial impaction 
Respirable airways 
Smaller airways 3-5 μm Deposition 
Alveolar airspaces 
1-2 μm Deposition 
<0.5 μm Exhalation 
 
However, drugs and other biomolecules that are targeted to intracellular machinery, gen-
erally require nanocarriers to improve mucus diffusion and cellular uptake by the epithelial 
cells. These paradoxical requisites turn complex the development of an efficient carrier system: 
the particles should comprise sizes between 0.5 and 5 µm during the inhalation, then swell and 
increase their size upon  depositing onto the lung, evade the macrophage clearance in the deep 
lung and enable the release of smaller particles that penetrate lung mucus and epithelial lining 
and deliver drugs, proteins or other biomolecules intracellularly, minimizing nonspecific side 




effect to the healthy tissue, as displayed in Figure 1.1.
37,48
 For suitable cellular internalization 
nanoparticles should not exhibit sizes larger than 150 nm.
49
 Notwithstanding, particles compris-
ing sizes ranging between 20 to 50 nm have shown to have higher cellular internalization.
50,51
 
Moreover, it has already been proved that if smaller nanoparticles (hydrodynamic diameter 
(HD) less than ≈ 34 nm and a noncationic surface charge) are used, specifically in pulmonary 
delivery, nanoparticles can rapidly translocate from the lung epithelium to mediastinal lymph 
nodes. This should provide high levels of drug to pulmonary lymph nodes, which could be used 
to deliver antibiotics and anti-inflammatory drugs to treat other lung infections, tumor metasta-





Figure 1.1-Mechanism of nanoparticle delivery through aerosol of nano-in-micro formulations - 
once in the lung epithelia, microcarriers must readily dissociate into the primary nanoparticles in an 
aqueous medium without significant destruction of the delivery advantages associated with the nanopar-
ticulate systems. Then, nanocarriers may travel to their site of action, due to specific targeting exhibited 
in nanoparticles surface, and exert their theragnosis effect. 
1.2.2. Devices for pulmonary inhalation – Dry powder inhalers  
Lung delivery of nano-in-micro formulations may rely on either dry solid particles as in 






 Table 1.2 shows a comparison between the different types of 
existing inhalers. 
Pulmonary drug delivery of controlled release formulations may provide an effective ap-
proach to orally deliver antibiotics for clearing persistent lung infections.  
 




Type of inhaler  Advantages  Disadvantages 
Nebulizers  













Difficult to use 
Use of propellants 
DPI  
Propellant-free 





Complex development and man-
ufacture 
Dose uniformity problems 
 
Although the general reviews do allude to the use of different inhaler devices, we here 
narrow the focus to the recent studies regarding DPIs. For the sake of simplicity, the term nano-
particles will be used to cover either solid nanoparticles, or other biomolecules at the nanoscale.  
Thus, the term ‘nano’ refers to all particulates, droplets or solid particles for which at least one 
dimension is 1-1000 nm. DPIs are at the forefront in the pulmonary delivery technology. They 
overcome problems such as desynchronized dose discharge during the inhalation process as 
they are breath actuated.
30,56
 DPIs are also suitable for delivering a broad range of drugs than 
pMDIs (which used to be the leading application form of inhalation but were surpassed by DPIs 
as they require difficult hand–lung coordination by the patient and use environmentally damag-
ing CFC propellants). Moreover, DPIs can deliver a range of doses from less than 10 µg to more 
than 20 mg via a single inhalation.
56
 Besides listing the marketed nebulizers and pMDIs, Table 
1.3 also displays several types of  DPIs that can be classified as “single-dose” devices, where a 
single dose is provided in a capsule; “multiple unit dose” devices, which contains a small 
amount of doses in capsules or blisters; or “multidose” devices; where the powder is stored in a 
reservoir and the doses are metered.
56,57
 The working principle of a DPI is to deliver a pre-




scribed dose of powder aerosol into air inhaled by the patient during a single breath in a process 
designated ‘fluidization’, preventing the powder from air ambient exposure. The vast majorities 
of fine drug particles are micronized drug blended with large carrier particles which enhance 
flow, reduce aggregation, and assist in dispersion.
40
 Pharmaceutical products to be used in the 
DPI may result in high local levels of drug in epithelial fluid of the airways and lower respirato-
ry tract.
36
 However, the application of drug nanoparticles for pulmonary delivery in DPIs is not 
straightforward, as it was already explained, since the direct inhalation of drug nanoparticles is 
not viable due to their easy aggregation. To overcome this problem, spray drying and, more re-
cently, supercritical fluid-assisted atomization techniques have been used to manufacture large 
composite porous particles or hollow particles composed of nanoparticles aggregates, to be then 
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1.2.3. Particle engineering 
1.2.3.1. Spray drying technique  
Spray drying technique has been extensively applied in the production of dry powder 
formulations due to its simplicity, scale-up, ease of operation and the ability to produce compo-
site materials. In 2010 spray drying was considered as one of the most interesting technologies 
used in the pharmaceutical field.
60
 Appealing to this technology, powders/particles properties 
such as size, morphology, density and level of residual solvent, can be manipulated. This re-
markable feature has led to its application in the formulation of a wide variety of powders or 
advanced solid forms. A wide range of products may be obtained, mainly: very fine powders for 
inhalation to large particles for direct compression, solid dispersions for enhanced bioavailabil-
ity and microcapsules for drug shelter and/or controlled release.
60
 However, spray dryers scale 
up have to be strategically designed so that the quality of the resultant materials is maintained 
and no considerable and expensive losses are exhibited.
60,61
 Spray drying technology is a one 
step process that comprises the atomization of the feed solution into a spray. The solvent in the 
atomized droplet is thermally removed in the spray drying chamber leading to the particles dry-
ing, which are then separated from the air through a cyclone or a filter bag. Typically, polymer-
ic or lipid-based materials are used as carriers to prepare drug loaded nanoparticles in the form 
of suspension, followed by spray drying under specific conditions in order to form large porous 
nanoparticle aggregates with spherical geometry and rough surfaces. However, such technique 
has some disadvantages including the possible degradation of heat sensitive fine particles and 
inefficient yields.
31,32,40,56,62–66
 Spray drying technique has been employed for decades in the 
manufacture of drug microparticles for inhalation therapy. Recently, Jun and colleagues pro-
duced micron-sized spherical agglomerates of pure sodium cromoglicate to improve aerosoliza-
tion performance in dry powder inhalers. Such achievement was accomplished using combined 
technologies as liquid anti-solvent precipitation followed by instant agglomeration of nanoparti-
cles into porous spherical microparticles by spray drying technique. The authors were able to 




1.2.3.2. Supercritical fluid assisted processes 
Supercritical fluid assisted processes have lately emerged as green and innovative alterna-
tives for a wide variety of processes such as: solubility enhancement of poorly soluble drugs, 




chromatographic extraction. An increasing interest regarding this research area has been trig-
gered by the numerous advantages that this technology offers over the conventional methods.
68
 
Supercritical fluids (SCFs) are defined as compressed gases or liquids above their critical pres-
sures and temperatures. SCFs possess central advantages as solvents or antisolvents for pharma-
ceutical manufacturing. Due to its low critical temperature (31.1 C), moderate pressure (7.38 
MPa), inert and environmentally friendly nature, non-flammability and low cost, carbon dioxide 
is the most used fluid under supercritical conditions (scCO2) for pharmaceutical approaches. 
One of the most extraordinary properties of scCO2 in processing nanoparticles is its tunable sol-
vent power that facilitates the extraction and separation of organic solvents allowing the produc-
tion of pure and dry particles or as a pure aqueous suspension, while enabling a clean and recy-
clable precipitation process at very low temperatures. Due to these extensive properties, applica-
tions using SCFs, particularly CO2, have been extensively investigated for respiratory delivery 
applications.
31,36
 There were two main conventional methods for obtaining microparticles using 
scCO2: the Rapid Expansion of Supercritical Solutions (RESS), where the solid material is dis-
solved in CO2 under supercritical conditions, and then the solution is rapidly expanded by low-
ering the pressure, promoting a rapid cooling rate and inducing supersaturation leading to mi-
croparticle formation;
68–72
 and supercritical antisolvent (SAS), where particles are produced 
when a solution is brought into contact with scCO2 in a semi-continuous method. This process 
has the advantage of controlling the physical form of powders by varying the working condi-
tions of temperature, pressure or solution flow rate. However, solvents used in this method must 
be completely miscible in scCO2, which may pose a problem when aqueous solvents are used 
since water is not miscible with scCO2.
32,56,68,72,73
 Particles from Gas Saturated Solutions (PGSS) 
is a scCO2 - assisted process based in two main steps, the first being the saturation of a solute-
containing solution with CO2 in a static mixer, and the second one the mixture’s expansion 
through a nozzle into a spray tower. The CO2 expansion from the resulting droplets leads to an 
atomization, which also happens due to the fast temperature and pressure reduction (Joule-
Thomson effect).
74,75
 Particle formation via polymerization-induced phase separation (PIPS) is a 
process that produces particles by means of a synthesis in a supercritical fluid medium, such as 
polymerization.
76
 Moreover, Supercritical Fluid Extraction of Emulsions (SFEE) uses scCO2 to 
extract the organic phase out of emulsions. Each emulsion droplet allow precipitation, encapsu-
lation or blending resulting in uniform particles.
32
 More recently, the supercritical-assisted spray 
drying (SASD), a process based on the solubilisation of controlled quantities of CO2 into the 
liquid solution has proved to have many advantages over conventional methods. It offers the 
possibility of operating in a continuous mode in mild operating conditions and the ability to use 
both organic and inorganic solvents while providing a good control over particle size and distri-






 Table 1.4 displays the advantages and disadvantages of spray drying technique and 
supercritical CO2 - assisted processes.  
 
Table 1.4-Spray drying vs scCO2.
31,81
  
Technique Advantages Disadvantages 
Spray-drying 
Furthest optimized 
On-step process to produce dry powder 
Control of particles’ properties 
Potential for producing antigenic nanoparti-
cles in-line with the aerosols 
Production of a broad size 
distribution 
Possible degradation of heat 
sensitive drugs 
Inefficient yields 
Supercritical CO2 - as-
sisted processes 
Use of mild conditions 
Efficient solvent extraction 
Clean and environmentally friendly 
Benefic physical properties of the supercriti-
cal fluids 
Narrow particle distribution 
High yields 
Produces successful drug nanoparticles 
Expensive equipment 
High critical pressure 





1.2.4. Design of nano-in-micro dry powder formulations 
As already mentioned, nanoparticles are unique carrier platforms of proteins and other 
macromolecules for pulmonary delivery due to their capacity to penetrate into intracellular 
compartments and the possibility of avoiding macrophages’ phagocytosis from increasing the 
carrier’s residence time in the lung therefore allowing a sustained drug release.
29,82
  
For DPI formulation, nanoparticles have been designed to reduce the interparticle attrac-
tion forces and to improve the DPI blending with carrier materials, forming Trojan, strawberry 
and nanoparticles aggregates (particles with nano-features).
52
 To be therapeutically effective, 
microparticles must readily dissociate into the primary nanoparticles in an aqueous medium 
without significant destruction on the delivery advantages associated with the nanoparticulate 
systems.
19
 Inhalable powders have to fulfill certain requirements; the increase of the respirable 
fraction with a decreasing average particle diameter is a fundamental matter of fact.
20
 The gen-
eral assumption is that particles smaller than 5 µm are not deposited in the upper airways but are 
able to penetrate into the lung. Systemically effective drugs which have to attain the alveoli, 
should even have a mass median aerodynamic diameter of less than 2 µm.
21
 To overcome these 
issues, the nanoparticles can be microencapsulated in order to improve their aerodynamic prop-
erties and stability and so, produce suitable lung delivery particles. Table 1.5 and Figure 1.2 
display the most promising nano-in-microparticles already developed.  
 
 
Figure 1.2-Nanoparticle-based dry powders for inhalation: 1 – Trojan particles; 2 – Strawberry 
particles; 3 – Particles with nanofeatures. 
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Table 1.5-Nano-in-micro formulations 















   Rifampicin PLGA/L-leucine 4.2
84
 
   Octreotide acetate n.a. 5.7
85
 
  Particles with nanofeatures Human IgG PLGA/lactose 4.2
86
 
   Clarythromycin PLGA/L-Leucine 5.3-8.9
87
 
   Thymopentin Mannitol/L-Leucine 4.1
19
 

















   Terbutaline sulphate Lactose 3.2 – 3.4
90
 
   Deslorelin-HPβCD PLGA 2.2/ 13.8
91
 
   pDNA Chitosan 12.2-13.2
92
 










1.2.4.1 Trojan particles 
Trojan particles are micron-sized Large Porous Particles (LPPS) that get deposit in the 
lungs thanks to their aerosolization and physical properties and then dissociate to the primary 
nanoparticles, avoiding phagocytosis and taking advantage of its drug delivery properties. 
Tsapis and coworkers produced large porous nanoparticles composed of dipalmitoylphosphati-
dylcholine (DPPC), dimyristoylphosphatidylethanolamine (DMPE) and lactose using spray dry-
ing, which allows the control of the drying time of the droplet avoiding nanoparticle diffusion. 
By measuring the geometric and aerodynamic diameter they noticed that the LPPs properties 
and the Fine Particle Fraction (FPF) improved when the nanoparticles were encapsulated.
83
  
Sung and coworkers formulated a dry powder for the treatment of tuberculosis by encap-
sulating rifampicin in PLGA nanoparticles and then spray dried into porous nanoparticle-
aggregate particle (PNAPs) with L-leucine. Experiments showed that the particles have both 
systemic deliver and long levels of drug for up to eight hours.
84
  
More recently, the spray freeze drying method was used to produce PNAPs containing a 
model peptide, octreotide acetate. When peptides are used in the process, temperature becomes 
a concern, which made this group to deviate from the conventional spray drying process to keep 
the model peptide active. The in vivo experiments showed higher levels of plasma aspartate 
amino-transferase when in comparison with delivery through subcutaneous injection. To im-
prove the encapsulation efficacy and the drug loading, hydrophobic ion pair complexes was 
used.
85
 Some examples of scanning electron microscopy (SEM) images of Trojan microparticles 
are depicted in Figure 1.3. 





Figure 1.3-SEM pictures of a representative panel of Trojan microparticles reported in literature: 
A) Reproduced with the permission of Elsevier:
93
 spray dried microparticles prepared with DPPC, hyalu-
ronic acid (HA) and PLGA nanoparticles; B) Reproduced with the permission of Elsevier:
94
 spray dried 
microparticles prepared with DPPC and PMMA-methoxy(polyethylene glycol)methacrylate (MeOPEG-
Ma) nanoparticles; C) Reproduced with the permission of Elsevier:
29
 spray dried microparticles prepared 
with mannitol and chitosan/TPP nanoparticles; D) Reproduced with the permission of Elsevier:
95
 micro-
particles prepared with colloidal silicon dioxide as drying auxiliary and oily-core PCL nanocapsules. 
 
1.2.4.2 Particles with nanofeatures 
Even though Trojan particles have shown some success, there are some drawbacks when 
it comes to the preservation of the particles integrity and their aerodynamic properties due to 
drying process of the NPs suspension. Another type of particles produced are the nano-
embedded microparticles that consist of micro-encapsulated drug-loaded NPs, which excipient 
is degraded when they reach the deep lung, releasing the nanoparticles.
82
  
Lately, polymeric nanoparticles production has been growing once its effectiveness in 
sustained release and high drug capacity has been shown. One of the most used polymers is 
PLGA (polylactil-glycol acid) because of its biodegrability and biocompability, and also for its 
long clinical evidence.
96
 Besides, it is used in a host of Food and Drug Administration (FDA)-
approved therapeutic devices and has a long safety record.
97
 Another common polymer is chi-
tosan, a polysaccharide biopolymer which has a high interest due to its low toxicity, biocompa-
bility, biodegradability and mucoadhesive properties.
29,98
 As for the inert excipients, sugars are 






 Mannitol is said to be advantageous comparing to lactose because it has 
less hygroscopicity, no reducing effect and it is also nontoxic.
19,98
 On the other hand, lactose is 
the only FDA-approved sugar carrier for dry powder aerosol formulations.
100
 Some nano-in-
microparticles were developed by co-spray-drying the nanoparticles with bulking agents and 
dispersibility enhancers, such as L-leucine, a nontoxic and nonirritant amino acid, known to im-
prove flowability and dispersibility.
101,102
 For instance, Kaye and colleagues produced nano-in-
micro particles aimed for antibody delivery in the lungs by SIMANIM (Simultaneously Manu-
factured Nano-in-Micro).
86
 A double-emulsion containing human IgG, lactose, PLGA and 
DPPC was spray-dried, leading to lactose microparticles loaded with PLGA nanoparticles, 
where the antibody was released for 35 days in a pH 2.5 media and was stable and active. With 
the addition of L-leucine the fine particle fraction improved from 37 % to 52 %, which was also 
concluded by Moghaddam and co-workers that spray-dried Clarythromycin-encapsulated PLGA 
nanoparticles with L-leucine to treat lung infections such as pseudomonas aeruginosa.
87
 The 
resulting micro-carriers had diameters between 5.3 to 8.9 μm and the presence of L-leucine 
showed improvements in yield and in FPF since it reduced the particles cohesiveness. Li and 
coworkers produced thymopentin-loaded solid lipid nanoparticles encapsulated in manni-
tol/leucine microparticles. From in vitro and in vivo studies it was shown that the mannitol pro-
vided protection to the peptide, which had a strong therapeutic effect, since the layer formed 
around the nanoparticles avoids lipids coalescence. Also the moisture sorption and surface ten-
sion diminished thanks to the presence of L-leucine.
19
  
Al-Qadi and colleagues developed microencapsulated chitosan nanoparticles for pulmo-
nary protein delivery, by co-spray-drying them with mannitol. The resulting microspheres have 
a mean diameter of 2.5 and 2.8 μm and quantitive analyses of hypoglycemic effect and lung 
distribution studies showed that this delivery system gets to the deep lung and releases insulin in 
its bioactive form.
29
 Even though spray-drying is the conventional technique to produce dry 
powders, the use of supercritical CO2 has been growing over the years. An example is the su-
percritical antisolvent technique, used by Chattopadhyay and collaborators to coprecipitate 
poly(methyl methacylate) (PMMA),  PLGA and Eudragit RS with a suspension of magnetite 
nanoparticles. This magnetic property of the particles allows a specific targeting due to the at-
tractive forces with the magnetic field applied to the target site. It was observed a slight differ-









1.2.4.3  Strawberry particles 
This particle designation first appeared during the 2005 Aerosol Society meeting and it is 
associated with micro-carriers coated with active nanoparticles connected via physical absorp-
tion.
52
 This formulation is advantageous because the use of micronized drug blended with larger 
carrier helps flow and prevents aggregation.
53
 Once the coated nanoparticles work as spacers 
between the microparticles, the adhesion between them is diminished, making the handling eas-
ier. The coating process can be done by electrostatic forces, where the different size particles 
have opposite charges, avoiding aggregation between themselves and only with each other.
103
 
There are also capillary and van der Waals forces and mechanical interlocking responsible for 
particle-particle and particle-surface interactions. Usually, lactose particles are the chosen carri-
er because, besides all the advantages already mentioned, their large size, when the airflow is 
introduced, allow the generation of primary drug particles that can then be carried until the deep 
lungs while the carrier impacts in the oropharynx and is cleared.
20,53
 It is also possible to nano-
coat proteins in micro-carriers using an ultrasound technique. Genina and associates used β-
galactosidase and lactose to produce appropriated pharmaceutical formulations for lactose intol-
erant patients and measured the proteins quantity in the surface by its enzymatic reaction prod-




1.2.5. Characterization of inhaled particles 
Upon testing a formulation for future lung delivery there are several parameters that 
should be confirmed, such as its safety, efficacy and quality.
104
 To address these features, there 
are specific characterizations that need to be carefully addressed. In this review, the most im-
portant evaluations are described. One of the most important features is the particle size diame-
ter, which must be known to evaluate the aerodynamic diameter (dae). The dae of a particle is 
defined as ‘the diameter of a sphere with an unit density that has the same terminal settling ve-




  Equation 1.1 
where 𝜌𝑝 is the particle mass density, 𝜌𝑜 is the unit density and x, the particle dynamic 
shape factor. Such factor is also defined as the ratio of the drag force of the particle to that of a 
sphere of equivalent volume. From this equation it is possible to verify that the dae. can be re-
duced by decreasing particle size or density, or by increasing the dynamic shape factor.
58
 Both 




sis and methods that use geometric features and physicochemical properties.
53,101
 In the other 
hand, by means of an in vitro aerosolization study using a multistage cascade impactor, it is 
possible to obtain the MMAD, which is determined as the particle diameter corresponding to 50 
% of the cumulative distribution and to find the fraction of emitted dose (ED%) that reach the 
deep lung. The fine particle fraction is the mass of particles under a certain cut-off diameter, 
usually around 5 μm, with reference to the emitted dose, i.e the particles proportion to exit the 
inhaler and which can also be determined using a Dosage Unit Sampling Apparatus (DUSA).
6,32
  
The selection of the optimal solid form is a crucial aspect upon the development of phar-
maceutical compounds, due to their ability to exist in more than one form or crystal structure 
(polymorphism). These polymorphs show different physical properties which affect their bio-
pharmaceutical properties.
104
 Solid state analyses are often used to guarantee both safety and 
efficacy of drugs or pharmaceutical compounds and to validate the control of the pharmaceuti-
cal manufacture process.
105
 X-ray power diffraction (XRD) is one of the most used techniques 
to attest the solid state of a formulation and it is used to define the intermolecular spacing of the 
unit cell, which defines a crystalline system. For lung delivery applications, it is important to 
have an amorphous carrier, not only for storage proposes, but because it also increases dissolu-
tion rate and it has high water adsorption capacity.  In the other hand, the Active Pharmaceutical 
Ingredient (API) is usually preferred in a crystalline form, since it maintains the bioavailablility 
of the drug, maximizing its efficiency and minimizing the required dosage.
20,32,53,106
 
 The dry powders’ properties and performance in the lungs can be determined by in vitro 
studies that can match the regulatory body criteria, even though in vivo events such as lung dep-
osition and pulmonary pharmacokinetics are difficult to experimentally test. The in vitro exper-
iments for inhalation particles use lung epithelial cell models which have the advantages of be-
ing simpler, more controllable and cheaper than the in vivo approach. The main goal is to de-
termine the transepithelial transport kinetics of test molecules in order to compare it with in vivo 
lung absorption.
107
 However, cell cultures used in in vitro studies do not provide an accurate 
correlation with in vivo absorption and also present limitations in absorption kinetic studies, 
making ex vivo studies preferable since, despite the limitations, they can reproduce the kinetics 
region of the lung-region absorption. Moreover, ex vivo models allow for a complete study of  
most of cell types involved in the lung tissue.
108
 Isolated perfused lung model, where the lung is 
outside the body, is commonly used as an ex vivo model. Even though the environment is artifi-
cial, the lung tissue keeps its architecture and functionality. The organ is maintained at a specif-
ic temperature and pressure and it is pumped with perfusate while the drug is delivered by the 
tracheal port. In order to obtain the rate of absorption the perfusate is sampled.
107,108
 Notwith-




standing, in vivo methods enables the direct acquisition of pharmacokinetic data from lung tis-
sue of live animals, usually small rodents, even though in this type of study, larger animals such 
as dogs, sheep or monkeys are more appropriate.
107
 Gamma scintigraphy is an in vivo non-
invasive imaging technique that uses radiopharmaceuticals that localize in different organs and 
are visualized in a gamma camera to determine drug delivery precisely, by giving a measure-
ment of the local bioavailability through the lung. The results obtained are an accurate percent-




1.3. CLINICAL TRIALS 
Unlike other delivery systems, the current excipients approved by the Food and Drug 
Administration (FDA) are very limited and not accepted worldwide. Such issue renders some 




In 2007, Rogueda and Traini published a review paper about the delivery of nanoparticles 
through pulmonary routes. At that time, publications were scarce, only one patent regarding 
DPI’s and covering sizes below 500 nm was available, and there were no available products on 
the market for the delivery of nanoparticles using DPI.
52
 The FDA approved the use of insulin 
DPIs (Exubera, Pfizer) in 2006, to treat patients with type 1 and type 2 diabetes, which was a 
major breakthrough for research in DPIs.
109,110
 However, one year later this product was re-
moved from the market due to some uncertainties over patient compliance and long-term safe-
ty.
110,111
 As the time goes by, Nolan and co-workers reported in 2011 an excipient free formula-
tion approach of making sodium cromoglicate, an antiasthmatic and anti-allergenic drug whose 
use in a DPI was firstly reported in 1998 into spherical nanoporous microparticles via spray dry-
ing technique.
112,113
 The results obtained by this group showed improved aerodynamic proper-
ties comparing to the drug by itself demonstrating that porosity and sphericity of drug particles 
are preponderant features to enhance aerosol deposition.
16,113
 Further optimization, regarding the 
aerodynamic properties, was achieved by Hu and collaborators by coupling continuous liquid 
solvent precipitation with immediate spray drying. Spherical agglomerates of pure drug nano-
particles were achieved with sizes more suitable for pulmonary delivery (4.46 ± 0.14 µm), thus 
increasing the FPF in approximately 50 %.
16
 
More recently, Nanotherapeutics Inc., challenged the National Institute of Allergy and In-
fectious Diseases (NIAD) to produce an inhaled version of the injectable antiviral drug Cidofo-




opment of inhaled Cidofovir could decrease the amount of people that are still vulnerable to 
smallpox due to their inability to be vaccinated. Several studies have already proved that this 
new respirable formulation of Cidofovir is very efficient against multiple pox models, when 
compared to injectable administration. In turn, increases the amount of powder retained in the 
pulmonary level and, quite possibly avoids nephrotoxicity (so far caused by the injectable 
form). Amazingly, the use of gold nanoshells to deliver such drug, as already started in human 
models.
40
 Table 1.6 summarizes the more recent ongoing clinical trials on dry powder formula-
tions for a wide range of pulmonary diseases. The listed dry powder formulations under clinical 
trials comprise crystalline and/or amorphous APIs blended in excipients of, for example, phos-
pholipid, monosaccharides, disaccharides, polysaccharides, additols, and surfactants such as 
oleic acid and 1,2 distearoyl-sn-glycero-3-phosphocholine (DSCP). These formulations could 
be classified as particles with nanofeatures. 
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Table 1.6-Clinical trials using dry powder formulations for a wide variety of pulmonary diseases. 
Clinical Trials Condition/ Drug Formulation/production MMAD(μm)/FPF Sponsor Status 
A Twelve Month Long Term Safety 
Study to Evaluate the Safety of Al-
buterol in a Dry Powder Inhaler 




surfactant (e.g. oleic ac-
id)/Milling 





Pharmacokinetic Evaluation and 
Tolerability of Dry Pow-
der Tobramycin by a Novel Device 
in Patients With Non Cystic Fibro-
sis Bronchiectasis 
Bronchiectasis/Tobramycin 









A clinical trial to access the safety 
of a measles vaccine (dry powder) 
administered by two different de-
vices (PMV-001) 








Serum Institute of 
India Limited 
Completed 
To determine the relationship be-
tween baseline reversibility and the 
efficacy of indacaterol (REVER-
BREZ) 
Chronic Obstructive Pulmo-












Ciprofloxacin Dry Powder for Inhala-
tion in Non-
cystic Fibrosis Bronchiectasis (Non-
CF BE) (RESPIRE 1) 
Bronchiectas/Ciprofloxacin n.a. n.a. Bayer Recruiting 
Sensitivity of Pharmacokinetics to 





tals/ anti-solvent process 
5.1-6.7/ n.a. 
 
University of Florida Recruiting 
n.a. – not available 
 





The present review has highlighted the current status as well as the major benefits and 
limitations of the already existing and the under development formulations for ‘dry powder in-
halers’. Particle engineering is a fresh and in vogue area that combines chemical engineering, 
biopharmaceuticals, biology, formulation science, colloid and interface science, solid state 
physics, aerosol and powder science and nanotechnology. Nanoparticulated systems have been 
showing a huge potential in the delivery of biological active substances. Recent progresses in 
aerosol formulations have led to the development of more efficient delivery systems able to 
produce small particle aerosols (nano-in-micro formulations) allowing higher powders deposi-
tion in the alveoli and deep lung region. The combination of nanotechnology and pulmonary 
delivery of aerosolizable drugs brings out new and exciting breakthroughs for the diagnosis and 
therapy of several types of lung and systemic diseases.  
Particle engineering requires a deeper understanding of particle formation processes. A 
wide range of research experts from different but complementary areas, are already working in 
the design of safe and effective formulations to make these therapies safer and more effective. A 
detailed research in the possible combination of nano-in-micro dry powder formulations making 
use of spray drying and/or supercritical assisted-atomization is behind the scope of this review.  
It is well-known that the new class of engineered spray dried particles and more specifi-
cally SASD formulations will definitely cause a shift in the thinking and structure of pharma-
ceutical organizations developing them. Although this type of research appears to be promising 
in lung disease therapeutics, some difficulties still need to be overcome before the potential for 
wide public use may be appreciated. The fate and effect of the particles, specifically the nano-
particles release from the micro platforms, needs to be fully understood before clinical trials 
may be performed. Safety and efficacy must be assured and optimization processes must be 
guaranteed so that large scale manufacturing processes can be achieved, reducing costs and 
waste materials. Despite the plentiful advantages and applications of supercritical fluid technol-
ogy, there is still room for improvement in the pharmaceutical industry. The influence of operat-
ing parameters on particle size and its morphology needs to be completely discerned. Potential 
efforts must be performed to defeat these challenges, as supercritical fluid technology has added 
a totally new dimension to the pharmaceutical research and formulation development. Moreo-
ver, successful design of engineered particles requires a thorough understanding and predictive 
modelling, so that the early development process can be completed in an acceptable time with a 




These are definitely the ultimate goals for the successful production and approval of dry 
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Gold nanoparticles (AuNPs) are the most investigated nanomaterials for theragnosis ap-
plications. In a research field where live cell assays, as well as the tracking of nanomaterials 
into cell’s environment, are of extremely importance, water-soluble AuNPs have been inten-
sively studied to overcome the toxic effects exerted by coatings. Unfortunately, AuNPs fluores-
cent tagging often fails due to self-quenching and a careful design must be carried out to keep 
optoelectronic properties and biocompatibility. In this work, the synthesis of fluorescent gold 
nanoprobes, able to enter within cell’s environment (biotags) and target the cell nucleus, was 
designed and the particles tracked by confocal laser scanning microscopy. The coating of 
AuNPs with maleimide poly(ethylene glycol) and fluorescent oligoaziridine biocompatible oli-
gomers, resulted in robust, optical active biotags that open novel insights into cancer theragno-
sis. 
 
2.2. INTRODUCTION  
Cellular internalization and nuclear targeting are two subsequent and challenging tasks 
that have been increasingly investigated over the past decades. The cell nucleus is the place 
where the genetic information and transcription machinery of the cell can be encountered and, 
therefore, its targeting has been demonstrated to be crucial for several diagnostic and therapeu-
tic purposes.
114
 In such targeting attempts, different types of nanoparticles (metallic, magnetic 
or polymeric) have been introduced into the cells environment.
115–118
 Particularly, gold nanopar-
ticles have been widely studied in the field of nanomedicine for theranostic aspirations. These 
nanomaterials display interesting optical, electronic, and molecular-recognition properties not 
shown by bulk gold.
12,24,119,120
 They are easily reproducible in a wide variety of shapes and sizes, 
and can be functionalized to perform specific functions, through the attachment of biologically 
active molecules, targeting sequences, imaging devices and biocompatible coatings.
121,122
  
The targeting of fluorescent agents to cells and tissues by using AuNPs has emerged as a 
main focus in cancer research since nonspecific toxicity can be minimized and transportation 
efficiency can be enhanced.
123–127
 However, AuNPs are well known to self-quench upon surface 
fluorescent tagging. Notwithstanding, under certain conditions, the fluorescence can be en-
hanced by the near-field of AuNPs, which is a subject of considerable interest.
13,128,129
 Aiming 
the development of robust gold biotags, able to target the cells environment, and ultimately the 




glycol) (PEG) and a fluorescent water-soluble oligoaziridine (OA). Although OA, was already 
investigated as a biosensor for fluorescence microscopic imaging of metal cations under physio-
logical conditions,
130
 we now demonstrate its efficient biotagging performance. To foster inter-
nalization features, while guarantying nanoparticle stability and avoiding unspecific interac-
tions, a biocompatible coating based on homobifunctional maleimide poly(ethylene glycol) 




Using a convergent strategy we were able to synthesize stable PEG-oligoaziridine fluo-
rescent water-soluble bilayered AuNPs through a simple and straightforward route. The cellular 
uptake of these novel gold nanoparticles was followed through fluorescence microscopy and 
their biocompatible profile was assured through the MTS assay. Morphological and spectral 
characterizations were also performed. 
 
2.3. EXPERIMENTAL PROCEDURES 
2.3.1 Materials 
A549 non-small lung carcinoma cell line was purchased from ATCC. Sodium azide was 
acquired from Amresco. Fetal bovine serum (FBS) was purchased from Biochrom AG. Tris 
Base was obtained from Fisher Scientific. CellLight® Actin-GFP, BacMam 2.0 (GFP) was at-
tained from Invitrogen, Life Technologies. Glass bottom dishes were dispensed by MatTek 
Corporation. Maleimide-PEG-Maleimide (MPM, Mw= 3.4 KDa) was bought from NANOCS. 
Amphotericin B, collagen solution, ethanol (EtOH), glutaraldehyde, Ham’s Nutrient Mixture-
F12, L-glutamine, penicillin G, phosphate-buffered saline (PBS), streptomycin, tetrachloroauric 
(III) acid (HAuCl4.3H2O), 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium reagent MTS, trisodium citrate and trypsin were purchased from 




2.3.2 Synthesis of gold nanoparticles 
The synthesis followed the Frens method.
135
 Briefly, 100 mL of 0.01 % (w/v) 
HAuCl4.3H2O were heated until reflux. Then, 1mL of trisodium citrate hydrate, 1 % (w/v) was 
added to the refluxing solution under constant stirring. After 25 sec, the slightly yellow solution 
turned faintly blue. Subsequently, the solution color changed to dark red, which was indicative 




of the formation of monodisperse spherical particles. The solution was boiled for more 5 min to 
allow the complete reduction of the gold chloride. The AuNPs obtained were then supplemented 
with 0.05 % (w/v) sodium azide and stored at 4 C. Gold nanoparticles produced by this method 
are referred as AuNPs. UV-Vis: max= 525 nm. IR (film)  (cm
-1
): 1575 (C=O), 1393 (COO), 
1078 (CO).  
2.3.3 Coating of gold nanoparticles with the oligoaziridine biosensor 
Different molar ratios of oligoaziridine (100:1, 500:1, 750:1, 1250:1, 2500:1, 5000:1) 
were added to the colloidal solution of AuNPs and vortexed at low speed, during 2 min. The 
samples were then ultracentrifuged at 14500 x g, during 20 min, at room temperature. The su-
pernatant was then removed and the pellet was redispersed in deionized water for all the subse-
quent tests. The nanoparticles produced by this method are denoted as Au-OA. Oligoaziridine 
biosensor: UV-Vis: max= 370 nm. IR (film)  (cm
-1
): 1658 (C=C), 1362 (S=O), 1156 (S=O), 
1038. Au-OA biotag: UV-Vis: max= 525 nm. IR (film)  (cm
-1
): 1650 (C=C), 1362 (S=O), 
1148 cm
-1
 (S=O), 1030, 1077. 
 
2.3.4 Coating of gold nanoparticles with homobifunctional maleimide 
poly(ethylene) glycol 
The AuNPs produced according to the Frens method were capped with MPM and are de-
noted as Au-MPM. Different ratios of MPM (PEG:AuNPs) (500:1, 750:1, 1250:1, 2500:1, 
5000:1, 10000:1) were added to 10 mL of AuNPs colloidal solution. The mixture was allowed 
to react for one hour under stirring.
134
 Afterwards, the reaction mixture was collected to 1.5 mL 
eppendorfs and centrifuged at 13500 x g, for 20 min at room temperature. The supernatant was 
removed and the pellet was redispersed in Tris buffer (pH 7.4) and stored at 4 C, until further 
use. Au-MPM biotag: UV-Vis: max= 525 nm; IR (film)  (cm
-1
): 1629 (C=O), 1552 (COO), 
1296 (CN), 1137 (COC); 1050, 1036. 
 
2.3.5 Coating of Au-MPM with oligoaziridine biosensor 
The oligoaziridine biosensor was also added to Au-MPM and the samples were ultracen-
trifuged using the protocol above described. The samples were then re-suspended in water and, 
again, different molar ratios of OA biosensor were added (100:1, 500:1, 750:1, 1250:1, 2500:1, 




for 20 min. The supernatant was removed and the pellet was redispersed in deionized water for 
subsequent analyses. The nanoparticles produced with this procedure are designated by Au-
MPM-OA biotag. UV-Vis: max= 525 nm. IR (film)  (cm
-1
): 1650 (C=C), 1635 (C=O), 1362 
(S=O), 1148 (S=O); 1030, 1077. 
2.3.6 Biotags properties and characterization 
The morphology of the nanoparticles was analyzed by Transmission Electron microscopy 
(TEM). Samples were visualized and recorded using Hitachi H8100 TEM itch ThermoNoran 
light elements EDS detector and digital image acquisition. Nanoparticle’s size was determined 
by dynamic light scattering (DLS). Briefly, nanoparticles were diluted in 800 μL of ultrapure 
water.
136
 Size measurements were then performed in a nano partica SZ-100 series instrument 
from Horiba scientific, in automatic mode and with a scattered light detection angle of 90°. Zeta 
potential quantification was carried out in the same nano partica SZ-100 series Horiba instru-
ment using a zeta dip cell with a scattered light detection angle of 173°. Thermogravimetric 
analysis (TGA) was performed on a TGA-DSC–STA 449 F3. Samples, previously lyophilized, 
were placed in platinum sample pans and heated under an argon atmosphere at a rate of 10 




2.3.7 Biotags spectral properties 
FTIR spectra were recorded in a Nicoletis 20 spectrophotometer (64 scans) from Thermo 
Scientific equipped with a Smart iTR auxiliary module. Fluorimetry assays were performed in a 
Perkinelmer LS 45 Luminescence Spectrometer. UV-Vis spectroscopy was recorded in an Infi-
nite 200 from Tecan using a Corning 384 Flat Bottom Black Polystyrene Low Volume/Flat mi-
croplate, kindly provided by Corning Corporation. The test was performed in a scan method 
from 260 to 700 nm. 
 
2.3.8 Cell culture and biotags transfection 
Cell culture experiments were performed using of A549 cell line. Cells were cultured in 
Ham’s Nutrient Mixture-F12 medium supplemented with 10 % v/v heat-inactivated FBS and 
antibiotic-antimycotic (penincilin G (100 U/mL)), spectromycin G (100 µg/mL) at 37C, under 
5 % CO2 humidified atmosphere. In vitro transfection studies were carried out by seeding cells 
in glass bottom dishes, dispensed by MatTek Corporation , at a density of 12x10
3
 cells per well, 




with 1 mL of Ham’s F12K medium supplemented with 10 % FBS without antibiotic for 24 h.
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Nanoparticles were lyophilized, sterilized, resuspended in Ham’s F12K medium (2 mg/mL) and 
filtered with a syringe and a filter with a membrane pore of 200 nm, before being added to the 
cells. Cell’s transfection with all types of nanoparticles herein produced was performed and was 
stopped over 4 h, by exchanging the culture medium by a complete Ham’s F12K medium. Sub-
sequently, cell growth was monitored using an Olympus CX14 inverted light microscope 
equipped with an Olympus SP-500 UZ digital camera. This last procedure was repeated for 2 
days. 
2.3.9 Fluorescence and Confocal Laser Scanning Microscopy 
 In order to evaluate the ability of nanoparticles to enter into the cells environment with-
out losing their electronic properties, both fluorescence and confocal laser microscopy assays 
were performed after in vitro transfection. First, the glass bottom dishes containing transfected 
live cells were visualized using a Zeiss AX10 microscope (Carl Zeiss SMT Inc.) and analyzed 
with Axio Vision Real 4.6 software. Formerly, the cells cytoplasm was marked with CellLight® 
Actin-GFP, BacMam 2.0 (GFP), and then, confocal images were obtained with a Zeiss LSM 
710 laser scanning confocal microscope (Carl Zeiss SMT Inc.) equipped with a plane-
apocromat 40x/DIC objective. Data analysis of Confocal Laser Scanning Microscopy (CLSM) 
images was performed with Zeiss software (Axio Vs40 V4.5) and Imaris Bitplane (Vs7.6.1 Bit-
plane). 
 
2.3.10 Evaluation of the biotags cytotoxic profile 
An MTS assay was performed to evaluate nanoparticles biocompatibility according to the 
manufacturer instructions. Twenty four hours prior to the experiment the cells were seeded at a 
density of 12x10
3
 cells per well into 96-well plates with 200 μL of cell culture medium supple-
mented with 10 % FBS, without antibiotics. The cells were then incubated with nanoparticles 
formulations for 24 and 48 hours. All the formulations of nanoparticles were resuspended in 
pre-warmed culture medium containing 10 % FBS and then added to each well. A total of three 
replicates were considered for each formulation. The absorbance of the samples was measured 
at 492 nm using a microplate reader Anthos 2010. Wells containing cells in the culture medium 
without materials were used as negative control. Ethanol (EtOH) 96 % was added to wells con-






2.4. RESULTS AND DISCUSSION  
2.4.1 Particles synthesis and characterization 
The particle design aimed the construction of bilayered, biocompatible and optical active 
gold nanoparticles. The first layer (PEG oligomer) was assembled into the AuNPs by the reac-
tion of the alcohol from citrate with the MAL-PEG-MAL homobifunctional oligomer (Au-





 and the successful AuNPs PEGylation led us to conclude that indeed AuNPs 
(synthesized using a Au
3+
 precursor), must be involved in this step. Next, a second layer (OA 
fluorescent oligomer) was added by reacting OA with the terminal maleimide from Au-MPM 
(Au-MPM-OA). Following this strategy (see schematic synthesis in Figure 2.1) we were able to 
synthesize stable nanogold biotags avoiding elaborated synthesis and purification. 
The MPM coating was confirmed by FTIR- ATR through the presence of the characteris-
tic (slightly shifted) ether bands (1552, 1296, and 1137 cm
-1
) (Figure 2.1A). Similarly, the OA 
coating was confirmed by the presence of sulfonamide bands (1658, 1362 and 1156 cm
-1
) 
(Figure 2.1B). As expected, in the final formulation Au-MPM-OA, both bands from MPM and 
OA were identified (1650, 1362 and 1148 cm
-1
), thus proofing the successful reaction between 
Au-MPM and OA.  
After the synthesis different nanogold formulations were developed. The influence of OA 
(fluorescent biosensor) and PEG oligomers on the particles morphology and size was investi-
gated using different molar ratios of OA and MPM (100:1, 500:1, 750:1, 1250:1, 2500:1, 
5000:1, 10000:1),
139
 leading to the production of Au-OA, Au-MPM and Au-MPM-OA formula-
tions. 
 





Figure 2.1-PEG-oligoaziridine bilayer coating of gold nanoparticles schematic synthesis (top) 
and the corresponding IR spectra (bottom) of (A) Au-MPM, (B) Au-OA; and (C) Au-MPM-OA. 
 
The nanoparticles morphology was assessed by TEM. We found that the best molar ratios 
for OA:AuNPs and MPM:AuNPs  were 750:1 and 5000:1, respectively. The produced biotags 





Figure 2.2-TEM images of the biotags (A) gold nanoparticles, (B) gold nanoparticles coated with 
oligoaziridine (Au-OA), (C) gold nanoparticles coated with MPM (Au-MPM) and (D) PEGylated gold 
nanoparticles coated with oligoaziridine (Au-MPM-OA). The insets show size measurements performed 
using the Image J software. 
 
The nanoparticles were also characterized in terms of their ability to form stable colloidal 
formulations with appropriate physicochemical properties for intracellular applications. Dynam-
ic light scattering was also performed to evaluate the nanoparticles size, and similar values were 
obtained using both methods. All formulations exhibited sizes well-suited for delivery into tu-
moral microenvironments. As expected, the AuNPs show sizes around 30 nm and a zeta poten-
tial of approximately -30 mV.
125,135
 (see Figure 2.2A and Table 2.1) After coating with OA, the 
zeta potential tends to became positive, thus favoring cellular internalization due to electrostatic 
interaction between negatively charged proteoglycans and positively charged nanoparticles.
136
 
Our data showed that all the produced formulations have positive zeta potential values within 
the range of colloidal stability (between -40 to +40 mV). 
  




Table 2.1-Particle size and zeta potential data for nanogold PEG-oligoaziridine coatings. 
Nanoparticles Particle size (nm) PDI Zeta potential (mV) 
AuNP 28±1 0.369 -34±4 
Au-OA
a 
30.7±0.5 0.371 18±1 
Au-MPM
a 
28.4 0.379 -31±4 
Au-MPM-OA
b
 28±1.5 0.396 20.4±2 
aAu-MPM/OA biosensor 5000:1 ratio. 
bAu-MPM/OA biosensor 750:1 ratio. 
 
The amount of organic components on the AuNPs was assessed by thermal gravimetric 
analysis (TGA) (Figure A.1, Appendix A). The total mass loss was 6.67 %, 6.11 % and 4 % for 
Au-MPM, Au-OA and Au-MPM-OA, respectively. By combining the data from TGA and In-
ductively Coupled Plasma (ICP) analyses, the amount of Au and S in the nanoparticles was de-
termined (see calculations in Appendix A) thus confirming a bilayered architecture (MPM/OA 
1:1 ratio). The synthesized bilayered nanogolds showed a high colloidal stability that was cor-
roborated by UV-Visible spectroscopy (Figure 2.3A) and by colorimetric analyses (Figure 
2.3B). By comparing the absorbance intensity of the characteristic band of AuNPs (spectrum 1 
in Figure 2.3A, max = 526 nm) of the formulations, we found that all coatings lower the inten-
sity of this band (more significantly in case of Au-OA, spectrum 3 in Figure 2.3A). However, 
for the formulation Au-MPM-OA (750:1 ratio) the intensity is recovered (spectrum 8 in Figure 
2.3A), demonstrating a synergistic effect between MPM and OA layers. For higher ratios 






Figure 2.3-Colloidal stability of the biotags: (A) UV-Vis spectra and (B) colorimetric evaluation: 
(1) AuNPs, (2) Au-OA 2500:1, (3) Au-OA 1250:1, (4) Au-OA 750:1, (5) Au-MPM, (6) Au-MPM-OA 
2500:1, (7) Au-MPM-OA 1250:1, (8) Au-MPM-OA 750:1. 
 
The optical properties of the biotags were evaluated in aqueous media. Interestingly, bio-
tags coating with OA leads to optical active nanoparticles, thus avoiding self-quenching events 
(Figure A.2, Appendix A). 
2.4.2 Qualitative evaluation of biotags cellular uptake 
In the present study, the A549 cell line was used as a model to study the cellular uptake 
of the OA biosensor, Au-OA and Au-MPM-OA nanogold formulations. Also an evaluation of 
the produced biotags was performed to conclude about their suitability for cell live imaging ap-
plications using microscopic fluorescence. Fluorescence (Figure 2.4) and CLSM (Figure 2.5) 
gave insights on cell internalization, without requiring any auxiliary reagents to ‘force’ their 
entry. The fluorescence images show that the OA biosensor (Figure 2.4A), as well as the syn-
thesized nanogolds, Au-OA (Figure 2.4B) and Au-MPM-OA (Figure 2.4C), were able to enter 
into the cells environment. It should be stressed out that all of the images regarding internaliza-
tion studies were taken with the same color ranges and contrast features. 
 





Figure 2.4-Fluorescence images of A549 cells transfected with (A) an oligoaziridine biosensor, 
(B) Au-OA and (C) Au-MPM-OA biotags. Original magnification x63. 
 
CLSM images showing intracellular localization of Au-OA and Au-MPM-OA are dis-
played in Figure 2.5A and Figure 2.5B, respectively. These images show that biotags are locat-
ed both within cell cytoplasm and nucleus, clearly demonstrating their potential application as 
imaging agent and/or as drug delivery agents when loaded with anti-cancer drugs. The high cel-
lular internalization verified for both nanogold formulations can be easily rationalized from 
their physico-chemical properties such as size, zeta potential, morphology and hydrophobicity. 
When comparing the cellular uptake of the different nanogold formulations, we noticed that Au-
MPM-OA exhibits a slightly higher internalization (Figure 2.5B and Figure 2.5D), a finding that 
was also corroborated by the analysis of Image J color histograms of the cell region (the arti-
facts/particles outside the cells were not taken into account, Figure A.3 in APPENDIX A). Co-
localization histograms represented in Figure 2.5B and Figure 2.5D also show a higher amount 
of co-localized pixels for Au-MPM-OA particles. In fact, PEGylation is known to enhance ma-
terials integration within biological systems.
115,140
 Thus, Au-MPM-OA are more likely to be 





Figure 2.5-Cellular uptake of the biotags CLSM images of A549 cells transfected with (A) Au-
OA and the respective 3D reconstruction (B); (C) A549 cells transfected with Au-MPM-OA and the re-
spective 3D reconstruction (D). Green color – CellLight
®
 Actin-GFP, BacMam 2.0; Blue color – Gold 
NanoProbe (GNP). Original magnification x40. Figures 2.5B and 2.5D were further processed using the 
Imaris Bitplane software. 
 
2.4.3 Evaluation of the cytotoxic profile of the biotags 
The cytotoxic profile was assessed after the cellular uptake took place. The MTS assay 
showed that cells in contact with the biotags showed higher cell viability than the positive con-
trol (K+) (ethanol) but lower than that of the negative control (K-) (culture medium), during the 
period of incubation (48 h). Although in literature there are different studies reporting contradic-




tory results regarding AuNPs cytotoxicity,
122,129
 we found that the biotag precursors, as well as 
the gold nanoparticles per se, did not affect cell viability, being above 80 % for all samples. Be-
sides, a significant difference in cell viability was obtained between the positive and negative 
control (p< 0.05), and cells exposed to the different precursors and biotags after 24 h (p*< 0.05) 
and 48 h (p#< 0.05) of incubation (Figure 2.6). Cell growth and adherence of the cells with in-
ternalized nanoparticles was also observed in the inverted microscopy micrographs (Figure A.4 
in Appendix A). 
 
 
Figure 2.6-Cellular activities measured by the MTS assay after 24 h and 48 h in contact with the 
biotags and respective precursors. MPM= MAL-PEG-MAL; OA= Oligoaziridine biosensor (OA). Nega-
tive control (K-); Positive control (K+). 
 
2.5. CONCLUSIONS 
Gold nanoparticles coated with a PEG-oligoaziridine bilayer were fully investigated and 
found to be stable, biocompatible, optical active and water-soluble biotags, able to target the 
cell nucleus. Live cell assays were assured in a faster, accessible and precise manner, enabling 
the acquisition of 3D images well representative of AuNPs course within the cells environment. 
Particularly, the reported methodology makes use of a simple and convergent approach that al-
lows straightforward coating of PEG and fluorescent oligoaziridine oligomers onto the AuNPs 
surface. The incorporation of a fluorescent oligoaziridine layer avoids major fluorescence self-
quenching, the major limitation of AuNPs fluorescent tagging. Furthermore, the PEG layer con-
fers not only the desired stability, but also a higher cellular internalization. We envisage that 
biotags tethering with specific antibodies or peptide sequences will be capable of selectively 




permit their use in cancer therapy. Such features, allied to powerful tools such as photothermal 
microscopy, fluorescence microscopy and cancer imaging make these biotags, especially Au-
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Biocompatible gold nanoparticles targeted with a laminin fragment were successfully en-
gineered using fluorescent oligo-oxazolines produced in supercritical carbon dioxide. The archi-
tecture and properties of the POxylated constructs were fully characterized and confocal laser 




Gold nanoparticles can be engineered to exhibit diagnosis and therapy (theragnosis) fea-
tures.
141,142
 Despite cargo and release functions, at both extracellular and intracellular levels, 
gold-based nanodevices are also able to penetrate into deep tissue and undergo cellular uptake. 
Surface design also provides a stealth surface to prevent opsonisation, increasing residence time 
and enhancing therapeutic delivery at specific sites. Usually, this goal is achieved by coating 
AuNPs with hydrophilic Poly(Ethylene glycol) (PEG). However, some recent reports state that 
increasing amounts of PEG may lead to undesired hepatic accumulation leading to an inflam-
matory response trigger by the liver,
8,143
 a fact that led pharmaceutical companies to investigate 
alternatives to PEGylation. Poly(ethyleneimine) (PEI) is reported as an useful hydrophilic cati-
onic polymer for transfection enhancement, however its use in biomedical applications is lim-
ited due to its known cytotoxicity.
63,144,145
 Related poly and oligo(2-alkyl-2-oxazolines) are an-
other class of hydrophilic and biocompatible polymers regarded as versatile PEG alternatives. 
Importantly, they are easily eliminated by renal clearance and, opposing to PEG, their properties 
can be gradually fine-tuned over a broad range by side chain design enabling different biomedi-
cal applications. In particular, poly(2-ethyl-2-oxazoline), an already FDA approved indirect 
food additive (adhesive, Aquazol), is of special interest since has been already conjugated 
with Ara-C, a low molecular weight drug,
8
 and model proteins.
9
 The synthesis of polyoxa-
zolines is well established, either by microwave
10
 or supercritical carbon dioxide (scCO2)-
assisted Cationic Ring-Opening Polymerization (CROP).
11
 In the last decade, our group fully 
explored the properties of oligo(2-alkyl-2-oxazolines) (OOxs) produced by a clean scCO2–
assisted CROP,
12
 and enlarged the scope of its applications by producing blue fluorescent low 
polydisperse oligomers.
146–148
 It is known that the distance of the fluorophore to the AuNP core 
is crucial to avoid interactions of the electrons of the fluorophore with the plasmon field (typi-






Herein, we report the optical features of stable fluorescent AuNPs and its impact in the perfor-
mance of cellular uptake into A549 lung cancer cells.  
Since the surface chemistry is vital for cell-nanoparticles interactions we evaluated the 
coating effect of oligo-oxazolines end-terminated with cysteamine and a N-substituted PEI hav-
ing pendant chromylium salts, obtained by post-functionalization of poly(2-ethyl-2-oxazoline). 
AuNPs were further tagged with a laminin fragment (YIGSR), known to bind to the overexpress 
1 integrins of A549 non-small cell lung cancer.
149,150
 Surprisingly, the nanoconstructs exhibit 
fluorescence, thus meaning that the OOxs carbamic acid starting end, responsible for coating 
fluorescence, is not affected by the GNPs plasmon field, and this polymer layer seems to ensure 
conservation of the optical properties. 
 
3.3 EXPERIMENTAL PROCEDURE 
3.3.1 Materials 
A549 non-small lung carcinoma cell line was purchased from ATCC. Fetal bovine serum 
(FBS) was purchased from Biochrom AG. Tris Base was obtained from Fisher Scientific. 
CellLight® Actin-GFP, BacMam 2.0 (GFP) was attained from Invitrogen, Life Technologies. 
Glass bottom dishes were dispensed by MatTek Corporation. Amphotericin B, collagen solu-
tion, ethanol (EtOH), glutaraldehyde, Ham’s Nutrient Mixture-F12, L-glutamine, penicillin G, 
phosphate-buffered saline (PBS), streptomycin, 3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium reagent (MTS), trisodium citrate, 
trypsin, ethyl oxazoline monomer, boron trifluoride etherate (BF3.Et2O), cysteamine, Laminin 
fragment (Cys-Asp-Pro-Gly-Tyr-Ile-Gly-Ser-Arg) (YIGSR), anhydrous dimethylformadide 
(DMF) and dihydrogen phosphate were purchased from Sigma Aldrich. Gold in the form of tet-
ra-chloroauric[III] acid trihydrate (HAuCl4.3H2O) and trisodium citrate hydrate were purchase 
from Alfaaesar.  
3.3.2 Gold nanoparticles synthesis 
AuNPs were synthetized according to the Frens method.
135 
Briefly, 100 mL of 0.01 % 
(w/v) HAuCl4.3H2O were heated to boiling. Then, 1mL of trisodium citrate hydrate 1 % (w/v) 
was added to the boiling solution under constant stirring. After 25 seconds, a slightly yellow 
solution turned faintly blue. Subsequently, the solution color changed to dark red, which is in-
dicative of the formation of monodisperse spherical particles. The solution was boiled over 5 
min, to allow the complete reduction of the gold chloride.
135
  




3.3.3 Synthesis of differently end-capped oligo-oxazolines 
Prior to particles’ functionalization, the living OOXs were polymerized in a stainless-
steel reactor and OEtOx was produced and BF3.OEt2 was used as the initiator. The mono-
mer/initiator ratio used for the polymerization was [M]/[I]¼ = 12. The reactor cell was charged 
with the monomer, the initiator, a magnetic stirring bar, and then immersed in a thermostatized 
water bath at 60 ºC. Carbon dioxide was introduced in the reactor in order to achieve the desired 
reaction pressure (from 16 to 20 MPa). After 20 hours of reaction, the pressure was slowly re-
leased until the reactor reach room temperature. Inside the reactor, a viscous foam was obtained 
(OEtOx). At the end of the polymerization the living oligomer was end-capped either with wa-
ter or cysteamine, generating OEtOx-OH (1) and OEtOx-SH (2), respectively. Post-
functioalization of 1 with 2,4-dihydroxybenzaldehyde produced a polycationic oli-
go(ethyleneimine-N-chromylium salt), OEI-CS (3) Figure 3.1. Briefly, cysteamine termination 
was obtained through the addition of a tenfold excess of cysteamine, solubilized in anhydrous 
DMF, relatively to the initiator. The mixtures were kept at 70 ºC using an oil bath under stirring 
for 24 hours. The oily oligomer solubilized in dry DMF was purified by dialyses against pure 
milliQ water. The resulting mixture was dried under vacuum and the resulting oily polymer pre-
sented a yellow brownish color. For the synthesis of the oligo-oxazoline-N-chromylium PEI 
salt, the living oligo-oxazoline was initially capped with water (OEtOx-OH, 1),
148
 (0.77 g, 7.8 
mmol) and 2 4-dihydroxybenzaldehyde (1.07 g, 7.8 mmol) and BF3.OEt2 (4.0 mL) were added. 
The reaction mixture became red and was allowed to react for 24 h at room temperature. After 
this period, diethyl ether was added and the polymer precipitated as a dark red solid. The hygro-
scopic solid was washed several times with diethyl ether and dried under vacuum (quantitative 
yield). Oligomers 2 and 3 are both soluble in water and show a blue fluorescence at 408 nm 
(exc=348 nm).
147
 The oligomers were characterized by IR, 
1
H NMR (Figure B.2, Appendix B) 





Figure 3.1-Scheme of synthesis of nanogold POxylated probes: (a) water, (b) 2,4-
dihydroxybenzaldehyde, BF3.OEt2, (c) cysteamine, (d) gold nanoparticles and (e) YIGSR. 
 
3.3.4 Gold nanoparticles functionalization 
AuNPs were capped with (2) and (3) (AuNPs:OOx molar ratios of 1:5000 and 1:2500, re-
spectively, at which no aggregation or flocculation occurs) producing Au-OEtOx-SH (4) and 
Au-OEI-CS (5), respectively. Afterwards, the mixtures were collected to 1.5 mL eppendorfs and 
centrifuged at 13500 X g, for 20 min, at room temperature. The supernatant was removed and 
the pellet was redispersed in milli-Q water. The resulting types of nanoparticles were further 
conjugated with the YIGSR: different ratios of a stocking solution were added to the Au-OOXs 
producing Au-OEtOx-SH-YIGSR (6) and Au-OEI-CS-YIGSR (7). The mixtures were allowed 
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to stir during 16 hours at room temperature under dark conditions. The resulting mixtures were 
centrifuged at 13500 X g and ressuspended in milli-Q water.
139
  
YIGSR was quantified using RP-HPLC and a ubondapack C18 10µm 3.9 x 100 mm with 
a gradient of acetonitrile:water (0.05% TFA + 5% TFA respectively) at 220 nm based on stand-
ard curves (R 
2
> 0.99). Briefly, the produced nanoparticles containing the oxazolines and the 
peptide sequence were centrifuged twice. The supernatant was removed, lyophilized and res-




3.3.5 Nanogold poxylated particles: proprieties and characterization 
The nanoprobes were characterized using various analytical techniques. The morphology 
of the nanoparticles was analyzed by Transmission Electron Microscopy (TEM). Samples were 
visualized and recorded using Hitachi H8100 TEM itch. ThermoNoran light elements EDS de-
tector and digital image acquisition. Nanoparticle’s size was determined by dynamic light scat-
tering (DLS). Briefly, the end-capped nanoparticles were diluted in 800 μl of milliQ ultrapure 
water in a Zetasizer Nano ZS instrument (Malvern Instruments) kindly provided by PARALAB. 
Zeta potential quantification was carried out in the same Zetasizer Nano ZS instrument using a 
zeta dip cell. Thermogravimetric analysis (TGA) was performed on a TGA-DSC–STA 449 F3. 
Samples, previously lyophilized, were placed in platinum sample pans and heated under an ar-
gon atmosphere at a rate of 10 °C/min to 700 °C.
137
  
FTIR spectra were recorded in a Nicoletis 20 spectrophotometer (64 scans) from Thermo 
Scientific equipped with a Smart iTR auxiliary module. Fluorimetry assays were performed in a 
Perkinelmer LS 45 Luminescence Spectrometer. UV-Vis spectroscopy was recorded in a Perki-
nElmer Lambda 25 UV/Vis Spectrometer with a slit width of 5 nm at a scan rate of 240 nm/min 
at 25 ºC, in a wavelength range from 350 to 750 nm, and then analyzed with PerkinElmer UV 
WinLab™ software. The test was performed in a scan method from 260 to 700 nm.  
 
3.3.6 Cellular uptake  
The proliferation of A549 cell line in the presence of Au-OOxs was evaluated by seeding 
the cells in 96-well plates at a density of 4 x 10
4
 cells/well with nutrient mixture Ham-F12 sup-
plemented with 10 % fetal bovine serum (FBS), for 24 h. After that, the medium was removed; 
the nanoparticles were ressuspended in Ham F-12 at a concentration of 200 µg/mL and placed 




medium was replaced by Ham-F12 supplemented with FBS and antibiotics. Cell proliferation 
was evaluated at 24 and 72 h. Cell growth and adherence of the cells with internalized nanopar-
ticles was monitored using an Olympus CX41 inverted light microscope equipped with an 
Olympus SP-500 UZ digital camera.  
The uptake of the nanoprobes was assessed by confocal laser scanning microscopy 
(CLSM). A549 cell line was seeded and grown in Ham-F12 containing 10 % FBS, on glass-
bottomed coverslips coated with collagen during 24 h. Afterwards, nanoparticles were placed in 
contact with cells for 4 h to allow nanoparticles internalization. After this period of time, cells 
medium was replaced by Ham-F12 supplemented with FBS and antibiotics. Then, the cells’ cy-
toplasm was marked with CellLight® Actin-GFP, BacMam 2.0 (GFP).
11
  
3.3.7 Evaluation of the cytotoxic profile 
Briefly, 4x10
4  
cells/well were seeded in a 96-well plate and cultured with Ham-F12 at 37 
ºC under a 5 % CO2 humidified atmosphere. Then, 200 µg/mL of nanoparticles were added, and 
the mitochondrial redox activity of the viable cells was assessed through the reduction of the 
MTS into a water-soluble brown formazan product as previously described. Wells containing 
cells in the culture medium without materials were used as negative control. EtOH 96 % was 




3.4 RESULTS AND DISCUSSION 
3.4.1 Nanoparticles characterization and cellular uptake 
The nanoprobes were characterized using various analytical techniques. TEM analysis, 
showed that the nanoparticles is nearly round or oval and uniform and has a narrow diameter 
distribution around 30 nm (Figure 3. 2E and F).  




Figure 3. 2-Cellular uptake of nanogold POxylated probes. CLSM images show A549 cells trans-
fected with (A) Au-OEtOx-SH; (B) Au-OEI-CS; (C) Au-OEtOx-SH-YIGSR; (D) Au-OEI-CS-YIGSR. 
Green color – CellLight
®
 Actin-GFP, BacMam 2.0; Blue color – nanogold POxylated probes. Original 
magnification x40. Figures 3.2B and 3.2D. TEM images show (E) Au-OEtOx-SH-YIGSR; and (F) Au-
OEI-CS-YIGSR nanoparticles. The insets show size measurements performed using the Image J soft-
ware. 
 
In fact, DLS measurements are consisted with these values and the zeta potential of the 
nanoprobes increase when laminin fragment is attached to Au-OEtOX-SH and when OEtOX-





Table 3.1-DLS and zeta potential measurements. 
Sample Size (nm) Zeta Potential (mV) 
AuNPs 27.71.1 -40 
Au-OEtOx-SH 28.70.7 -30 
Au-OEtOx-SH-YIGSR 29.21.8 -15 
Au-OEI-CS 29.41.4 -9 
Au-OEI-CS-YIGSR 311 -9 
 
The uptake of the nanoprobes was assessed by CLSM. By comparing the results obtained 
for the differently coated systems, neutral Au-OEtOx-SH and cationic Au-OEI-CS (Fig-
ure 3.2A and B, respectively), a higher uptake was observed when a non-charged coating 
was used. Despite the charge effect, the data might be also explained with the higher 
concentration of OOxs chains attached to the GNP in the neutral system (AuNPs:OOx 
molar ratio of 1:5000), thus leading to an extra stabilization of the nanoparticles and im-
proved passive targeting. As expected, an enhanced cellular uptake is verified when 
YIGSR is conjugated to the nanoconstructs. Interestingly, an enriched nuclear location is 
observed in the CLSM images (Figure 3.2 C and D). This higher internalization seems to 
be a result of the particles design: size, morphology, zeta potential and recognition active 
sites. Cell growth and adherence in the presence of the nanocarriers can be depicted in  
Figure B.1 (Appendix B). 
The successful coating with OOxs or immobilization with YIGSR into the particles sur-
face was also corroborated by a significative broadening of the characteristic UV-Vis band of 
AuNPs (max = 530 nm) (Figure 3.3A). Increased molar ratios and consequently increased 
number of molecules attached to AuNPs lower the intensity of this band. Still, the AuNPs here-
in depicted did not show signs of aggregation or flocculation (Figure 3.3A and B). The fluores-
cence properties of the produced particles were confirmed in aqueous media under ultraviolet 
irradiation of 350 nm light (Figure 3.3C and D). 




Figure 3.3-Colloidal stability and optical properties of nanogold POxylated probes and intermedi-
ates: (A) absorbance spectra (top) and colorimetric evaluation (bottom) of AuNPs s, 4, 5, 6 and 7; (B) 
fluorescence spectra of 4 (grey) and 5 (orange); (C) absorbance and fluorescence spectra of 2 (grey) and 3 
(orange). Studied compounds: gold nanoparticles (AuNPs), OEtOx-SH (2) and OEI-CS (3), Au-OEtOx-





The interactions between OOx’s and YIGSR, with AuNPs were also proven by FTIR-
ATR spectroscopy as shown in Figure 3.4. Specifically, the S-H stretch of laminin fragment at 
2610 cm
-1
 is shifted to 2545 cm
 -1
 in Au-OEtOx-SH-YIGSR spectrum (b, Figure 3.4A). The 
characteristic peak of OEtOx-SH at 1628 cm
-1
 is slightly shifted in Au-OEtOx-SH to 1598 cm
-1
 
and then, due to the interaction of  YIGSR with the produced particles, to 1620 cm
-1
 in Au-
OEtOx-SH-YIGSR and is related with N-H stretch. The latest particles also present another 
shifted peak at 1656 cm
-1
 that is indicated as a C=N stretch (c, Figure 3.4A). Other specific peak 
representative of the C-N stretch of the terciary amine is demonstrated in the spectra of Au-
OEtOx-SH, YIGSR and Au-OEtOx-SH-YIGSR at 1393, 1398 and 1393 cm
-1
, respectively (d, 
Figure 3.4A). In turn, the amide characteristic peak of OEI-CS at 1614 cm
-1
 also appears in Au-
OEI-CS and is slightly shifted (1618 cm
-1
) to higher values in Au-OEtOx-CS-YIGSR (a, Figure 
3.4B). The YIGSR attachment to Au-OEI-CS also deviates the C-N stretch of the tertiary amine 
in (1356 cm
-1
) to upper values in Au-OEI-CS-YIGSR (1360 cm
-1
). The same is observed in the 
C=C-C aromatic string: 1394 cm
-1
 in Au-OEI-CS, 1397 cm
-1
 in laminin fragment and 1405 cm
-1
 
in Au-OEI-CS-YIGSR (b, Figure 3.4B). 
 
 
Figure 3.4-FTIR-ATR spectra of nanogold POxylated probes and intermediates: synthetic peptide 
(YIGSR), oligomers OEtOx-SH (2) and OEI-CS (3), AuNPs, Au-OEtOx-SH (4), AuOEI-CS (5), Au-
OEtOx-SH-YIGSR (6) and Au-OEI-CS-YIGSR (7). Regions a, b and c correspond to the characteristic 
bands of the materials. 
 
The amount of organic components on the AuNPs was assessed by thermal gravimetric 
analysis (TGA) and is depicted in Figure 3.5. The total mass loss was 8.06 % and 3.20 % for 
Au-OEtOx-SH-YIGSR and Au-OEI-CS-YIGSR, respectively. By combining the data from 
TGA analyses and HPLC peptide quantification, the amount oligomers and YIGSR were quan-
tified (see calculations in Appendix B).  




Figure 3.5-TGA curves of Au-OEtOx-SH-YIGSR (6) and Au-OEI-CS-YIGSR (7). 
 
3.4.2 Evaluation of the cytotoxic profile of the nanogld POXylated particles 
Particles biocompatibility (when no drug is used) was accessed by evaluating the meta-
bolic activity of A549 cell line. Briefly, 4 x 10
4 
cells/well were seeded in a 96-well plate and 
cultured with Ham-F12 at 37 ºC under a 5 % CO2 humidified atmosphere. Then, 200 µg/mL of 
nanoparticles were added, and the mitochondrial redox activity of the viable cells was assessed 
through the reduction of the MTS into a water-soluble brown formazan product as previously 
described. Wells containing cells in the culture medium without materials were used as negative 
control. EtOH 96 % was also added to some wells, to be used as a positive control.
130
 As 
demonstrated in Figure 3.6, the particles and the oligomers have proved to be biocompatible as 
cell viability was always above 80 % and even higher after 72 hours. Besides, a significant dif-
ference in cell viability was obtained between the positive and negative control (p < 0.05), and 
cells exposed to the different precursors and the nanoparticles after 24 h (p* < 0.05) and 72 h 





Figure 3.6-Cellular activities measured by MTS assay after 24 h and 72 h in contact with engi-
neered AuNPs and respective precursors. Negative control (K-): live cells (no particles added); Positive 
Control (K+): dead cells (with 96 % ethanol). 
 
3.5 CONCLUSIONS 
In summary, stable, biocompatible and laminin fragment conjugated AuNPs were suc-
cessfully engineered using fluorescent oligo-oxazolines (PEG alternatives) produced by a 
scCO2-assisted protocol. Besides avoiding PEG hepatoxicity, nanogold POXylation circum-
vents grafting with expensive probes and particles fluorescence quenching by the surface plas-
mon resonance effect. The nanoconstructs have an ideal size for intracellular delivery and the 
additional conjugation with the laminin fragment strongly increased particles uptake by A549 
cell line. Due to their optical and targeted capabilities, future conjugation with therapeutic drugs 
is envisaged for theragnostic applications, thus fostering efficient, greener, low cost, multifunc-
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Lung cancer is the most common and prominent cause of cancer death worldwide. The 
lack of locally and effective deliveries of therapeutic biomolecules to the deep lungs are the ma-
jor causes of such low survival rates. To address this problem, nanotechnology and pulmonary 
delivery have been combined to generate effective delivery systems, able to target the deep 
lungs and exert a positive therapeutic effect in lung cancer regression.  
In such attempt, gold nanoparticles (AuNPs), which have been widely investigated as car-
riers and biosensors for lung cancer treatment, were conjugated with micronization technologies 
in order to produce respirable microparticles with theragnostic abilities. AuNPs were previously 
functionalized with “green” biocompatible and fluorescent coatings, and further conjugated 
with specific sequences for a targeted delivery. The micronization process was achieve using 
supercritical assisted spray drying (SASD), a process based on sustainable supercritical CO2 
technology. Nano-in-micro formulations comprising a chitosan matrix were successfully pro-
duced resulting in clean ultrafine dry powders with adequate aerodynamic sizes (3.2-3.8 µm) 
and morphologies and excellent fine particle fraction (FPF) (25.8 - 42.4 %). The optimal bio-
degradation and release profiles enabled a sustained and controlled release of the nanoparticles 
embedded opening new prospects for future lung theragnosis through the pulmonary route. 
 
4.2 INTRODUCTION 
With the significant increase of lung cancer incidence in the past 50 years, among both 
women and men, there has been a huge demand for the development of new strategies to ad-
dress this health problem. Due to the limitations associated with the conventional treatment of 
several diseases, novel pulmonary therapeutics have been vastly investigated as it enables to 
target the drug delivery directly to the lungs for both local and systemic treatments. Such type 
of treatment allows for sustained release, reduced therapeutic dose and improved patient com-
pliance. However, the design of inhaled carriers with suitable properties for an accurate deep 
lung deposition and effective delivery are two of the major challenges that need to be overcome. 
Respirable formulations should comprise aerodynamic sizes ranging from 1 to 5 µm (dry) in 
order to successfully reach the lungs, swell upon deposition in the moist lung, and provide a 
sustained controlled drug release through the polymeric matrix. Such features enable not only a 






Nanoparticles have been foreseen as effective platforms to provide a controlled release of 
drugs or other biomolecules in the lungs. Due to their nanometric scale, nanoparticles can pene-
trate into the deep tissue and then suffer cellular uptake. Moreover, innovative designs of nano-
particles can allow for the tailoring of multifunctional airway targeting nanocarriers enabling 
the integration of multiple functions, such as cell targeting, ultra-sensitivity imaging and thera-
py, all into one system.
152–155
 
However, nanoparticles are in a size range which is not suitable for deep lung delivery 
and can be easily exhaled or mucociliary cleared out before reaching the underlying 
epithelia.
9,16,42
 Therefore, the major challenge for pulmonary delivery of nanoparticles is to find 
a proper carrier system. Increased effectiveness of an inhalation treatment may be achieved by 
the quick dissolution of powder particles in the airway mucus and rapid diffusion to the destina-
tion tissue.
4
 Hence, novel systems incorporating nanoparticles into swellable and respirable mi-
cro-scale structures have been engineered to overcome the issues of storing and delivering the 
drugs and other biomolecules to the lungs. Micro and nano technologies are enabling the design 
of new materials and methods with enormous impact on medical technology, greatly improving 
the performance of many existing drugs and enabling the use of entirely new therapies. From all 
the formulations available for inhalation, dry powders are usually preferred as they exhibit the 
most suitable behavior for pulmonary delivery such as stability and bioavailability of active in-
gredients, when compared to their aqueous counterparts. 
29,30
 
In this contribution, new nano-in-micro platforms were developed for controlling pulmo-
nary delivery and combine both the benefits of multifunctional nanoparticles and the respirable 
microspheres. The developed systems comprised of targeted and always-on fluorescent gold 
nanoformulations, already described in our recent works, embedded in a chitosan (CHT) poly-
meric matrix. The innovative design of our gold nanoprobes (GNP) allow for the integration of 
both cell targeting (through a laminin fragment receptor known to bind to the overexpress 1 
integrins of A549 non-small cell lung cancer
149,150
) and imaging (through the gold core to more 
advanced imaging techniques
156
 and through the conjugation with oligo-oxazolines for fluores-
cent microscopy purposes
146–148
) for lung cancer screening. In fact, surface functionalized 
AuNPs have been extensively exploited to face the urgent need to further develop novel multi-
functional nanosystem theragnosis of lung complications.
7,8
 
CHT is a natural biopolymer obtained through the alkaline N-deacetylation of chitin.
152,157
 
Although it is not yet approved by FDA for any drug delivery product, it has several desirable 
advantages, including biodegradability, non-toxicity and biocompatibility. CHT is also pH re-
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sponsive and commonly used for smart drug controlled released and different delivery systems 
have been engineered using supercritical carbon dioxide (scCO2)-assisted processes.
158–160
  
These properties together with the mucoadhesive features and ability to improve drug ab-




In this study, CHT bearing different formulations of GNP (CHT-GNP) were synthesized 
in a laboratory scale using SASD apparatus. The resulting micronized powders were fully char-
acterized and evaluated as novel biodegradable systems that confer a controlled and sustained 
release of the GNP entrapped. The optimal aerodynamic features and performances, nearly 
match the DPIs currently available on the market. Furthermore, the conjugation of targeted and 
always-on fluorescent gold nanoformulations with a biodegradable and biocompatible excipient 
enabled the production of inhaled systems able to interact with cancer cells, bringing new in-




Gold in the form of tetra-chloroauric[III] acid trihydrate (HAuCl4.3H2O) and trisodium 
citrate hydrate were purchase from Alfa Aesar. Dissodium hydrogen phosphate sodium and so-
dium chloride was purchased from AppliChem Panreac. Acetic acid glacial (99.7 % purity) was 
purchased from Carlo Erba Reagents. Ethanol absolute anhydrous (99.9 % purity) was pur-
chased from Scharlau. Ethyl oxazoline monomer, boron trifluoride etherate (BF3.Et2O), cys-
teamine, anhydrous dimethylformamide (DMF) dihydrogen phosphate trisodium citrate hydrate, 
Laminin fragment (Cys-Asp-Pro-Gly-Tyr-Ile-Gly-Ser-Arg) (YIGSR), and lysozyme chloride 
from Grade VI: from chicken egg white were purchased from Sigma-Aldrich. Chitosan (viscosi-
ty 5-20 mPa.s, 0.5 % in 0.5 % acetic acid at 20 C) was purchased from Tokyo Chemical Indus-
try. Hydranalcoulomat AD from Sigma-Aldrich was used in Karl Fischer. All components were 
used as received without any further purification. Industrial carbon dioxide (purity  99.93 %) 





4.3.2 Nanoparticles formulation 
The nanoparticles production was already described in CHAPTER 3. Briefly, AuNPs 
were synthetized according Frens’s:
135
 100 mL of 0.01 % (w/v) HAuCl4.3H2O were heated to 
boiling. Then, 1 mL of trisodium citrate hydrate 1 % (w/v) was added to the boiling solution 
under constant stirring. After 25 seconds, a slightly yellow solution turned faintly blue. Subse-
quently, the solution color changed to dark red, which is indicative of the formation of mono-
disperse spherical particles. The solution was boiled over 5 min, to allow the complete reduction 
of the gold chloride.
135
 Afterwards, the nanoformulations were grafted with “green” oligomers 
synthetized using scCO2, OOxs. OOxs were polymerized in a stainless-steel reactor and OEtOx 
was produced and BF3.OEt2 was used as the initiator. The monomer/initiator ratio used for the 
polymerization was [M]/[I]¼ = 12. The reactor cell was charged with the monomer, the initia-
tor, a magnetic stirring bar, and then immersed in a thermostatized water bath at 60 ºC. Carbon 
dioxide was introduced in the reactor in order to achieve the desired reaction pressure (from 16 
to 20 MPa). After 20 hours of reaction, the pressure was slowly released until the reactor reach 
room temperature. Inside the reactor, a viscous foam was obtained (OEtOx). At the end of the 
polymerization, the living oligomer was end-capped either with cysteamine or water, generating 
OEtOx-SH (1) and OEtOx-OH (2), respectively. Post-functioalization of 2 with 2,4-
dihydroxybenzaldehyde produced a polycationic oligo(ethyleneimine-N-chromylium salt), OEI-
CS (3). AuNPs were capped with OEtOx-SH (AuNP:OOx molar ratio 1:5000) and OEI-CS 
(AuNP:OOx molar ratios 1:2500) producing Au-OEtOx-SH and Au-OEI-CS, respectively. Af-
terwards, the mixtures were collected to 1.5 mL eppendorfs and centrifuged at 13500 x g, for 20 
min, at room temperature. The supernatant was removed and the pellet was redispersed in mil-
liQ water. Further conjugation of the produced particles with a YIGSR, known to bind to the 
overexpress 1 integrins of A549 non-small cell lung cancer,
13,163
 was also performed, produc-
ing Au-OEtOx-SH-YIGSR and Au-OEI-CS-YIGSR. The mixtures were allowed to stir during 
16 hours at room temperature under dark conditions. The resulting mixtures were centrifuged at 
13500 x g and ressuspended in milliQ water.
11
 
4.3.3 SASD process and apparatus: Production of chitosan microparticles 
Dry powder formulations were prepared using SASD, in which solutions of CHT (0.06 % 
w/v) and nanoformulations differently functionalized (9 % v/v) were prepared in 1 % acid water 
and 18.6 % (v/v) of ethanol and homogenised under stirring. Liquefied CO2 is pumped with a 
high-pressure liquid pump (HPLC pump K-501, Knauer), which is then heated and sent to the 
static mixer (model 37-03-075, Kenics-Chemineer, 4.8 mm ID x 191 mm L, 27 helical mixing 
elements). The casting solution containing both nanoparticles and chitosan was pressurized 
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through a high pressure pump (HPLC 305, Gilson) to the static mixer that promotes a near-
equilibrium mixing of scCO2 and the liquid solution. Pressure is measured with a Setra pressure 
transducer (0.1 psig stability). The solution was then sprayed through a 150 µm diameter nozzle 
into a thermostated aluminum precipitator (± 0.1 ºC), operating at near atmospheric pressure, 
where particles are formed by drying the droplets using a heated air flow (70 °C). The formed 
particles exit the precipitator from the bottom and enter into a cyclone where they are separated 
from the gas stream and collected in a reservoir and in a filter bag (FSI, nylon mono-filament, 
50 μm).
164
 Tmix = 70 °C; Tpreci = 90°C; pCO2 = 10 MPa. 
4.3.4 Morphological and physical-chemical characterizations 
Particle size analysis (sieve and Feret’s diameter) was determined using an optical parti-
cle analyzer system (Morphologi G3 Essentials, from Malvern Instruments Ltd). The particles 
were characterized by the volume mean diameter (Dv) and the relative width of the distribution 




 Equation 4.1 
where Dv,90, Dv,10 and Dv,50 are the diameters at 90 %, 10 % and 50 % cumulative volume. 
To observe morphology, the microparticles were imaged via scanning electron microscopy 
(SEM) (Hitachi, S-2400 instrument) with an accelerating voltage set to 15 kV and various am-




FTIR spectra were recorded in a Nicoletis 20 spectrophotometer (64 scans) equipped with 
a Smart iTR auxiliary module (ThermoScientific). 
X-ray powder diffraction (XRD) analysis was performed in a RIGAKU X-ray diffrac-
tometer (model Miniflex II). Samples were placed in a holder and analyzed through CuKα radi-
ation (30 KV/15 mA), with a 2θ angle ranging between 2° and 55° with a scan rate of 1°/min.  
Moisture content of each formulation was accessed using Karl Fischer assay (Metrohm). 
1.5 mg of powder were accurately weighted and introduced in the reaction cell. Moisture con-




4.3.5 Entrapment Efficiency 
The entrapment efficiency was determined by measuring the amount of Au atom (mg/L) 




Jobin-Yvon (model Ultima). Briefly, powder samples (20 mg) were dissolved in 1 mL of aqua 
regia solution overnight. GNP precursors from each sample were used as controls. Based on the 
ICP results it was possible to calculate the amount of Au (in mg) entrapped within the microcar-




× 100  Equation 4.2 
where mr is the amount of Au remaining within the particles and mi is the Au amount 
loaded into the casting solution. This percentage matches the percentage of the whole GNP en-
trapped. 
 
4.3.6 In vitro aerosolization study 
An in vitro dry powder aerosolization study was carried out for the nano-in-micro formu-
lations using a seven stages Andersen Cascade Impactor (ACI) (Coopley Scientific). In a typical 
procedure 30 mg of powder were loaded into 5 hydroxypropylmethylcellulose capsules 
(Aerovaus). The capsules were individually placed in a handheld, dry powder, breath activated 
inhaler device (PlastiApe device HR model 7), previously weighted, which is coupled to the 
ACI device. The 7 metal plates within the cascade impactor were covered with pre weighted 
glass microfiber filters (MFV1 diameter 80 mm, Filter Lab). The DPI punctures the capsule pri-
or to the inhalation and a high capacity pump is actuated to simulate an inspiration: air flow rate 
60 L/min during 4 s, according to the European pharmacopeia.
167
 After the dispersion, the filters 
and the dry powder inhalers (DPI) were weighted again. The emitted dose (ED %), which corre-
sponds to the total loaded powder mass exiting the capsules and inhaler, was determined gravi-




× 100 Equation 4.3 
where mfull and mempty are the weights (mg) of the capsule before and after simulating the 
inhalation and mpowder is the initial weight (mg) of the powder in the capsule. 
The FPF was determined by the interpolation of the percentage of the particles with less 
than 5 μm diameter emitted from the capsules in each ACI experiment. The Mass Median Aer-
odynamic Diameter (MMAD) was determined as the particle diameter corresponding to 50 % of 
the cumulative distribution. The Geometric Standard Deviation (GSD) was determined by the 
following equation: 
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 Equation 4.4 
where d84 and d16 are the diameters corresponding to 84 % and 16 % of the cumulative 
distribution, respectively. 
 
4.3.7 In vitro cumulative release studies and nanoparticles stability 
The release of GNP from the microspheres was evaluated at two distinct pHs: 7.4 and 
6.8, pH of healthy cells and pH of lung cancer cells, respectively. Approximately 20 mg of the 
powders were transferred to a special membrane size cut off 1 μm, and incubated in 1.5 mL of 
different pH solutions in a shaking (35 rpm) water bath at 37 ºC. Then, the samples were centri-
fuged at 14500 x g for 20 min and the supernatant was removed. Afterwards, 30 μL of the cor-
respondent buffer solutions were added to resuspend the pellet. The samples were placed in a 
384 Well Black with clear flat bottom polystyrene and read UV-Vis spectrophotometer micro-
plate reader. From the absorbance obtained and from the previous ICP results (initial amount of 
Au or nanoformulations entrapped) it was possible to calculate the amount of nanoparticles (in 
mol and in mg) being released from the microcarriers. UV-visible spectroscopy was recorded in 
an Infinite 200 from Tecan using a corning 384 flat bottom black polystyrene low volume/flat 
microplate, kindly provided by Corning Corporation. The test was performed in a method from 
260 to 700 nm.  
Nanoparticles release from swelling-controlled systems was modelled by the Korsmeyer-
Peppas equation as follows: 
𝑀𝑡
𝑀∞
= 𝑘𝑡𝑛 Equation 4.5 
where Mt/M∞ is the fraction of the drug release at time t, k is the rate constant and n is the 
diffusional exponent. The n-value is obtained from the slope of the Korsmeyer-Peppas plot and 
represent different release mechanisms. For spherical geometries: n = 0.43 for Fickian diffusion; 




4.3.8 In Vitro Biodegradation Studies 
An in vitro biodegradation study of the microparticles was carried out in the presence of 
lysozyme. A solution of lysozyme in PBS (pH 7.4) was prepared (0.2 mg/mL) and 20 mg of 




tion in a shaking (100 rpm) water bath at 37 °C for 30 min. Then, the samples were centrifuged 
at 13,500 rpm for 8 min and the supernatant was removed. The weights of the swollen micro-
particles (W0) were determined. Then 1 mL of fresh lysozyme solution was added to the swol-
len microparticles. At certain intervals starting from determination of W0, the steps of centrifu-
gation and weighing were repeated and the final weights (Wt) of microparticles at these intervals 
were determined. The percent weight remaining of the samples due to enzymatic degradation 
was determined according to the following equation: 
Wr% = 100 −
W0−Wt
W0
× 100 Equation 4.6 
where W0 is the weight of sample after 1 h swelling in lysozyme solution and Wt is the 




4.3.9 Confocal Laser Microscopy (CLSM): nano-in-micro cell interactions with 
cells environment  
Cell culture experiments were performed using of A549 cell line. Cells were cultured in 
Ham’s Nutrient Mixture-F12 medium supplemented with 10 % v/v heat-inactivated FBS and 1 
% of antibiotic-antimycotic (penincilin G (100 U/mL)), spectromycin G (100µg/mL)) at 37 C, 
under 5 % CO2 humidified atmosphere.
155
  
Microparticles’ interactions with cells and consequent nanoparticles’ release and cellular 
uptake were qualitatively assessed using a Zeiss LSM 710 laser scanning confocal microscope 
(Carl Zeiss SMT Inc.) equipped with a plane-apocromat 40 x/DIC objective. Priori to cellular 
incubation with the nano-in-micro formulations, cells cytoplasm was marked with CellLight
®
 
Actin-GFP, BacMam 2.0 (GFP). Immediately afterwards, cells were seeded in glass bottom 





well in Ham’s Nutrient Mixture-F12 medium supplemented with 10 % v/v heat-inactivated 
FBS. Twenty four hours later, nano-in-micro formulations (1 mg/mL) were added. After 4 h, 
microparticles interactions with cells were qualitatively evaluated. Nano location within the mi-
croparticles was also assessed using CLSM. Data analysis of CLSM images was performed with 
Zeiss software (Axio Vs40 V4.5) and Imaris Bitplane (Vs7.6.1, Bitplane).Cellular uptake for 
the nanoparticles alone was also investigated in our previous works (CHAPTER 3).  
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4.3.10 Evaluation of the cytotoxic profile  
An MTS assay was performed to evaluate nano-in-micro formulations biocompatibility. 
Twenty four hours prior to the experiment the cells were seeded at a density of 4x10
3
 cells per 
well into 96-well plates (Orange Scientific) with 200 μL of cell culture medium supplemented 
with 10 % FBS and 1 % of antibiotic-antimycotic (penincilin G (100 U/mL), spectromycin G 
(100 µg/mL)). Formerly, 1 mg/mL of microparticles were added to wells and incubated with 
cells at 37 
◦
C in a 5 % CO2 humidified atmosphere, for 3 days.  
After 1 and 3 days of incubation, the culture medium was removed and replaced by a 
mixture of 100 µL of fresh culture medium and 20 µL of MTS/PMS (phenazine methosulfate) 
reagent solution. A total of three replicates were considered for each formulation. The absorb-
ance of the samples was measured at 492 nm using a microplate reader Anthos 2010 (Bio-
chrom). A similar procedure performed for the nanocarriers was previously reported in CHAP-
TER 3. Wells containing cells in the culture medium without materials were used as negative 




4.3.11 Statistical Analysis  
All statistical analysis, unless noted, (GraphPad, Prism and Origin) were performed using 
one-way ANOVA analysis of variance following the Bonferroni post-hoc test with a significant 
set at p<0.05.  
 
4.4 RESULTS AND DISCUSSION  
4.4.1 Microparticles morphology and physical-chemical characterization  
The volume mean diameter (Dv50) represents 50 % of a cumulative distribution of micro-
particles’ diameter and it can provide an appropriate estimation of particle size for dry-powder 
inhalation purposes. Microparticles produced by SASD technology have no significant differ-
ences between the volume mean diameters, ranging from 3 to 4 μm ideal for inhalation devices. 
Similar span values were obtained for all types of chitosan microparticles herein engineered, 
with the exception of CHT-Au, indicating that they have the same distribution width (Figure 
4.2). The production yield of the nano-in-micro formulations achieved for this process was be-




The entrapment of produced gold nanoprobes, was determined through ICP analysis. 
Briefly, approximately 20 mg of powders were degraded in fresh aqua regia and gold atom (Au) 
content was measured and compared to the amount of Au existing in each GNP precursor 
(measurements performed priori to GNP encapsulation). The results are also displayed in Table 
4.1. GNP’s entrapment values vary among the samples being the highest value 51.8%. Such 
result implies that the remaining GNPs were lost during powder formation, either by leaving the 
system with the CO2 flow or by degradation. Interestingly, the addition of laminin fragment 
(YIGSR) to the nanoparticles increases their encapsulation into the micropowders. Further cal-
culation and measurements are displayed in Table C.2 (Appendix C). 
 
Table 4.1-Nano-in-micro formulations, physical characteristics. 





CHT 3.6 1.3 - 15.4 
CHT-Au 3.2 2.9 34.7 14.8 
CHT-Au-OEI-CS 3.7 1.7 17.2 12.4 
CHT-Au-OEI-CS-YIGSR 3.4 1.7 51.8 16.2 
CHT-Au-OEtOx-SH 3.8 1.4 38.6 14.9 
CHT-Au-OEtOx-SH-YIGSR 3.4 1.7 46.5 12.5 
 
All CHT-AuNP microparticles produced under the specified conditions are spherical, 
with mean diameters between 3.2 and 3.8 μm and have smooth surface as shown in SEM imag-
es in Figure 4.1.  
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Figure 4.1-SEM images of the produced microparticles: (A) CHT; (B) CHT-Au (x 20 000); (C) 
CHT-Au-OEtOx-SH; (D) CHT-Au-OEtOx-SH-YIGSR; (E) CHT-Au-OEI-CS; (F) CHT-Au-OEI-CS-
YIGSR (x 10 000). 
 
The moisture content of each formulation was accessed through the Karl Fisher assay and 
found to be in the range of 12.4 – 16.2 %. The XRD patterns for all the formulations are dis-
played in Figure C.1 (Appendix C). Figure C.1A shows the crystallinity pattern of nude 
AuNP.
170
 Upon co-atomization with CHT, no crystalline peaks are presented in all the formula-
tions (Figure C.1B) with the exception of CHT-Au-OEI-CS. This particular pattern shows both 
the broadening at 20º, characteristic of processed CHT, and the characteristic peaks of AuNP. 
Slight deviations may be a result of nanoparticles interactions with the polymeric chains involv-




by this particular formulation may be a consequence of such interactions resulting in a pro-
nounced crystalline arrangement. All the other CHT-GNP formulations do not show any crys-
talline pattern, exhibiting only the amorphous state of processed CHT (broadening at 2 = 20º). 
The importance to have an amorphous carrier for lung delivery applications has been widely 
reported in the literature. Such amorphous state is responsible not only for stabilizing the Active 
Pharmaceutical Ingredient (API), but it also increases the dissolution rate and it has high water 
adsorption capacity, contributing for a sustained release and rapid cellular absorption. On the 
other hand, the API is usually preferred in a crystalline form, since it maintains the bioavailabil-
ity of the drug, maximizing its efficiency and minimizing the required dosage.
32,153
  
FTIR-ATR spectra of the powders were also acquired and can be found in Figure C.2 
(Appendix C). The resemblance between the acquired spectra, either for CHT or CHT-GNP 
powders is evident and can be explained by the large amount of chitosan in comparison to the 
engineered nanoparticles. In turn, FTIR-ATR spectra of the nanoformulations were already dis-
cussed in our previous chapter.  
 
4.4.2 In vitro aerosolization study  
The powder aerosolization characteristics of the CHT-GNP formulations were assessed in 
vitro using a dry powder breath activated inhaler device with the aid of an Anderson Cascade 
Impactor. The percentage of powders deposited on each stage of the ACI, inhaler, capsule and 
induction port was calculated gravimetrically and is plotted on Figure 4.2. 
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Figure 4.2-Powder dispersion among the different micronized powders by ACI. 
 
Cascade impaction measurements displayed on Table 4.2 were obtained through disper-
sion of 4 consecutive capsules (n = 3). The emitted dose (ED) which comprises the amount of 
powder that fluidize through the inhaler varied between 66  2 % and 86.8  0.3%. It was also 
found for these formulations that the FPF, the respirable fraction that is most likely to deposit in 
the deep lung, was 26 ± 2 % to CHT and between 32.8 ± 0.4% and 47 ± 2 % for all CHT-GNP 
formulation, matching almost the already marketed DPIs currently available.
152,153
 In Figure 4.2 
it can be seen that the majority of the powder is lost in the induction port, which simulates the 
upper airways. Such event may be due to the formation of turbulent eddies in this area, humidity 
or chitosan mucoadhesive property. The Au content (mg) in each stage of the ACI for each dif-
ferent formulation was also assessed and its distribution is depicted in Figure C.3, (Appendix 
C). The obtained Au dispersion among the different stages is in accordance with the cascade 





Table 4.2-Cascade Impactor Measurements. 
Sample ED (%) FPF (%) MMAD (µm) GSD 
CHT 75±2 26±2 1.40±0.04 2.9±0.1 
CHT-Au 86.8±0.3 32.8±0.4 3.2±0.1 2.8±0.1 
CHT-Au-OEI-CS 66±2 41±1 1.5±0.1 3.3±0.1 
CHT-Au-OEI-CS-YIGSR 72.2±0.1 47±2 1.8±0.07 3.1±0.1 
CHT-Au-OEtOx-SH 70.2 ± 1 42±3 1.3±0.2 3.3±0.1 
CHT-Au-OEtOx-SH-YIGSR 81±1 47±2 1.8±0.2 2.9±0.1 
 
4.4.3 Statistical analysis of the cascade impactor measurements 
The obtained cascade impactor measurements were analyzed using Graph Pad, perform-
ing a one-way analysis of variance (ANOVA) with a Bonferroni’s multiple comparison test for 
a significance level of 5 %. The incorporation of nude AuNP into CHT microspheres causes a 
significant difference (p < 0.001 ***) in the mass median aerodynamic diameter of the particles 
for higher values. However, the formulations containing Au-OEI-CS or Au-OEtOx-SH decreas-
es again the MMAD to similar values to the ones presented for CHT microspheres not showing, 
therefore, any significant difference with CHT or among each other, but presenting a high sig-
nificance when compared to CHT-Au (p < 0.001 ***). New incorporations of the GNP contain-
ing YIGSR increase again the MMAD. For instance, there is a high significant difference be-
tween CHT-Au-OEtOx-SH-YIGSR with CHT (p < 0.01 **), CHT-Au-OEtOx-SH, CHT-Au (p 
< 0.001 ***), but there is no significant difference with CHT-Au-OEI-CS-YIGSR. This last one 
formulation also shows a significant difference with CHT-Au (p < 0.001 ***), CHT (p < 0.05 *) 
but no significant difference with CHT-Au-OEI-CS. The differences noticed may be a result of 
the oligomers interaction with YIGSR and they together interaction with CHT.  
A similar trend is observed for the ED of the particles. There is a significant difference 
between CHT microparticles and all the formulations with an exception of CHT-Au-OEI-CS-
YIGSR. The encapsulation of AuNPs in CHT microspheres increases the ED of the powders. 
However the addition of the oligomers decreases such emitted fraction, which increases again 
with the grafting of YIGSR in the nanoformulations, to values similar to the ones observed for 
CHT only (the significance value for CHT-Au-OEtOx-SH-YIGSR is p < 0.05 *). 
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The incorporation of AuNP does not show any statistical significance of powders’ FPF. 
However, the addition of the oligomers and peptide sequence significantly increases the FPF of 
the powders (p <0.001 ***).  
The geometric standard deviations (GSD) of the engineered powders shows a significant 
difference between CHT and CHT-Au-OEtOx-SH (p <0.001 ***) and CHT-Au-OEI-CS (p < 
0.05 *) for higher values of this parameter. The incorporation of the YIGSR lowers again the 
GSD of the powders, existing therefore no statistical significant difference between the com-
plete formulations and the CHT microparticles.  
 
4.4.4 In vitro cumulative release studies 
The cumulative release profile of the nanoparticles from the microformulations is depict-
ed in Figure 4.3. Two different pHs were used in this particular study: physiological pH (7.4) 
and a more acidic pH to mimic the lung-lining fluid of a lung cancer situation (6.8). For this in 
vitro release study only 3 formulations were investigated: CHT-Au, as a control sample; and 
both CHT-Au-OEtOx-SH-YIGSR and CHT-Au-OEI-CS-YIGSR since they are the more com-
pleted formulations and the ones of interest in cellular applications. The release profile was 
monitored by measuring the amount (mg) of the Au atom released from the microsystems. 
Briefly, the amount of particles released was monitored through a UV-Vis spectrophotometer 
microplate reader. The characteristic UV-Vis spectra (with the AuNP characteristic peak) were 
observed in all time points taken, allowing for a monitoring of GNP stability (data not shown). 
Based on the peak absorbance of the released particles ( = 530 nm), and the amount of gold of 
the initial solution (corroborated either through UV-Vis and ICP) a calibration curve was creat-
ed and all the concentrations, and therefore masses, released along the time were acquired and 
compared to the total amount of Au atom existing in the same amount of each powder (meas-






































Figure 4.3-Au release profile from CHT microspheres at two distinct pHs (6.8, full symbols and 
7.4, open symbols). 
 
As shown in the figure, the release profile for pH 7.4 is similar among all samples and the 
amount of gold released was varied between 25 to 29 %. As for pH 6.8, the amount of gold re-
leased during the 4 days presents different values for the different formulations: 55 % for CHT-
Au; 44 % for CHT-Au-OEI-CS-YIGSR; and 90 % for CHT-Au-OEtOx-SH-YIGSR. The differ-
ent Au release profiles may be explained by the different polymeric arrangement of the 
nanoformulations, which results in different nano-in-micro interactions. For instance, the aro-
matic groups in OEI-CS may contribute to a more hydrophobic character of the oligomer which 
leads to a slower release when compared to OEtOx-SH and even nude AuNP. 
CHT pKa is known to be around 6.5. Therefore, at pH 6.8, CHT amino groups are partial-
ly protonated turning the powders matrix more hydrophilic than at pH 7.4 where the amino 
groups are mainly deprotonated. Such effect on CHT amino groups appears to cause a faster 
release at pH 6.8 than at pH 7.4.  
The diffusion mechanism of the nanoparticles through the microcarriers was evaluated by 
fitting the obtained data with Korsmeyer and Peppas equation, as displayed in Figure C.4 
(Appendix C). Based on the diffusion exponent (n) of all the formulations (between 0.33 and 
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4.4.5 In vitro biodegradation study 
The in vitro enzymatic degradation study of the developed formulations was carried out 
in PBS, pH 7.4 in the presence and absence of 2 mg/mL lysozyme as already described in the 
literature.
152,171
  In this study, the remaining weight percentage of the microparticles as a func-
tion of time was determined and taken as a measure of degradation. Figure 4.4 shows the degra-
dation profiles of the three chosen formulations in the two mediums mentioned. 
 



















Figure 4.4-Degradation profile of micronized powders, in the presence of lysozyme (Lys) and ab-
sence (PBS). 
 
The degradation rate in the presence of lysozyme is higher than in PBS for formulations 
CHT and CHT-Au. Lysozyme reacts with CHT, hydrolyzing the glycoside bonds between the 
glucosamine and acetylglucosamine units.
172
 CHT-Au formulation is the less degradable formu-




may be attributed to a steric hindrance stabilized that tend to hinder the diffusion of the enzyme 
through the matrix of the microspheres and consequently retarding their degradation. On the 
other hand, Au-OEtOx-SH-YIGSR and Au-OEI-CS-YIGSR encapsulation into CHT micro-
spheres seems to be similar in both PBS and Lys and the degradation rate increases to more than 
80 %. It is hypothesized that oligomers and peptide encapsulation may cause a similar degrada-
tion trend in both media.  
 
4.4.6 Nano-in-micro: Nano location within microspheres and powders interac-
tion with cells environment 
To address nanoparticles location within the microsphere and the powder formulation in-
teraction with cells environment, CLSM was used.  
The whole microsphere was placed on glass-bottomed coverslips containing culture me-
dia. The particles were immediately visualized under CLSM and their images can be depicted in 
Figure 4.5. Chitosan autofluorescence in DAPI region enabled the localization of whole parti-
cles (Figure 4.5A). Oligo-oxazolines (OOxs) are also fluorescent in the blue region. However, 
based on both systems own fluorescence it was possible to separate both channels using Zeiss 
confocal software and no channel’s overlapping was observed (exc of the laser = 405 nm; emm 
for OOx = 435 nm; emm for CHT autofluorescence = 495 nm). As already discussed in CHAP-
TER 3 the distance placement of the carbamic moiety in OOx (responsible for its fluorescence) 
enables the creation of new GNP non-quenched by the gold core. Due to this extraordinary fea-
ture, these new GNP were encapsulated within CHT microspheres and their always-on fluores-
cence was confirmed through CLSM (Figure 4.5B and D). Respective 3D reconstructions are 
displayed in Figure 4.5C and E, respectively. No 3D reconstruction of CHT microspheres was 
possible due to the photobleaching of CHT autofluorescence that occurs over time.  
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Figure 4.5-CLSM images of the produced microspheres: (A) CHT, (B) CHT-Au-OEtOx-SH-
YIGSR and (D) CHT-Au-OEI-CS-YIGSR microspheres. 3D reconstructions of B and D are displayed in 
(C) and (E), respectively. 
 
The CHT-Au-OEtOx-SH-YIGSR and CHT-Au-OEI-CS-YIGSR formulations were also 
placed in contact with cells environment (Figure 4.6A and B, respectively). As it can be seen, 
the engineered formulations were able to adhere to cells surface. The ability for such nanoparti-







Figure 4.6-CLSM of A549 cell line incubated with 1 mg/mL of micronized powders: (A) CHT-
Au-OEtOx-SH-YIGSR and (B) CHT-Au-OEI-CS-YIGSR. Ch1 – channel 1, red: GNP (emm = 435 nm); 
Ch2 – channel 2, blue: CHT autofluorescence (emm = 495 nm); Ch 3 – channel 3, green, A549 cell line 
marked with CellLight® Actin-GFP; Merged: channels overlapping.
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4.4.7 Metabolic activity of A549 cell line in the presence of the microspheres  
The cytotoxic profile was assessed through an MTS assay (Figure 4.7). Cells in contact 
with the microparticles showed higher cell viability than the positive control (K+) (ethanol) and 
similar or slightly above (108 %) the negative control (K-) (culture medium) during the period 
of incubation (72 h). Nanoparticles and the oligomers used for their synthesis have already 
proved to be biocompatible in CHAPTER 3. Their incorporation into chitosan microspheres do 
not seem to alter their biocompatibility, as cell viability is above 80 % for all samples. Besides, 
a significant difference in cell viability was obtained between the positive and negative control 
(p < 0.05*), and cells exposed to the different microsystems after 24 h (p < 0.05*) and 72 h (p < 
0.05*) of incubation. 
 
 
Figure 4.7- Metabolic activity of A549 cell line measured by MTS after 24and 72 h in contact 







In the present work, CHT-GNP microparticles were successfully engineered through sus-
tainable methodologies in a lab scale SASD apparatus. The obtained micronized powders exhib-
it appropriate morphological characteristics, as well as adequate aerodynamic and delivery per-
formances. The sustained release profile observed at both pHs showed that CHT is a suitable 
carrier to be used in lung cancer situations through pulmonary delivery. Upon contact with lung 
cancer cells, the developed formulations adhere to cell membranes which, in turn, will promote 
a proper release of the nanosystems. The targeted and fluorescent character of the GNP as well 
as the core material, enable the use of such formulations in lung cancer imaging. Future integra-
tion of drugs into the GNP makes these nano-in-micro formulations potential candidates for sus-
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Lung adenocarcinoma is a subtype of the most common type of lung cancer, non-small 
cell lung cancer (NSCLC), and is currently associated with frequent mutations in KRAS and 
TP53 genes.  
In an attempt to develop reliable systems that can silence at least one of this mutated 
genes, novel micronized layer-by-layer (LbL) nanovehicles comprising a nanolayer of siRNA 
for KRAS gene silencing were successfully engineered. The micronization was addressed using 
sustainable methodologies that make use of supercritical carbon dioxide (scCO2) like Super-
critical Assisted Spray Drying (SASD) technology. Due to its extraordinary properties like bio-
compatibility, biodegradability and mucus adhesion, chitosan (CHT) was elected as the carrier 
system for the siRNA LbL nanoparticles. Gene silencing of KRAS gene (using both nano and 
nano-in-micro systems), cell adhesion of the microsystems and cellular internalization by the 
nanoparticles, adequate release profiles and aerodynamic properties for pulmonary administra-
tion were achieved. In vivo biodistribution of the produced siRNA powders in healthy mice was 
also assessed and showed an alveolar distribution of the produced formulations. These results 
strongly suggest that the combination of LbL and SASD technologies for the production of 
siRNA powders provide a potential strategy to deliver siRNA to the lungs and address gene 
therapy in lung adenocarcinomas. 
5.2 INTRODUCTION 
Small interfering RNAs (siRNAs) consist of 21-23 nucleotides that can interfere with the 
expression of specific genes in mammalian cells. These bioactive molecules have potential ap-
plications in several untreatable and lethal diseases, like cancer and viral infections, and senes-
cence-associated diseases. Some clinical trials have already been performed by making use of 
siRNA to knockdown particular proteins expression in these diseases. Notwithstanding, the de-
livery of functional siRNA to target cells is still a major challenge that needs to be carefully ad-
dressed. Nucleotides per se are not suitable for systemic administration due to their poor phar-
macokinetics properties. Naked siRNA is rapidly degraded by endonucleases present in the 
bloodstream. Moreover, efficient intracellular delivery of siRNA across biological barriers and 
targeted cells is not straightforward since cells lack of efficient mechanisms to uptake nucleo-
tides due to siRNA large size and highly anionic character. 
22,26,173,174
 
To overcome these barriers, a multitude of new formulations that compact siRNA into 




vitro and in vivo applications. 
26
 LbL nanoparticles that use the mechanism of sequential deposi-
tion of adsorbed polyelectrolytes with complementary functionality (e.g. charge) to build a sta-
ble film with high siRNA content represent one of the more exciting drug delivery platforms to 
effectively carry the nucleotide to the target site and release it in a sustained manner. Such local 
and controlled delivery are of major clinical importance since they circumvent the undesired 




Lung cancer for instance (including both NSCLC and small cell lung cancer (SCLC)), is 
the most common and leading cause of cancer death in both men and women worldwide and is 
an attractive cancer type for local and systemic siRNA delivery treatment. 
1,2,177
 The most com-
mon NSCLC subtype is lung adenocarcinoma, which is associated with frequent mutations in 
KRAS (~20-30%) and TP53 (~50%). Hence, targeted inhibition of KRAS expression and 
stimulation of TP53 effector functions are attractive therapeutic strategies for this particular 
lung cancer. KRAS is reported to be promising target for siRNA based therapy. In fact, Xue and 
collaborators have already demonstrated that oncogenic RAS can play a crucial role in tumor 
maintenance and that siRNA can effectively inhibit this gene. 
177
  
Effective siRNA delivery to the lungs can be achieved through pulmonary administration. 
Such local delivery enables the administration of reduced siRNA doses compared to systemic 
delivery, decreasing possible side effects and improving patient compliance. In fact, recent re-
ports in literature describe the pulmonary delivery of siRNA for efficient gene silencing in the 
lungs.
2,26,178
 Therefore, pulmonary administration of siRNA is becoming desired as new thera-
peutic platforms for lung diseases, like cancer.  
The design of proper inhalable siRNA formulations is of extremely importance. Besides 
ideal aerodynamic diameter (1-5 µm), particles morphology and flowability properties, the in-
tegrity of siRNA must also be preserved in order to achieve an efficient pulmonary siRNA ther-
apy. ScCO2-assisted processes for the production of dry powder formulations have been suc-
cessfully implemented. Moreover, some reports already describe the successful application of 




Therefore, in an attempt to produce dry powder formulations of siRNA targeted for 
KRAS mutation in lung adenocarcinoma, inhalable systems were engineered on a laboratory 
scale using SASD. CHT, as a natural polysaccharide generally accepted as biocompatible and 
biodegradable, was chosen as a carrier microsystem. For controlled release of the siRNA and to 
guarantee that it remains stable until it reaches the desired site of action, LbL nanosystems were 
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used as siRNA film carriers. Mesoporous silica nanoparticles (MSN) were used as the assembly 
core (due to their biodegradable and biocompatible features and ability to serve as a reservoir to 
other biomolecules of interest), poly-L-arginine (PLA) as a polycation and hyaluronic acid 
(HA) as the polyanion in the outermost of the nanoparticle to provide a targeted platform to the 
cell line in the study (due to the biding of HA to cells’ CD44 receptors overexpressed).
180
 Such 
constructs will enable a specific binding and controlled siRNA release, once CHT is degraded 
by the airway mucus and lining fluid enzymes.  
The produced combined formulations were fully characterized in terms of their morpho-
logical properties, gene silencing and biocompatibility abilities, and aerodynamic features. In 
vitro release profiles were also investigated followed by an in vivo biodistribution proof-of-
concept assay of the produced powders in healthy mice. 
5.3 EXPERIMENTAL PROCEDURE 
5.3.1 Materials  
Stable tdTomato expressing KP derived lung adenocarcinoma lines (KP cells) were pre-
viously synthetized in Tyler’s lab by following the protocol described by Wen and co-
workers
177
 KRAS 1211 modified siRNA (5’-UAAAGUCUAGGACACGCUGUUUU-3’) was 
purchased from Dharmacon. AllStars negative Alexa Fluor 488 siRNA (AF 488 siRNA) was 
purchased from Qiagen. Silencer Negative Control siRNA (NC siRNA), NucBlue Live 
ReadyProbes Reagent (Hoechst 33342) and Lipofectamine® 2000 Transfection Reagent were 
purchased from ThermoFisher Scientific. Corning 384 flat bottom black polystyrene low vol-
ume/flat microplate were kindly provided by Corning Corporation. QuantiGene RNA assay and 
KRAS and MRPL53 reference genes were purchased from Affymetrix. RNA ladder were pur-
chased from NEB. Hollow fiber module 300 kDa modified polyethersulfone (mPES) were pur-
chased from Spectrum Labs. Hyaluronic acid (HA, 40 kDa) was purchased from Lifecore Bio-
medical. CellTiter Glo kit was purchased from Promega. Heparin sodium (PH-3005) was pur-
chased from Celsus laboratories. Dulbecco’s modified eagle’s medium F12 (DMEM F12), fetal 
bovine serum (FBS) and penicillin/spectromycin were purchased from Media Tech. Ribogreen 
assay and RNAse free water were purchased from Life Technologies. IR-780 iodide dye, poly-
L-arginine (PLA, 5-15 kDa), hyaluronidase from bovine testes type VIII (Hdase), proteinase K 
from Tritirachium album (Pkase), lysozyme chloride from Grade VI: from chicken egg white, 
ttraehtyl orthosilicate (TEOS), trimethylamine, cetyltrimethylammonioum bromide (CTAB), 
methanol, phosphate buffer saline, dibasic sodium phosphate, citric acid and sodium citrate 




purchased from Sakura Finetek. Acetic acid glacial (99.7 % purity) was purchased from Carlo 
Erba Reagents. Ethanol absolute anhydrous (99.9 % purity) was purchased from Scharlau. Chi-
tosan (viscosity 5-20 mPa.s, 0.5 % in 0.5 % acetic acid at 20 C) was purchased from Tokyo 
Chemical Industry. Hydranalcoulomat AD was also from Sigma-Aldrich and was used in Karl 
Fischer. Dry powder insufflator was purchased from Penn Century. All components were used 
as received without any further purification. Industrial carbon dioxide (purity  99.93 %) from 
Air Liquid was used. 
 
5.3.2 Preparation of IR-780 loaded mesoporous silica nanoparticles (MSN) 
MSNs were synthesized by adapting the several methods described in the literature for 
the synthesis of this type of nanoparticles.
181,182
 Briefly, 4.2 mmol of CTAB and 2.3 mmol of 
triethanolamine were mixed with 100 mL of H2O and heated at 80 ºC for 1 h (until dissolved). 
Then, 70 mmol of TEOS were quickly added and the solution was stirred for another 1 hour. 
The particles were isolated by high speed centrifugation (30,000 x g, 30 min) and washed once 
with water and once with methanol (MeOH). Particles were resuspended in 200 mL of MeOH 
followed by the addition of 2 mL of 12 M HCl. The suspension was refluxed at 80 ºC for 14 h 
and the particles were recovered by centrifugation (30,000 x g, 30 min), followed by two wash-
es with methanol.  
IR-780 iodide is a near-infrared (NIR) fluorescence dye with great importance in therag-
nosis. 
183
 In this study, this dye was loaded into MSN to monitor nanoparticles entrapment effi-
ciency into CHT microspheres. IR-780 dye loading was accomplished by using the solvent 
evaporation method with slight modifications. To load the dye in the pores of the particles, 90 
mg of MSN were soaked in a concentrated solution of the dye (2 mg/mL in MeOH), with the 
aid of an ultrasonic bath, and the procedure was repeated 3 times. The solvent used for the dye 
dissolution was evaporated after each impregnation, under reduced pressure, in order to accom-
plish a more complete dye pore filling and improve the loading efficiency of the nanocarriers.
182
 
After the last procedure, the particles were washed with 500 µL of ultrapure water to remove 
the IR-780 dye not loaded into the MSNs. The particles were recovered by high speed centrifu-
gation (30,000 x g, 15 min). The resulting particles were recovered and dried under reduced 
pressure overnight. The amounts of loaded and unloaded dye were quantified by measuring par-
ticles and their supernatant fluorescence in a microplate reader (Infinite 200 from Tecan,) and 
compared against a calibration curve. 
 
CHAPTER 5-Micronized Layer-by-Layer nanovehicles for siRNA pulmonary delivery: a 
novel approach for lung cancer therapy 
87 
 
5.3.3 siRNA Layer by Layer (LbL) assembly nanoparticles 
The nanoparticle LbL assembly was developed on the basis of the previously established 
methods, with slightly modifications. 
25,180
 
For LbL assembly, 5 mg of MSN_IR-780 were redispersed in 10 mL of PBS 0.2X. A so-
lution of 1.5 mg/mL of the polycation PLA (5 – 15 kDa) in RNAse free water, was added drop-
wise to the nanoparticles dispersion, under stirring. The solutions were allowed to mix for 30 
sec more in an ultrasonic bath, followed by purification in a bench scale tangential flow filtra-
tion (TFF) development systems with data acquisition and pressure indicator (Spectrum Labs 
KrosFlo Researcher II). Such filtration process was performed using a 300 kDa modified pol-
yethersulfone hollow fiber module (Spectrum Labs MidiKros D02-E300-05-N) at a flow rate 
of 200 mL/min (no pressure applied). A total of 4 washes were performed. To incorporate siR-
NA, purified nanoparticles were mixed with a siRNA solution (in Rnase free water) containing 
a mixture of a KRAS siRNA and AF 488 siRNA (120 nmol and 16 nmol, respectively). Control 
samples containing NC siRNA and AF 488 siRNA were also prepared in the same proportions 
for control purposes. Again, the addition was performed by adding dropwise the siRNA mixture 
to the purified nanoparticles, under stirring. Once more, the solutions were sonicated for extra 
30 sec to allow particles–siRNA interaction/collision. Again, the particles were purified using 
another 300 kDa modified polyethersulfone hollow fiber module at a flow rate of 200 mL/min 
(no pressure applied). The purified polycation/siRNA nanoparticles were further mixed with a 
new solution of 1.5 mg/mL of the polycation PLA (5 – 15 kDa) in RNAse free water. The add-
ing and purification procedure were the same as described above. Finally, the resulting particles 
were conjugated with a previously chilled (4 ºC) hyaluronic acid (HA) (40 kDa) solution (2 
mg/mL) containing 100 nM dibasic sodium phosphate (pH 7.4). The HA solution was added in 
a single, strong and efficient mode to the purified nanoparticles placed in an ultrasonic bath, and 
placed at 4 ºC for 30 min. Further purification was performed using the same type of hollow 
fiber modules at a flow rate of 140 mL/min with a pressure of 0.07 MPa. 
 
5.3.4 Physicochemical characterization of the LbL assemblies 
All size, zeta potential and polydispersity index measurements were performed using a 
Malvern ZS90 zeta-sizer. Transmission electron microcopy (TEM) was assessed using a JEOL 
2010 FEG Analytical Electron Microscope (JEOL). Samples were prepared by dropcasting na-




The loading of siRNA on the LbL nanoparticles was examined by (1) measuring the 
amount of fluorescent siRNA present in the nanoparticles after siRNA layering, against a stand-
ard fluorescent curve; and (2) using specific enzymes to digest HA (hyaluronidase)
184
 and PLA 
(Proteinase K),
185
 followed by an addition of an heparine solution (to compete for the siRNA), a 
quantification using Ribogreen assay and an siRNA integrity evaluation through electrophoresis 
in an agarose gel.  
siRNA release assays were evaluated using 3 different buffer solutions: phosphate buffer 
saline solution at pH 7.4 to mimic cells’ physiological pH, phosphate buffer saline solution at 
pH 6.8 to mimic the intracellular environment of cancer cells, and citrate buffer solution, pH 5.5 
to mimic the endosomal environment of cancer cells.
186
 The release assays were performed as 
the following: 500 µL of nanoparticle suspension (n = 3, for each pH) were centrifuged at high 
speed (30,000 x g, 15 min). The supernatant was recovered and stored for siRNA quantification. 
The nanoparticles were redispersed in 1 mL of each buffer solution and the siRNA released 
from the microparticles was evaluated during 3 days, with the aid of Ribogreen quantification 
assay, according to manufactures instructions. Prior to Ribrogreen quantification, heparine (10 




5.3.5 Preparation of CHT-LbL siRNA Powders by Supercritical Assisted 
Spray Drying (SASD) 
A dry CHT-LbL siRNA and dry CHT-MSN powders (for aerodynamic properties as-
sessment, X-Ray Diffraction, and specific surface area analysis) were both prepared based on 
the SASD method, already described in CHAPTER 4, with slightly modifications. The LbL as-
semblies were centrifuged at high speed (30,000 x g, 30 min) and the resultant pellet was placed 
in a casting solution of chitosan (CHT) (1 % w/v) prepared in 1 % (v/v) of acid water and 20 % 
(v/v) of ethanol and homogenized under stirring. Liquefied CO2 was pumped with a high-
pressure liquid pump (HPLC pump K-501, Knauer), which was then heated and sent to the stat-
ic mixer (model 37-03-075, Kenics-Chemineer, 4.8 mm ID x mm L, 27 helical mixing ele-
ments). The casting solution containing both nanoparticles and CHT was pressurized through a 
high pressure pump (HPLC 305, Gilson) to the static mixer that promotes a near-equilibrium 
mixing of scCO2 and the liquid solution. Pressure is measured with a Setra pressure transducer 
(0.1 psig stability). The solution was then sprayed through a 150 µm diameter nozzle into a 
thermostated aluminum precipitator (± 0.1 ºC), operating at near atmospheric pressure, where 
particles are formed by drying the droplets using a heated air flow (70 °C). The formed particles 
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exit the precipitator from the bottom and enter into a cyclone where they are separated from the 
gas stream and collected in a reservoir and in a filter bag (FSI, nylon mono-filament, 50 μm).
164
 
Tmix = 70 °C; Tpreci = 90 °C; pCO2 = 10 MPa 
 
5.3.6 Morphological and physical-chemical characterizations 
Particle size analysis (sieve and Feret’s diameter) was determined using an optical parti-
cle analyzer system (Morphologi G3 Essentials, from Malvern Instruments Ltd). The particles 
were characterized by the volume mean diameter (Dv) and the relative width of the distribution 




  Equation 5.1 
where Dv,90, Dv,10 and Dv,50 are the diameters at 90 %, 10 % and 50 % cumulative volume. 
To observe morphology, the microparticles were imaged via scanning electron microscopy 
(SEM) (JEOL) at various amplifications. All the samples were mounted on alumin stubs using 
carbon tape and were sputter-coated with 5 nm Pt/Pd.
165
  
X-ray powder diffraction (XRD) analysis was performed in a RIGAKU X-ray diffrac-
tometer (model Miniflex II). Samples were placed in a holder and analyzed through CuKα radi-
ation (30 KV/15 mA), with a 2θ angle ranging between 2° and 55° with a scan rate of 1°/min.  
Moisture content of each formulation was accessed using Karl Fischer assay (Metrohm). 
1.5 mg of powder were accurately weighted and introduced in the reaction cell. Moisture con-
tent was determined by subtracting the background signal.
36,166
  
Surfaces areas were calculated by the Brunauer Emmett Teller (BET) method and were 
determined in a Micromeritics ASAP 2010 Physisorption Analyser, using 50 mg of samples. 
The analysis was performed in two phases first by heating the sample up to 320 K for 42 h, in 
order to release all adsorbed gases in the particle. Secondly, the temperature was lowered and 
maintained at 77.35 K during the time of analysis.   
LBL siRNA nanoparticles distribution among CHT microparticles was evaluated through 
different techniques. Fluorescent siRNA spreading onto CHT microparticles was analyzed using 
Olympus FV1200 Laser Scanning Confocal (Olympus). Scanning TEM (STEM) and energy 
dispersive X ray spectroscopy (EDX) maps were simultaneously recorded using JEOL 2010 




ware. Such techniques combination enabled to visualize the surface of the solid template (mi-
crospheres) and assign specific elemental peaks. 
 
5.3.7 Entrapment Efficiency 
Since no fluorescence intensity decrease was noted due layers deposition, during the LbL 
assembly procedure, the entrapment efficiency was determined by measuring the amount of IR-
780 dye presented in the powders. Briefly, 1 mg of CHT-LbL siRNA powders were dissolved in 
water and IR-780 dye fluorescence was assessed in a microplate reader.  




× 100   Equation 5.2 
where mr is the amount of IR-780 dye remaining within the particles and mi is the amount 
IR-780 dye presented in the LbL assemblies loaded into the casting solution. This percentage 
matches the percentage of the whole LbL nanosystems entrapped. 
 
5.3.8 In vitro aerosolization study 
An in vitro dry powder aerosolization study was carried out for the CHT-MSN formula-
tions using seven stages Andersen Cascade Impactor (ACI) (Coopley Scientific). In a typical 
procedure 30 mg of powder were loaded into 5 hydroxypropylmethylcellulose capsules 
(Aerovaus). The capsules were individually placed in a handheld, dry powder, breath activated 
inhaler device (PlastiApe device HR model 7), previously weighted, which is coupled to the 
ACI device. The 7 metal plates within the cascade impactor were covered with pre weighted 
glass microfiber filters (MFV1 diameter 80 mm, Filter Lab). The DPI punctures the capsule pri-
or to the inhalation and a high capacity pump is actuated to simulate an inspiration: air flow rate 
60 L/min during 4 s, according to the European pharmacopeia.
167
 After the dispersion, the filters 
and the dry powder inhalers (DPI) were weighted again. The emitted dose (ED %), which corre-
sponds to the total loaded powder mass exiting the capsules and inhaler, was determined gravi-




× 100 Equation 5.3 
where mfull and mempty are the weights (mg) of the capsule before and after simulating the 
inhalation and mpowder is the initial weight (mg) of the powder in the capsule. 
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The Fine Particle Fraction (FPF) was determined by the interpolation of the percentage of 
the particles with less than 5 μm diameter emitted from the capsules in each ACI experiment. 
The Mass Median Aerodynamic Diameter (MMAD) was determined as the particle diameter 
corresponding to 50 % of the cumulative distribution. The Geometric Standard Deviation 




 Equation 5.4 
where d84 and d16 are the diameters corresponding to 84 % and 16 % of the cumulative 
distribution, respectively 
 
5.3.9 In vitro cumulative release studies: nano and siRNA simultaneous release 
The releases of LBL assemblies and simultaneous siRNA from the microparticles were 
evaluated at two distinct pHs: physiological pH (7.4) and a more acid H to mimic the lung-
lining fluid of a lung cancer situation (6.8). Approximately 3 mg of the powders were trans-
ferred to a special membrane size cut off 1 μm, and incubated in 1.5 mL of different pH solu-
tions in a shaking (35 rpm) water bath at 37 ºC. At pre-determined end points, the solutions 
were removed and replaced for 1.5 mL fresh buffer solutions. The removed solutions were cen-
trifuged at 30,000 x g for 15 min and the supernatant was removed. Afterwards, 50 μL of water 
was added to resuspend the pellet. The samples were placed in a 384 Well Black with Clear Flat 
Bottom Polystyrene and read spectrophotometer microplate reader. From the fluorescence ob-
tained and from the amount of IR-780 dye initially entrapped in the microparticles, it was possi-
ble to estimate the amount (%) of LbL nanoparticles being released from the micropowders.  
In a simultaneous experiment, the amount of siRNA being released from the microcarri-
ers was also quantified. Briefly, at determined time points, the 1.5 mL of buffer solutions were 
removed and replaced for fresh 1.5 mL of buffer solutions. To the removed buffer, 100 µL of a 
heparine solution (10 mg/mL) were added in order to compete for the siRNA. Afterwards, 
Ribrogreen assay was performed to quantify the amount of siRNA released to from the micro-
spheres.  
Nanoparticles and siRNA release from swelling-controlled systems was modelled by the 
Korsmeyer-Peppas equation as follows: 
𝑀𝑡
𝑀∞




where Mt/M∞ is the fraction of the drug release at time t, k is the rate constant and n is the diffu-
sional exponent. The n-value is obtained from the slope of the Korsmeyer-Peppas plot and rep-
resent different release mechanisms. For spherical geometries: n = 0.43 for Fickian diffusion; 




5.3.10 In vitro performance of nano and nano-in-micro systems 
KP tdTomato expressing cells were used in our experiments and grown in DMEM media 
supplemented with 10 % v/v heat-inactivated fetal bovine serum (FBS) and 1 % of antibiotic-




Gene silencing of siRNA LbL nanoparticles was assessed in KP tdTomato-expressing 
cell line. Briefly, the cells were seeded on a 96-well plate overnight at a density of 1.2 x 10
4
 
cells/well, and treated with increasing concentrations of LbL nanoparticles of which the 
amounts were normalized to the siRNA loading (10, 50, 100 nM). The cells were treated with 
KRAS-targeting siRNA LbL nanoparticles, and compared with NC siRNA nanoparticles and 
lipofectamine controls. Three days after the treatment, cellular expression was evaluated 
through the QuantiGene RNA assay, according to the manufacturer’s instructions. KRAS was 
used as the target gene and MRPL 53 was used as a reference gene. The experiment was repeat-
ed for the microformulations. The amount of powders administered was normalized to the 
amount of siRNA encapsulated.  For this, two different concentrations of powders in solution 
were used: 0.45 mg/mL and 0.09 mg/mL, for either CHT or CHT-LbL siRNA microparticles. 
Cytotoxicity assays were performed using CellTiter Glo, according to the manufactures 
instructions. Briefly, cells were seeded in a 96-well plate at a density of 1.2 x 10
4
 cells/well for 
24 h. Afterwards, cells were treated with the nanoparticles at various concentrations (normal-
ized to siRNA concentrations: 10, 50, 100 nM). Cellular ATP was monitoring at 24 h and 72 h 
of incubation by replacing the medium by 100 µL of fresh media and 20 µL of the reagent mix-
ture. Cell viabilities were normalized to an untreated control. The same procedure was repeated 
for the CHT-LbL siRNA powders. Again, the amount of powders administered was normalized 
to the amount of siRNA encapsulated and were the same as for the gene silencing assay. 
Cellular uptake of nanoparticles was assessed by confocal microscopy and flow cytome-
try.  
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The confocal microscopic images were taken using an Olympus FV1200 Laser Scanning 
Confocal. Briefly, KP tdTomato cell line was seeded at a density of 1.2 x 10
4 
cells/well on glass 
bottom dishes coated with collagen with 1 mL of DMEM supplemented with 10 % of FBS, dur-
ing 24 h at 37 C, under 5 % CO2 humidified atmosphere. Afterwards LbL nanoparticles were 
placed in contact with cells. One and 4h after, the medium was replaced by DMEM supplement 
with 10 % of FBS and 1 % of antibiotic-antimycotic, and the cells were imaged. Further 3D re-
construction was performed using Imaris Bitplane (Vs7.6.1, Bitplane). 
The quantity of uptake was measured by flow cytometry. Briefly, the cells were seeded in 
a 48-well plate at a density of 50 x 10
4
 cells/well with 1 mL of DMEM supplemented with 10% 
of FBS, during  24 h at 37 C, under 5 % CO2 humidified atmosphere. Then, cells were treated 
with LbL fluorescently labeled nanoparticles at a concentration of 100 μg/mL for 1 and 4 h, fol-
lowed by washing and trypsinization. The cell-associated fluorescence was analyzed by a BD 
LSRFortessa flow cytometer (BD Biosciences) 
Microparticles’ interactions with cells were carried out by seeding cells in glass bottom 
dishes coated with collagen at a density of 4 x 10
3
 cells per well, for 24 h. Afterwards, nano-in-
micro formulations were placed in contact with cells  for 1 and 12 h and their interactions were 
imaged. 
 
5.3.11 In Vivo experiments 
Female BALB/c mice (4-6 weeks old) were purchased from Taconic, and the AIN-93 pu-
rified diet was from PharmaServ/Testdiets. Mice were kept on the AIN-93 diet for at least a 
week before experimentation to reduce levels of body autofluorescence. All in vivo experimen-
tation as carried out under the supervision of the Division of Comparative Medicine (DCM), 
Massachusetts Institute of Technology, and in compliance with the Principles of Laboratory 
Animal Care of the National Institutes of Health. 
Mice were divided in 4 groups: i) untreated; ii) treated with CHT-LbL siRNA (30 min); 
iii) treated with CHT-LbL siRNA (24 h); treated with CHT powders (24 h). Prior to the pow-
ders administration, the mice were anesthetized with isoflurane and hold on their back. The tra-
chea was exposed to a dry powder insufflator for mouse (Penn Century) and 1.5 mg of pow-
ders (2.8 µg of siRNA) was administered through the trachea.  
After the pre-determined times points, the mice were sacrificed and lungs fluorescence 




Imaging System (Caliper Instruments). Imaging and biodistribution data were normalized to the 
autofluorescence of the untreated mice. 
Further biodistribution analyses were performed both using confocal microscopy (Olym-
pus FV1200 Laser Scanning Confocal) and two photon correlation microscopy with the aid of 
Olympus FV1000 Multiphoton Laser Scanning Confocal Microscope (Olympus) for deep tissue 
imaging of the lung, using a 25 x, N.A. 1.05 objective at 840 nm. 
Quantigene analyses of target gene silencing were performed by isolating total RNA from 
the sliced lungs using quantigene processing kit for tissue (Affymetrix, Santa Clara, CA) ac-
cording to the manufacturers' protocol. Again, KRAS was used as the target gene and MRPL 53 
as a reference one.  
In vivo toxicity of the CHT-LbL siRNA powders was assessed using serum and lung tis-
sue samples isolated from both the treated and control mice at the end of the experiment. Blood 
biochemistry of liver and kidney panels was analyzed by Charles River Laboratories. Lungs 
tissues were fixed with O.C.T. and processed by the Swanson Biotechnology Histology Facility 
Core. The samples were sectioned for H&E staining. Sectioned images were collected using a 
Nikon light microscope, an Olympus FV1200 Laser Scanning Confocal and an Olympus 
FV1000 Multiphoton Laser Scanning Confocal Microscope. 
 
5.3.12 Statistical Analysis  
All statistical analysis, unless noted, (GraphPad Prism and Origin) were performed using 
one-way ANOVA analysis of variance following the Bonferroni post-hoc test with a significant 
set at p < 0.05.  
 
5.4 RESULTS AND DISCUSSION  
5.4.1 LbL nanoconstructs – characterization and in vitro performance  
LbL architectures consisting of 4 layers (PLA-siRNA-PLA-HA) were engineered onto 
the surface of MSN_IR-780 (32 nm in hydrodynamic size and -32.2 mV in zeta potential) via 
sequential adsorption and TFF purifications from solutions of polycations and polyanions. Due 
their promising in vivo applications and several advantages, like low cytotoxicity, film stability, 
high transfection efficiency, among others, PLA was elected as the polycation to be used in this 
construct, and HA as the polyanion. The ability of HA to bind overexpressed CD44 receptors 
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existing in a vast majority of cancer cell lines, like KP-derived lung adenocarcinomas, promot-




The deposition of PLA onto MSN_IR-780 was clearly demonstrated by the increase in 
the size of the particles as well as a complete reversal of surface charge, as shown in Figure 
5.1A and B, respectively. Following additions of both siRNA, PLA, and HA were also corrobo-
rated by the increase in the particles’ size (slightly for siRNA and PLA, and pronounced for HA 
layer) and complete surface charge reversal. The thick HA layer on the outer surface provides 
an enhanced degree of hydration to our particles, contributing to particles’ steric stability. 
180
 
The uniformity of the layer deposition was evidenced by the maintenance of the polydispersity 
following each layer, as depicted in Figure 5.1C. The electron micrographs of MSN_780-IR 
(Figure 5.1D) and LbL nanoparticles (Figure 5.1E) reveal the appearance of an outer shell, con-
firming the deposition of the polymeric film on the core particles. 
 
 
Figure 5.1-Physicochemical characterization of siRNA LbL nanoparticles. Effects of additional 
layers on (A) hydrodynamic diameter, (B) Zeta potential, and (C) polydispersity index (PDI) of the LbL 
nanosystems. TEM images of (D) MSN_IR-780 and (E) siRNA LbL nanoconstructs. 
 
The layering of siRNA onto the MSN_IR-780/PLA construct was measured using Ri-
bogreen assay immediately after siRNA deposition. The amount of AF 488 siRNA was also 
monitored by measuring the amount of fluorescent siRNA (no Ribrogreeen added) against a 
standard curve. The presence of siRNA after the remaining layers were deposited was also ad-






K (for PLA degradation),
185
 and a final conjugation of heparin to compete for the siRNA. 
173
 
Ribogreen quantification was also performed, and the amount AF 488 siRNA was also meas-
ured. The results are displayed in Table 5.1.  
 
Table 5. 1-siRNA loading onto LbL nanosystems 
5 mg of 
MSN_IR-780 
siRNA (initial amount) 
siRNA (LbL nano-
particles) 
AF 488 siRNA (LbL 
nanoparticles) 
After siRNA 
layering  2040 µg (120 nmol of siRNA 
(Kras or NC + 16 nmol of AF 
488 siRNA) 
11.4 % of initial siR-
NA= 232.2 µg 
1.2 % of initial siRNA 
= 25.1 µg 
After enzymes 
degradation 
10.7 % of initial siR-
NA = 219.1 µg 
1.1 % of initial siRNA 
= 23.3 µg 
 
The siRNA integrity was also evaluated using an agarose gel electrophoresis (Figure D.1, 
Appendix D). For this, heparin, generally used to unpack nucleic acids from nuclei acid/cationic 
vectors,
173
 was used to enable the detection of electrophoretic band of siRNAs. 
It was also found that the LbL constructs exhibited a controlled release over an extended 
period of time as depicted in Figure 5.2. Nevertheless, at pH 5.5 (that mimics the endosomal pH 
of a cancer cell) 
186
 the release is slightly higher than for pHs 6.8 and 7.4. The stability resolved 
temporally at these pHs is a key feature of this construct as it is undesirable to lose large 
amounts of siRNA during circulation until it reaches the tumor tissue. 
25
. Moreover, the use of 
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Figure 5.2-siRNA release from LbL nanoconstructs. 
 
The ability of such nanoparticles to silence KRAS was investigated in tdTomato –
expressing KP cells and is displayed on Figure 5.3. Increased concentrations of particles and, 
consequently, siRNA were investigated. Gene expression of treated cells was compared to un-
treated ones. Lipofectamine controls of both types of siRNA were also performed. It was found 
that the LbL nanoparticles containing KRAS siRNA were able to achieve more than 50 % of 
gene silencing compared to the untreated cells, as LbL nanoparticles containing NC siRNA 






Figure 5.3-Gene expression of KRAS in tdTomato–expressing KP cell line. 
 
The cytotoxic profile of the produced nanocarriers was also investigated. As Figure 5.4 
demonstrates, little cytotoxicity was observed by the Lbl assemblies herein enginereed. The 
results show that either HA or PLA are biocompatible and that there is little toxicity related to 





Figure 5.4-Cell viability of tdTomato-expressing KP cells 24 and 72 h after being in contact with 
the engineered LbL nanosystems. 
 
Confocal laser scanning microscopy (CLSM) of the siRNA LbL nanosystems showed 
nanoparticles’ binding to the cells after 1 h of incubation as displayed in Figure 5.5A. In fact, 
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some of the particles appear to be already internalized, evidenced by punctate fluorescence in 
the cytosolic compartments. After 4 h of incubation, brighter green spots (from AF 488 siRNA) 
associated with the nucleus are observed (in blue), as it can be seen in Figure 5.5B. Such in-
crease in cellular internalization was corroborated by flow cytometry in Figure 5.5C. There is a 
two times increase in cellular uptake after 4 h of incubation (64.6 % of cells have nanoparticles 
internalized). Figure D.2 (Appendix D) also depicts a 3D reconstruction of such cells after 4 h 
using brightfield, where particles internalization is easily noted.  
Such high internalization was already anticipated since HA-coated LbL nanoparticles can 
easily engage with CD44 receptor overexpressed by this type of cell line. In fact, HA is consid-
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Figure 5.5-CLSM images of td Tomato-expressing KP cell line incubated with the LbL siRNA 
nanoparticles, after (A) 1 and (B) 4h. Ch1 – Hoechst, nuclear location (exc = 405 nm; emm = 461 nm); 
Ch2 – AF 488, siRNA (exc = 463 nm; emm = 520 nm); Ch3 – Ds-Red2 , tdTomato Kp cell line (exc = 
559 nm ; emm = 581 nm); Merged – overlapping of channels 1,2 and 3; and 3D reconstruction. (C) Flow 
cytometry analysis of the nanoparticles uptake after 1 and 4 hours. 
 
5.4.2 Morphology and physical-chemical characterizations of the micronized 
powders 
Particle size and morphology are two critical factors affecting powder inhalation. The 
produced powders were characterized in terms of their volume mean diameter (Dv,50), which 
represents the cumulative diameter of 50 % of microparticles and provides an appropriate esti-
mation of particle size for dry-powder inhalation purposes. Microparticles produced by SASD 
technology have no significant differences between the volume mean diameters. The mean di-
ameters of 3.1 to 4.2 μm are ideal for inhalation purposes.
173
 Similar span values were obtained 
for all types of CHT microparticles herein engineered, indicating that they have the same distri-
bution width (Table 5.2). As we were only addressing biodistribution of the developed powders, 
both siRNA LbL nanosystems (KRAS and NC) were conjugated in a way to enhance the 






























CHT 4.2 0.9 - 1.4 7.1 0.008 4.7 
CHT-MSN 3.1 0.8 - 0.7 6.3 0.009 5.9 
CHT-LbL siRNA 3.5 1 28.7 0.9 - - - 
a Based in IR-780 dye encapsulation efficiency.  
 
The entrapment efficiency of the LbL nanosystems was assessed by measuring the fluo-
rescence of IR-780 dye present in the microspheres. It is hypothesized that the remaining LbL 
siRNA nanosystems were lost during powder formation either by leaving the system with CO2 
flow or by degradation. Further measurements are depicted in Table D.1 (Appendix D). Due to 
the theragnostic properties of IR-780 dye, it can be used for future in vivo photothermal (PTT) 
application, enhancing the ability of our systems to kill cancer cells.
183
 
The moisture content of each formulation was also assessed through a Karl Fisher assay 
and the results show a great improvement in comparison to our other studies (CHAPTER 4). 
Generally, in a drying operation the lower the moisture content, the better the product.
188
 The 
residual moisture of less than 1 % indicates a complete drying process. Although the differences 
among the obtained values are not statistically significant, it seems that the moisture percent-
ages decrease with the nanoparticles addition.  
The XRD patterns of MSN and samples CHT and CHT-MSN are displayed in Figure D.3 
(Appendix D). Due to the amount needed to perform an XRD analysis, the sample CHT-LbL 
siRNA was not investigated using this technique. However, the pattern is expected to be very 
similar to the one obtained for CHT-MSN. The characteristic spectra and peak of amorphous 
SiO2 is depicted at 2 = 20º for MSN. Similarly, the characteristic pattern of processed CHT 
also shows a broadening at 2 = 20º. This type of broadening is also depicted for CHT-MSN 
powders.  
The results obtained for BET specific surface area analysis are also shown in Table 5.2 
According to pores classification adopted by IUPAC, 
98
 the particles all present mesopores (1.5 
nm < d < 50 nm). The analysis to BET isotherms (Figure D.4, Appendix D ) shows that the pro-
duced microparticles follow a Type II isotherm. Such isotherm indicates the formation of an 
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adsorbed layer where the thickness increases with increasing relative pressure until it equals the 
saturation vapor pressure, when the adsorbed layer becomes a bulk liquid. The uptake at A rep-
resents the completion of the monolayer, and gives an estimation of how much adsorbate is re-
quired to form a monolayer covering solid surface. At this point begins a quasilinear section 
representing the formation of the multilayer.
189
 The relative small values for surface area also 
indicate a more energetically favorable state.
101
  
As displayed in Figure 5.6, the produced micronized powders present some difference in 
their morphology. CHT particles present a more rough surface and relatively distorted spheres. 
On the other hand, CHT-LbL siRNA powders show a smoother surface with different extended 
of regularity. STEM images and EDX analysis of such samples are displayed Figure D.5, Ap-
pendix D. From the obtained results, the LbL siRNA nanoparticles appear to be located in the 
outermost of the particle, even after 5 min of sonication (Figure D.5-C).  
 
 
Figure 5.6-SEM images of the produced microparticles: (A) CHT (x 16,000); (B) CHT-LbL siR-
NA (x 30,000). 
 
To further investigate nanoparticle localization inside the microparticles, the micro-
spheres were observed using CLSM and a 3D reconstruction was performed with the aid of 
Imaris Bitplane. The whole microspheres were placed on glass-bottomed coverslips containing 
culture media. The particles were immediately visualized, and their images are depicted in Fig-
ure 5.7. Chitosan autofluorescence in DAPI region enabled the localization of whole particle. 
AF 488 siRNA can be seen in the images in green, representing nanoparticles location along the 
microparticle. As it can be observed, nanoparticles appear to be located on the outermost of the 
powders (Figure 5.7A), corroborating the results obtained by STEM and EDX conjugation. Up-




on the inside of the formed microparticle. However, the presence of siRNA LbL nanoparticles 
can be also denoted on the interior of the particle (Figure 5.7B). As already described in the lit-
erature, there are no universal procedures to describe particles formation, but there are general 
tendencies that can be used to explain the particle formation step. The shriveling depicted in 
SEM images may be a result of a high Peclet number (Pe) or as changing Pe situation. Briefly, 
the Pe is influenced by a combination of material properties of the solute and the solvent pro-
cessing parameters that, in turn, determine the evaporation rate. Therefore, the Pe number is a 
function of the ratio between solvent evaporation rate and the diffusion coefficient of the given 
solute. Hence, if the solvent evaporation rate is higher than the dissolved or suspended compo-
nents diffusion, the surface will tend to become more enriched in the component with the higher 
Pe number, resulting on shriveled structures. As the nanoparticles possess even higher Pe, they 
will preferentially accumulate on the shell surface. The highest structural organization of nano-
particles hindrances the shell deformation mechanisms.
101,190
 Again, the factors governing parti-
cle formation like the air temperature to aid particles drying process as well as the slightly in-
crease in EtOH percentage (in comparison to our previous works), may be contributing factors 
to a rapid solvent evaporation. On the other hand, silica has also been described in literature as a 
drying auxiliary agent and as CO2 absorbent.
191
 The very low moisture content observed for this 
particles also corroborate an efficient drying process.  
 
Figure 5.7-3D reconstruction of (A) LbL siRNA – CHT micronized powders and (B) their trans-
versal cut. Green: AF 488 siRNA (exc = 473 nm; emm = 520 nm); Blue – DAPI, CHT autofluorescence 
(exc = 405 nm; emm = 461 nm). 
 
5.4.3 In vitro aerosolization study 
The powder aerosolization characteristics of CHT-MSN and CHT powders were assessed 
in vitro using a dry powder breath activated inhaler device with the aid of an Anderson Cascade 
Impactor (ACI). The percentage of powders deposited on each stage of the ACI, inhaler, cap-
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sule and induction port was calculated gravimetrically and is plotted on Figure 5.8. In this par-
ticular study, the aerosolizable properties of CHT-LbL siRNA powders were not assessed due to 
the limited quantity of powder achieved, and needed for in vivo biodistribution assays. 
 
 
Figure 5.8-Powder dispersion among the micronized powders by ACI. 
 
Cascade Impactor measurements displayed on Table 5.3 were obtained through the dis-
persion of 4 consecutive capsules (n = 3). The emitted dose which comprises the amount of 
powder that fluidize through the inhaler varied between 70.3  1.7 % and 75  2 %. It was also 
found for these formulations that the fine particle fraction (FPF %), the respirable fraction that 
that is most likely to deposit in the deep lung, was 54  3 % to CHT and 44   4 % for the CHT-
MSN formulation, nearly matching the DPIs currently available on the market.
152,153
 In Figure 
5.8 it can be seen that the majority of the powder is lost in the inhaler and induction port, which 
simulates the upper airways. Such  may be due to the formation of turbulent eddies in this area, 





Table 5.3-ACI measurements. 
Sample ED (%) FPF (%) MMAD (µm) GSD 
CHT 75±2 54±3 1.6±0.1 2.2±0.1 
CHT-MSN 70±2 44±5 1.7±0.1 1.8±0.1 
 
The results were analyzed using Graph Pad, performing a two-way analysis of variance 
(ANOVA) with a Bonferrroni’s multiple comparison test for a significance level of 5%. Alt-
hough a slight difference between the obtained values may be denoted, none of the samples 
show any significant difference in any of the ACI measurements. However, due to more pro-
nounced shivering denoted for CHT microparticles, an enhanced flowability of this particular 




5.4.4 In vitro cumulative release studies: nano and siRNA simultaneous release 
The cumulative release profile of the LbL siRNA nanoparticles and the siRNA per se, are 
depicted in Figure 5.9. Two different pHs were used in this study: 7.4 to mimic the physiologic 
pH; and 6.8 to mimic the lung lining-fluid of a lung cancer situation. For these in vitro studies, 
only CHT-LbL siRNA formulation was assessed. To evaluate the nanoparticles release from the 
microparticles, the IR-780 dye fluorescence was monitored at pre-determined end points. For 
the siRNA release from the powders, Ribrogreen assay was used to quantify the amount of siR-
NA released along the same end points.  
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Figure 5.9-In vitro release assays of A) siRNA; B) LbL nanoparticles from micronized powders. 
 
As demonstrated in the figure, siRNA is released from the micronized powders at a high-
er rate or pH 6.8, as already expected according to the release assays of siRNA from the LbL 
nanosystems. On the other hand, according to the IR-780 dye intensity, the release profile of the 
nanosystems from the micropowders varies between 72 and 80 % for pHs 7.4 and 6.8, respec-
tively. Such result was already expected as described in the previous chapter. Briefly, since 
CHT pKa is 6.5, it is expected that at pH 6.8, CHT amino groups are partially protonated, lead-
ing to powders hydrolysis and consequently, a faster release.  
The diffusion mechanism of the LbL nanosystems and siRNA through the microparticles 
were both evaluated by fitting the obtained data with Korsmeyer and Peppas equation (Figure 
D.6, Appendix D ). Based on the diffusion exponent (n) of both systems in both pHs (between 




5.4.5 In vitro performance of nano-in-micro formulations 
The ability of the CHT-LbL siRNA powders to silence KRAS gene was investigated in 
tdTomato–expressing KP cells and is displayed on Figure 5.10. Increased concentrations of par-
ticles and, consequently, KRAS siRNA were investigated. Gene expression of treated cells was 
compared to untreated ones. It was found that the CHT-LbL siRNA microparticles were able to 
achieve more than 90 % of gene silencing compared to the untreated cells. Considering both the 




only half of that amount corresponds to LbL KRAS siRNA nanoparticles, and 13.3 % of the 
total siRNA that those particles cover AF 488 siRNA (and therefore only 86.7 % is KRAS siR-
NA) it is possible to say that 120 µg of powders contain approximately 33 nM of KRAS siRNA 
and 30 µg, 8.3 nM of KRAS siRNA. 
 
Figure 5.10-Effects of CHT-LbL siRNA microparticles on KRAS gene expression in tdTomato–
expressing KP cell line (72 h). 
 
Cell viability of the micronized powders was also addressed. As Figure 5.11 demon-
strates, there is little cytotoxicity demonstrated by the micronized powders (cell viability always 
above 80 %). Although slight differences may be observed, there is no significant statistical dif-
ference between the negative control (cells) and the cells incubated with the powders.  
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Figure 5.11-Cell viability of tdTomato–expressing KP cell line in the presence of micronized 
powders. 
 
Powder interactions with cells after 1 and 12 h were also investigated using CSLM and 
their images are displayed in Figure 5.12. In this particular imaging, brightfield channel was 
also used to more clearly understand particle location. Also, no nuclear staining was used to 
avoid overlapping with CHT autofluorescence in DAPI region. After 1 h of incubation, green 
dots from AF 488 siRNA can be depicted among the cellular environment and already appear to 
be not confined to microparticles location (in blue) (Figure 5.12A). After 12 h of incubation, the 
siRNA spreading from the CHT microparticles is even more evidenced and accentuated among 
the cellular environment as demonstrated in Figure 5.12B. Such results are in agreement with 
the release profile obtained for both the LbL nanosystems as well as the labeled siRNA from the 
microspheres. It is also worth mentioning that microparticle adhesion to cells may be actually 
attributed to the outermost location of the LbL nanoparticles. In fact, since HA is the last layer 
in our LbL assembly, their interaction with CD44 receptors in tdTomato expressing KP cell line 





Figure 5.12-CLSM of td Tomato-expressing KP cell line incubated with the LbL siRNA micro-
particles after (A) 1 and (B) 12 h. Ch1 – DAPI, microparticles autofluorescence (exc = 405 nm ; emm = 
461 nm); Ch2 – AF 488, siRNA (exc = 473 nm ; emm = 520 nm); Ch3 – Ds- Red2, tdTomato Kp cell line 
(exc = 559 nm ; emm = 581 nm); Merged – overlapping of channels 1,2,3 and brightfield; and 3D recon-
struction.  
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5.4.6 In vivo biodistribution of the CHT-LbL siRNA powder 
In order to achieve an effective gene silencing by siRNA in vivo, it is important to under-
stand siRNA biodistribution and pharmacokinetics. It is well known that naked siRNA is easily 
degraded by the endonucleases presented in the bloodstream and, when injected intravenously, 
it is mostly accumulated in the kidneys and excreted in the urine (size below threshold for rapid 
renal excretion < 20nm). Nevertheless, biodistribution and pharmacokinetic behavior of siRNA 
after pulmonary administration are poorly described in the literature. In a proof-of-concept 
study, we attempted to address siRNA biodistribution following pulmonary delivery in healthy 
female BALB/c mice. CHT microparticles (no LbL nanosystems incorporation) were used as a 
control. Mice lungs treated with CHT-LbL siRNA microparticles were imaged using IVIS sys-
tem after 30 min and 24 h (Figure 5.13). The administered dose to each mouse was 1.5 mg of 
powder, containing approximately 2.8 µg of siRNA (for CHT-LbL siRNA powders). Untreated 
lungs from healthy mice were also imaged in order to normalize lung autofluorescence. CHT 
microparticle autofluorescence is also easily depicted on IVIS imaging. 
 
 
Figure 5.13-Micronized powders biodistribution in mice lungs: (A) Accumulation of the particles 
in mice lungs over pre-determined periods of time (exc = 465 nm ; emm = 520 nm); (B) Region-of- inter-





The extracted lungs were scanned using two imaging techniques: two photon correlation 
microscopy (TPCM) and CLSM, as shown in Figure 5.14. Both microscopic imaging showed a 
higher fluorescence intensity on the green channel for samples CHT-LbL siRNA. By looking 
mainly to the TPCM images it appears that there is a higher particle density at 24 h than on 30 
min, which is a contradictory result to IVIS epi-fluorescence measurement. Nevertheless, the 
high presence of collagen fibers (imaged by second harmonic generated polarized light) for the 
30 min sample may also contribute to a lack of macroscopic perception for the particles there 
presented. CHT autofluorescence can be also corroborated by the presence of green dots in both 
images of both techniques. However, according to the TPCM image of CHT (where no tissue 
autofluorescence is presented) it is easily denoted that the green density and intensity is much 
lower than in the LbL siRNA-CHT particles. Lung tissue autofluorescence is mainly depicted in 
blue in CLSM. 
As expected, untreated lungs do not exhibit any green fluorescence on TPCM, and only a 
limited autofluorescence in the green channel is observed in CLSM, proving that the green dots 
evidenced at the other samples do correspond to microparticles localization.   
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Figure 5. 14-Lung sections scans using TPCM and CLSM. Collagen fibers of lung tissue are de-
picted in white and microparticles depicted in green. (A) CHT-LbL siRNA 30 min; (B) CHT-LbL siRNA 
24 h; (C) CHT 24 h; (D) Untreated lung tissue where only lungs autofluorescence is observed in CLSM. 





Lungs section histology is displayed in Figure 5.15. Sections unstained (Figure 5.15-1) 
and stained with Hematoxylin and Eosin (H&E) (Figure 5.15-2 and 3). These results were ana-
lyzed using TPCM (Figure 5.15-1 and 2) and a Nikon light microscope (Figure 5.15-3). Figure 
5.15-1 reveals the presence of microparticles in lung sections, mainly depicted in CHT-LbL 
siRNA 30 min and 24 hours (in green) (Figure 5.15 A1 and B1, respectively). H&E staining 
revealed the presence of more blue coloration (hematoxylin staining) in the lungs of animals 
treated with CHT-LbL siRNA powders (Figure 5.15-A3 and B3). Since hematoxylin stains 
acidic (or basophilic) structures it will bind to the siRNA presented in the powders. Neverthe-
less, animals receiving CHT microparticles showed evidence of mild inflammation, as corrobo-
rated by the slight increase in the blue staining from hematoxylin, probably related with the ap-
pearance of white cells. Such result is in agreement with some reports in the literature that 
showed pro-inflammatory effect in animals’ lungs after administering CHT microparticles.
192
 
Yet, additional experiments are required to help clarify whether the produced CHT microparti-
cles do trigger in vivo inflammatory response by the lung. The autofluorescence of the H&E 
staining sections are depicted in Figure 5.15-2. 
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Figure 5.15- Histology analysis of lung sections: (A) CHT-LbL siRNA 30 min; (B) CHT-LbL 
siRNA 24 h; (C) CHT 24 h; (D) Untreated of (1) unstained; and (2),( 3) H&E stained lung tissue sections 
isolated from the mice. (1) and (2) were imaged using TPCM (using a 25x, N.A. 1.05 objective at 840 





Serum biochemistry analysis of the blood recovered at the end of the experiment (24 h) is 
displayed on Table 5.4. 
The results were compared to the dynamic reference range given by Charles River, and 
show no sign of liver or kidney damage, suggesting that the micronized powders and the LbL 
nanosystems exhibited little toxicity at the administered dose. 
 
Table 5.4-Serum levels of ALT, AST, BUN and CREAT at the end of the 24 h treatment in BALB/c 
mice. 
 ALT (U/L) AST (U/L) BUN (mg/dL) CREAT (mg/dL) 
CHT-LbL siRNA 151 ± 93 265 ± 102 14 ± 1.5 0.2 ± 0.03 
CHT 295 ± 154 763 ± 194 15 ± 1.2 0.3 ± 0.07 
Untreated 198 ± 114 626 ± 163 17 ± 2 0.3  0.05 
Dynamic Range 3-500 3-1000 2-130 0.2-25 
a Data are mean  error (n=3 per group). b ALT – alanine aminotransferase; AST – aspartate aminotransfer-
ase; BUN – blood urine nitrogen; CREAT – creatinine. 
 
5.5 CONCLUSIONS  
In the present study, LbL nanosystems comprising a nanolayer of KRAS siRNA were 
successfully engineered. The developed LbL assemblies were able to attain a significant impact 
on the reduction of KRAS gene expression in the KP lung cell line. Micronization of these 
nanosystems into CHT powders using SASD technology enabled the design and production of 
reliable systems for pulmonary delivery of siRNA. The ability of the micronized siRNA to re-
duce KRAS gene expression in vitro reveals the nucleic acid stability even after powder produc-
tion. Moreover, the controlled and sustained release obtained for the biomolecules entrapped in 
the microparticles (both nanosystems and siRNA per se) proved that our micronized systems 
are suitable for a controlled pulmonary delivery. In vivo biodistribution of the micro formula-
tions in healthy mice showed an alveolar distribution of the developed powders and no serum 
toxicity was noticed in the end of the treatment. However, some additional experiments may be 
required to clarify whether the CHT micropowders may trigger an in vivo inflammatory re-
sponse by the lung. Nevertheless, the results provide a potential strategy to deliver siRNA to the 
lungs and address gene therapy in lung adenocarcinoma situation. The presence of the IR-780 
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dye in the MSN core of the LbL nanoassemblies will further allow combining therapeutic ap-
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6.1 Final overview and concluding remarks 
Local administration of biopharmaceutics to the lung is known as the most promising ap-
proach for deep lung delivery enabling both local and systemic treatments in several complica-
tions. Such type of treatment enables a targeted therapy while minimizing systemic toxicity. 
The advantages of such type of administration have been the focus of the most recent research 
regarding lung cancer treatment.  
The work detailed in this thesis reveals the extraordinary advantages of combining nano-
technology, molecular biology, polymer science, chemical engineering and supercritical fluid 
technologies, to develop robust and reliable pulmonary delivery systems for the treatment of 
non-small cell lung cancer. The major goals of the present thesis were: i) to produce new bio-
compatible, biodegradable and targeted nanoplatforms that could be use in theragnosis lung 
cancer situations; ii) to produce nano-in-micro dry powders formulations with suitable aerody-
namic properties and adequate release and degradation profiles, while preserving nanoparticles 
integrity; and iii) to evaluate in vivo powders biodistribution in mice lungs. For this purpose, 
nanoparticulated systems with therapeutic and/or diagnosis capabilities were embedded into 
respirable microparticles to be delivered to the lungs. In order to minimize costs, environmental 
impact, and eventual toxicity, the particles for pulmonary inhalation engineered during this 
PhD, were produced using sustainable methodologies like supercritical assisted spray drying 
(SASD), a process based on scCO2 technology. 
With the goal of designing a biocompatible, biodegradable theragnostic system, in the 
initial stages of the work (CHAPTER 2 and 3) there was a major concern on engineering robust 
functionalized nanosystems with environmental friendly coatings able to provide stealthy and 
fluorescence properties. Gold nanoparticles (AuNPs), having already shown remarkable im-
pairments on lung cancer theragnosis, were elected as the nanocores to build our lung cancer 
theragnostic strategy.  
In CHAPTER 2, AuNPs were coated with maleimide poly(ethylene glycol) (MPM) in or-
der to provide a stealth character, improve nanoparticles’ stability and foster their internaliza-
tion. A second layer comprising of an oligoaziridine biosensor, polymerized under supercritical 
conditions, was added to the nanosystems in order to confer a fluorescent capability to the na-
noparticles. Such straightforward incorporation avoids fluorescence quenching by the AuNPs’ 
plasmon resonance effect, the major limitation of AuNPs fluorescent tagging. Moreover, the 
results showed that the produced biotags were able to enter into cells environment, and qualita-




penetration of these biotags. These extraordinary features together with the biocompatibility 
demonstrated by the biotags enabled the production of feasible nanodevices that once conjugat-
ed with specific antibodies, anti-cancer drugs and photothermal therapy (PTT) can produce ex-
traordinary outcomes in cancer theragnosis.  
Notwithstanding, conscious that the use of synthetic compounds, like MPM, may lead to 
hepatotoxicity, the work in this PhD evolved in a way of substituting this type of polymers, 
while maintaining nanoparticles’ stability, fluorescence and biocompatibility, as stated in 
CHAPTER 3. Further strengthen in the specific character towards particular tumor cell lines 
was also a requirement in order to improve nanoprobes specificity to tumor tissue. Hence, PEG 
coatings were substituted by “green” oligo(2-alkyl-2-oxazolines) produced using scCO2 assisted 
protocols, a clean and friendly-environment technology built on the principles of green chemis-
try. Post–functionalization of the oligo-oxazolines (OOxs) enabled effective coatings on 
AuNPs’ surface, resulting in stable and still, fluorescent nanoparticles. The placement of the 
fluorescent moiety on the OOxs, opposed to the moiety that grafts to the nanoparticles’ surface, 
limits fluorescence quenching by the AuNPs’ plasmon resonance effect. This remarkable find-
ing allowed for the development of new, stable, stealthy and fluorescent AuNPs avoiding fur-
ther steps of grafting with expensive probes. The developed systems presented ideal sizes for 
intracellular delivery and the additional conjugation of the peptide YIGSR strongly increased 
particles uptake by the lung cancer cell line under study (A549). The problematics around the 
use of PEGs are, therefore, circumvented and due to the optical and targeted capabilities of the 
produced particles, further conjugations with anti-cancer drugs or other therapeutic molecules 
enable the use of this type of nanosystems for cancer theragnosis applications. 
The micronization of the developed gold nanoprobes (GNP) into chitosan (CHT) poly-
meric matrix, as reported in CHAPTER 4, was successfully achieved by making use of sustain-
able methodologies like SASD. Remarkably, the engineered powders exhibit suitable aerody-
namic characteristics for inhalation and optimal biodegradation and release profiles. CHT, used 
as a polymeric carrier to the GNP proved to be a suitable material to be used in pulmonary de-
livery to treat lung cancer, as it releases from 50 to 90% of the nanocarriers (depending on the 
type of nanoparticles embedded) after 4 days, when incubated at pH 6.8.  
It is believed that the new class of SASD formulations will impact the production pipe-
line of pharmaceutical companies. Notwithstanding, to rapidly take this particle engineering 
platform to clinical translation, there is a need to produce proof-of-concept studies using most 
common and, if possible, currently FDA approved nanocarriers and materials. In this attempt, a 
switch in the nanocore material was performed and mesoporous silica nanoparticles (MSN) 
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were used as the nanotemplate for layer-by-layer (LbL) assemblies, due its biocompatible and 
biodegradable character, as demonstrated in CHAPTER 5. LbL assemblies using a siRNA 
nanolayer and more common and/or FDA approved polyelectrolytes enabled an outstanding 
gene silencing in KRAS oncogene, mutated in lung adenocarcinoma cell lines. The combination 
of SASD and LbL technology with genetic therapy led to the manufacturing of nano-in-micro 
formulations with ideal release profiles and enhanced aerodynamic properties, moisture content 
and fine particle fractions (FPF). Controlled and sustained releases of either siRNA LbL (  
80% after 5 days at pH 6.8) and siRNA per se (  14% after 5 days at pH 6.8) were obtained 
demonstrating, again, that CHT was an accurate choice for the carrier system. Although some 
additional experiments may be required to clarify whether the CHT micropowders may trigger 
an in vivo inflammatory response by the lung, the alveolar biodistribution of the nano-in-micro 
formulations and no serum toxicity evidenced in healthy mice, suggest that the developed for-
mulations are suitable for future in vivo lung cancer gene therapy thought the pulmonary route. 
Additionally, the loaded IR-780 dye into MSN pores also enables the combination of gene ther-
apy with PTT, potentially increasing therapeutic outcomes. 
A comparison between the two different types of nano-in-micro platforms developed in 
this thesis is demonstrated in Table 6.1. Briefly, all the engineered formulations exhibit similar 
volume mean diameters (Dv,50) varying between 3.1 and 4.2 µm and span values varying be-
tween 0.8 to 2.9, being the highest value mainly attributed to the presence of aggregates. The 
high emitted dose percentages (ED %) and fine particle fractions (FPF) obtained for all the 
manufactured powders demonstrate that there are high percentages of powders likely to deposit 
in the deep lung. In fact, the majority of the values obtained for FPF, match the already market-
ed DPIs currently available, as already discussed along the respective chapters. The major dif-
ference depicted among the two types of formulations produced in CHAPTER 4 and 5 is related 
to particles moisture content. Such pronounced differences may be attributed to the improve-
ments that the lab scale SASD apparatus suffered in order to produce excellent ultrafine parti-
cles for pulmonary delivery with sufficient siRNA loading to generate therapeutic effect. In this 
particular case, the amount of water used in the casting solution was extremely low, when com-
pared to the ones used in CHAPTER 4, in order to provide a faster drying process enabling the 
preservation of siRNA integrity. Further centrifugation processes to remove the water excess of 
the GNP formulations in CHAPTER 4 could potentially decrease the moisture content of CHT-
GNP formulations. 
Nevertheless, the findings herein highlighted are of extreme importance and prove that 




bined with the optimal release profiles above mentioned, and with the sustainability beyond this 
type of manufacturing, make these nano-in-micro formulations, potential candidates for sus-
tained pulmonary delivery, achieving, therefore, one of the major goals of this PhD. 
 
Table 6.1 – Comparison of aerodynamic properties and cascade impactor measurements obtained through 













CHT (chapter 4) 3.6 1.3 - 15.4 75±2.0 26±2 1.4±0.04 2.9±0.1 
CHT-Au 3.2 2.9 34.7 14.8 86.8±0.3 32.8±0.4 3.2±0.1 2.8±0.1 
CHT-Au-OEI-CS 3.7 1.7 17.2 12.4 66±2 41±1 1.5±0.1 3.3±0.1 
CHT-Au-OEI-CS-
YIGSR 
3.4 1.7 51.8 16.2 72.2±0.1 44±2 1.8±0.07 3.1±0.1 
CHT-Au-OEtOX-SH 3.8 1.4 38.6 14.9 70.2 ± 1 42±3 1.3±0.2 3.3±0.1 
CHT-Au-OEtOX-SH-
YIGSR 
3.4 1.7 46.5 12.5 81±1 47±2 1.8±0.2 2.9±0.1 
CHT (chapter 5) 4.2 0.9 - 1.4 75±2 54±3 1.6±0.1 2.2±0.1 
CHT-MSN 3.1 0.8 - 0.7 70±2 44±4 1.7±0.1 1.8±0.1 
CHT-LbL siRNA 3.5 1 28.7 0.9 n.a. n.a. n.a. n.a. 
 
Ultimately, the investigation conducted in this thesis and the findings that resulted from it 
enabled the successful development of potential aerosolizable systems for lung delivery. On the 
other hand, the nanosystems engineered along this PhD also empowered the developed micro 
powders allowing for their future use in lung cancer theragnosis. The goals of this thesis were 
successfully achieved and bring new insights for the use of pulmonary delivery in lung cancer 
situations. 
 
6.2 Future prospects 
“There’s plenty of room at the bottom” was a lecture given by the physicist Richard 
Feyman at an American Physical Society in 1959. Since then, this well-known expression has 
been linked directly to the nanotechnology world and to the infinite possibilities that arise from 
it. Therefore, if there is plenty room to manipulate individual atoms, there is also plenty of room 
for improvement in the strategies described in this thesis.  
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Although the works herein detailed may present huge advances in particles’ engineering 
for effective pulmonary delivery and lung cancer therapy, more efforts need to be done to trans-
late these approaches into clinical applications. Additional in vivo contributions regarding the 
use of SASD technology must be addressed in order to convince the pharmaceutical industries 
to adopt such strategy. Accurate pharmacokinetics and pharmacodynamics studies, (meaning 
what happens to the particles after their deposition in the lungs and what are the effects of such 
particles/biomolecules in the body, respectively) need to be fully investigated to assure clinical 
relevance. There is also a need to perform in vivo toxicology studies of such type of formula-
tions, mainly using CHT as carrier system. Pre-clinical studies involving the determination of a 
therapeutic margin, more histopathology evaluations (mainly of proximal and distal regions of 
the respiratory tract), and other in vitro specific methods, like growth factor release and enzy-
matic activities, should be addressed to bring these products to clinical trials. 
Moreover, the use of supercritical technology to build nanoparticles coatings must also 
attain clinical relevance in order to evoke a change in industry mind-set.  
Once these approaches are effectively implemented into industry, extraordinary therapeu-
tic advances will definitely arise, improving to a great extend several pulmonary and systemic 
complications. 
Forthcoming works that can arise from this thesis and be implemented in a near future in-
clude: 
i) Evaluation of gene therapy efficacy in lung adenocarcinoma bearing mice, using 
the nano-in-micro systems developed in CHAPTER 5, and the investigation of 
possible improvements in tumor regression by combining such treatment with 
PTT; 
ii) In vivo administration of the nano-in-micro platforms produced in CHAPTER 4 
and assessment of the theragnosis potential of these systems, mainly in combina-
tion with PTT; 
iii) Substitution of the water soluble oligomers produced in CHAPTER 3 by co-
oligomers comprising both hydrophilic and hydrophobic parts (already synthe-
tized by the author during this PhD), to enhance drug loading into the nanocarri-
ers, and micronize such systems and assess their ability to chemically kill tumor 
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The information in this appendix is related to CHAPTER 2. 
 
Estimation of the number of ligands per gold nanoparticle 
According to TEM images and DLS measurements (Figure 2.2 and Table 2.1), the aver-
age diameter of the nanoparticles is 28 nm. Assuming the spherical shape for the particles, the 

















 mg. From TGA analysis of MPM coated 
AuNP (Figure A.1) the amount of gold core is 1.4 mg. So the number of gold nanoparticles 




. Also, from the TGA data, the amount of MPM (Mw= 





) / 3400 = 1.77x10
16
 and the number of MPM molecules per one 
AuNP is NMPM/NAu = 2807.  
From TGA analysis of OA coated AuNP the amount of gold core is 2.63 mg. So the 




. Also, from the TGA data, 
the amount of OA (Mw= 997.50g/mol) present is 0.171 mg. Therefore, the number of OA mole-




) / 997.5 = 1.03x10
17
 and the number of OA molecules 
per one AuNP is NOA/NAu = 8712.  
In order to understand how much OA and MPM are grafted onto particles’ surface in the 
sample Au-MPM-OA, an ICP analysis for the sulfur atom was performed. Considering that 
each mol of S origins 1 mol of OA, the amount of OA/AuNP (grams) is 9.63x10
-3
. Therefore, 







 g. Hence the mass of MPM in the weight loss from Au-
MPM-OA (0.064 mg), is (1.6 - 1.536 - 1.48x10
-5
) = 6.40x10 
-5
g. Therefore, the number of mol-




/ 997.50 = 8.93x10
15
 (results obtained from 












, the number of molecules of MPM per one AuNP is 1636 as the number of molecules 





Figure A.1-TGA curves of (A) Au-MPM, (B) Au-OA and (C) Au-MPM-OA nanoparticles. 
 
 







Figure A.3-Image J color histograms (A) CLSM images of A549 cells transfected with Au-OA, 
green histogram; (B) CLSM images of A549 cells transfected with Au-OA, blue histogram; (C) CLSM 
images of A549 cells transfected with Au-MPM-OA, green histogram; (D) CLSM images of A549 cells 
transfected with Au-MPM-OA, blue histogram. Green color – CellLight® Actin-GFP, BacMam 2.0; Blue 





Figure A.4-Optical micrographs of A549 cell line transfected with the produced biotags and re-
spective precursors after 24 h and 48 h of incubation: Gold nanoparticles (AuNPs); Maleimide-PEG-
Maleimide (MPM); Oligoaziridine Biosensor (OA); Gold nanoparticles coated with oligoaziridine (Au-
OA); Gold nanoparticles capped with Maleimide-PEG-Maleimide (Au-MPM); Gold nanoparticles capped 
with Maleimide-PEG-Maleimide and oligoaziridine (Au-MPM-OA); Negative control (K-) and Positive 












Figure B.1-Optical micrographs of A549 cell line transfected with the produced biotags and re-
spective precursors after 24 h and 72 h of incubation: Gold nanoparticles (AuNPs), oligomers OEtOx-SH 
(2) and OEI-CS (3), and nanogold POxylated probes Au-OEtOx-SH (4), Au-OEI-CS (5), Au-OEtOx-SH-




Figure B.2- H1 NMR spectra of OEI-CS. 
 
From MALDI-TOF analysis of oligomer 3, eight different distributions were found: four 
with CO2 incorporation (Mw= 974 g/mol) and four without (Mw= 1549 g/mol). The incorporation 






Figure B.3-MALDI-TOF spectra of OEI-CS. Matrix: DHB + Na. i) Raw data; ii) Treated data: 
CO2 insertion – blue, black, cyan and red; No CO2 insertion – yellow, green, orange and pink 
 
 Estimation of the number of ligands per gold nanoparticle 
According to the DLS measurements (Table 3.1), the average diameter of the gold nano-
























The amount of YIGSR added to that was 5.17 x10
-5 
M and the detection limit for the 
YIGSR was found to be 5.17 x10
-8 
M (which is 0.1% of the original concentration). Considering 
both values and considering that no trace of peptide was found in the HPLC chromatogram and 
that the thiol groups from the peptide have high affinity to the AuNPs core, the binding of the 
peptide was considered to be 100%. 
Bearing this, the amount of YIGSR per AuNP could be estimated. For this experiment, 
the amount of peptide added to the AuNPs was 1.36 x10
-6 
g or 1.41 x10
-9 
mol; based on the mo-
lar ratio 100:1 (peptide: AuNP). From TGA analysis of OEtOx-SH-YIGSR (6) (Figure 3.4) the 





. Also, the weight of organic molecules was 0.12896 mg (1.6 mg 
of the initial sample – 1.47104 mg from the gold core). If the amount of peptide in the organic 
part is 1.36 x10
-6 
g (or 1.36 x10
-3 
mg) than, the amount of OEtOx-SH (Mw= 1449.15 g/mol, es-
timated through 
1
H NMR) lost was (1.6 - 1.47104 - 1.36 x10
-3
) = 1.28 x10
-4 
g. Therefore, the 




) / 1449.15 = 5.30x10
16
 
and the number of OEtOx-SH molecules per one AuNP is NOEtOx-SH/NAu = 7993.49. As for the 
YIGSR sequence, the amount of YIGSR molecules (NYIGSR) per GNP is NYIGSR/NAu = 127.64. 
Thus the total number of organic molecules per nanoparticle is 8121.13. 
The same study was performed for Au-OEI-CS-YIGSR (7). Briefly, from TGA analysis 





. Again, the amount of peptide added to the AuNP was 1.36 x10
-6 
g or 1.41 x10
-9 
mol; based on the molar ratio 100:1 (peptide: AuNP). Therefore, the amount of 
OEI-CS (Mw= 1549 g/mol, estimated through MALDI-TOF) in the organic material is (3 - 2.447 
- 1.36 x10
-3
) = 9.46403 x10
-2 





) / 1549 = 3.38x10
16
 and the number of OEI-CS molecules per one 
GNP is NOEI-CS/NAu = 2809.64. The amount of YIGSR molecules (NYIGSR) per AuNP is 





The information in this appendix is related to CHAPTER 4. 
 
Table C.1-SASD Yields (%). 







Table C.2-Encapsulation efficiencies. 
a – measured through ICP. The total amount of Au (mg) in the initial solution (next column) was calculated 
by multiplying Au concentration (mg/L) for the total volume used for the powders production: 60 mL for CHT-
AuNP, CHT-Au-OEtOx-SH-YIGSR and CHT-Au-OEI-CS-YIGSR; 25 mL for CHT-Au-OEtOx-SH and CHT-Au-
OEI-CS 
b - measured through ICP. The total amount of Au (mg) in approximately 20 mg of powders was calculated 




























CHT-AuNP 95.2 5.71 8.94 20.14 4470 1.98 34.7 
CHT-Au-OEI-CS 56.97 2.22 5.51 20.52 1549 0.38 17.2 
CHT-Au-OEI-CS-
YIGSR 
61.06 3.66 10.35 20.18 3697 1.9 51.8 
CHT-Au-OEtOx-SH 65.49 1.64 8.36 20.43 1423 0.63 38.6 
CHT-Au-OEtOx-
SH-YIGSR 


































































Figure C.4-Au release profile from CHT microspheres: Korsmeyer and Peppas fitting. The colors 





The information in this appendix is related to CHAPTER 5. 
 
 
Figure D.1-Integrity of siRNA in the LbL siRNA nanosystems: (1) Kras siRNA; (2) NC siRNA; 
(3) AF 488 siRNA; (4) LbL Kras siRNA nanosystems; (5) LbL NC siRNA nanosystems. RNA ladder 
was used as marker and is depicted in at the most left of the gel. 
 
 
Figure D.2-CLSM images of td Tomato expressing KP cell line incubated with the LbL siRNA 
nanoparticles after 4h. Ch1 – Hoescht, nuclear location (exc = 405 nm; emm = 461 nm); Ch2 – AF 488 































28.7%: 0.03 mg/mL 
(in 71.9 mg of pow-
der) 
133.4 ug (in 





a Based on the IR-780 dye loading efficiency  
 
 
Figure D.3- X-ray diffraction patterns of MSN, CHT and CHT-MSN. 
 
 







Figure D.5-STEM images and EDX spectrum of the micronized powders: (A) CHT; (B) CHT-
LbL siRNA; and (C) CHT-LbL siRNA after 5 min in ultrasonic bath. Silicon atomic/weight % (respec-
tively): CHT – 0.40 / 0.77 %; CHT-LbL siRNA - 1.69 / 3.19 %. 
 
 
Figure D.6-Release profile from CHT microspheres: Korsmeyer and Peppas fitting. The colors 
from the adjustment curves are in agreement with the colors from the symbols. 
 
